

Covid-19



HSS/ Horizon Scanning
Living Document **V22 June/July 2022**



HTA Austria
Austrian Institute for
Health Technology Assessment
GmbH

Covid-19

HSS/ Horizon Scanning
Living Document **V22 June/July 2022**

Projektteam

Projektleitung: PD Dr. Claudia Wild

Projektbearbeitung

Updates: Mirjana Huic, MD, MSc, PhD

Projektbeteiligung

Kontroll- und Formatierarbeiten: Ozren Sehic, MA; Smiljana Blagojevic, Dipl.-Ing.

Korrespondenz: Claudia Wild, claudia.wild@aihta.at

Umschlagfoto: @ Mike Fouque – stock.adobe.com

Dieser Bericht soll folgendermaßen zitiert werden/This report should be referenced as follows:

AIHTA Policy Brief Nr.: 002_V22 2022: Covid-19, HSS/ Horizon Scanning, Living Document June/ July 2022.

Wien: HTA Austria – Austrian Institute for Health Technology Assessment GmbH.

Interessenskonflikt

Alle beteiligten AutorInnen erklären, dass keine Interessenskonflikte im Sinne der Uniform Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org) bestehen.

IMPRESSUM**Medieninhaber und Herausgeber:**

HTA Austria - Austrian Institute for Health Technology Assessment GmbH
Garnisongasse 7/Top20 | 1090 Wien – Österreich
www.aihta.at

Für den Inhalt verantwortlich:

Priv.-Doz. Dr. phil. Claudia Wild, Geschäftsführung

Die **AIHTA Policy Briefs** erscheinen unregelmäßig und dienen der Veröffentlichung der Forschungsergebnisse des Austrian Institute for Health Technology Assessment.

Die **AIHTA Policy Briefs** erscheinen in geringer Auflage im Druck und werden über den Dokumentenserver „<https://eprints.aihta.at/view/types/policy=5Fbrief.html>“ der Öffentlichkeit zur Verfügung gestellt.

AIHTA Policy Brief Nr.: 002

ISSN 2710-3234

ISSN online 2710-3242

© 2022 AIHTA – Alle Rechte vorbehalten

Content

Content	3
1 Background: policy question and methods	7
1.1 Policy Question.....	7
1.2 Methodology	7
1.3 Selection of Products for “Vignettes”	10
2 Results: Vaccines.....	12
3 Results: Therapeutics	13
3.1 Current therapeutic management of patients with COVID-19 (outpatients and hospitalised patients): Summary	14
3.2 Individual therapeutics.....	26
3.2.1 Remdesivir (Veklury®).....	26
3.2.2 Lopinavir + Ritonavir (Kaletra®).....	28
3.2.3 Favipiravir (Avigan®)	28
3.2.4 Darunavir	29
3.2.5 Chloroquine (Resochin®) and.....	29
3.2.6 Hydroxychloroquine (Plaquenil®)	29
3.2.7 Camostat Mesilate (Foipan®)	29
3.2.8 APN01/ Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2)	31
3.2.9 Tocilizumab (Roactemra®)	32
3.2.10 Sarilumab (Kevzara®)	33
3.2.11 Interferon beta 1a (SNG001) (Rebif®, Avonex®) and Interferon beta 1b (Betaferon®, Extavia®).....	41
3.2.12 Convalescent plasma (CVP) transfusion	41
3.2.13 Plasma derived medicinal products	42
3.2.13.1.1 REGN-COV2 - combination of two monoclonal antibodies casirivimab/imdevimab (REGN10933 and REGN10987, Ronapreve).....	44
3.2.13.1.2 LY-CoV555 - neutralizing IgG1 monoclonal antibody (bamlanivimab) and LY-CoV016 - recombinant fully human monoclonal neutralizing antibody (etesevimab).....	44
3.2.13.1.3 AZD7442 - combination of two monoclonal antibodies (tixagevimab AZD8895 + cilgavimab AZD1061) - Evusheld	45
3.2.13.2 Sotrovimab (VIR-7831 monoclonal antibody, Xevudy)	47
3.2.13.3 Regdanvimab (CT-P59, Regkirona)	47
3.2.14 Combination therapy – triple combination of interferon beta-1b, lopinavir–ritonavir and ribavirin vs. lopinavir–ritonavir or other triple combination of interferons.....	50
3.2.15 Solnatide	50
3.2.16 Umifenovir (Arbidol®).....	52
3.2.17 Dexamethasone and other corticosteroids.....	52
3.2.17.1 Inhaled corticosteroids: Budesonide	52
3.2.18 Anakinra (Kineret®).....	55
3.2.19 Colchicine.....	55
3.2.20 Nafamostat (Futhan®)	55
3.2.21 Gimsilumab.....	56
3.2.22 Canakinumab.....	56
3.2.23 Lenzilumab	57
3.2.24 Vitamin D.....	58
3.2.25 Baricitinib (Olumiant)	59

3.2.26 Molnupiravir (Lagevrio)	66
3.2.27 Ivermectin.....	73
3.2.28 Aspirin	73
3.2.29 Aivaptadil (Zysami)	74
3.2.30 Dimethyl fumarate	74
3.2.31 Artesunate.....	74
3.2.32 Tofacitinib (Xeljanz)	74
3.2.33 Fluvoxamine.....	78
3.2.34 Nirmatrelvir and ritonavir (Paxlovid)	78
3.2.35 AT-527.....	84
3.2.36 Plonmarlimab (TJM2)	85
3.2.37 Mavrilimumab	86
3.2.38 SAB-185	90
3.2.39 Ensovibep (MP0420)	91
3.2.40 Bemcetinib.....	92
3.2.41 Y180 - Mpro inhibitor	93
3.2.42 Ensitrelvir	94
3.2.43 Poly-ICLC (Hiltonol).....	95
3.2.44 Nitric Oxide Nasal Spray.....	96
References.....	99

Figures

Figure 1.2-1: A living mapping of ongoing randomized trials, living systematic reviews with pairwise meta-analyses and network meta-analyses.....	9
Figure 1.2-2: Global Coronavirus COVID-19 Clinical Trial Tracker - a real-time dashboard of clinical trials for COVID-19	10

Tables

Table 1.2-1: International Sources	8
Table 3.2-1: Summary of findings table on Sarilumab compared to Standard Care for Hospitalised COVID-19	39
Table 3.2-2: Bebtelovimab Pseudotyped Virus-Like Particle Neutralization Data for SARS-CoV-2 Spike Protein Variants.....	48
Table 3.2-3: Summary of findings table, on budesonide vs standard care (2 RCTs: Ramakrishnan, Yu)	54
Table 3.2-4: Summary of findings table, on baricitinib + remdesivir (1 RCT: Kalil 2020).....	64
Table 3.2-5: Summary of findings table, on baricitinib monotherapy vs placebo in hospitalised COVID-19 patients (Marconi 2021, Ely 2021, RECOVERY trial 2022)	65
Table 3.2-6: Summary of findings table, on molnupiravir vs standard care/placebo (4 RCTs: Caraco, 2021; Jayk Bernal, 2021; Fischer, 2021; Koudinya Tippabhotla 2022).....	71
Table 3.2-7: Summary of findings table, on tofacitinib vs standard care/placebo (2 RCTs: STOP-COVID Guimaraes 2021; Murugesan 2021).....	77
Table 3.2-8: Summary of findings table, on nirmatrelvir/ritonavir vs placebo (1 RCT: Hammond, 2022)	83
Table 3.2-9: Summary of findings table, on mavrilimumab vs placebo (2 RCTs: Cremer, 2021; Pupim, 2021).....	88

History of Changes	V22 June / July 2022
June/July 2022	Addition chapter on ensitrelvir (chapter 3. 2.42), Poly-ICLC (chapter 3. 2.43), nitric oxide nasal spray (chapter 3. 2.44)
June/July 2022	Methodology (1.2) – no changes
June/July 2022	Vaccine (chapter 2) – reporting is stopped, see earlier version (V17_August and September 2021) for more details
June/July 2022	Update Summary (chapter 3.1)
June/July 2022	Remdesivir (chapter 3.2.1) – no changes
June/July 2022	Favipiravir (chapter 3. 2.3) - see earlier versions (V15_June 2021 and V17_August and September 2021) for more details
June/July 2022	Darunavir (chapter 3. 2.4) – see earlier version (V15_June 2021) for more details
June/July 2022	Camostat Mesilate (chapter 3. 2.7) – no changes
June/July 2022	APN01/rhACE2 (chapter 3. 2.8) – no changes
June/July 2022	Tocilizumab (chapter 3. 2.9) – see earlier version (V14_May 2021 and V18_October and November 2021) for more details
June/July 2022	Update Sarilumab (chapter 3. 2.10)
June/July 2022	Interferon beta (chapter 3. 2.11) – see earlier version (V18_October and November 2021) for more details
June/July 2022	Convalescent plasma (chapter 3. 2.12) - see earlier version (V17_August and September 2021) for more details
June/July 2022	Update Plasma derived medicinal products (chapter 3. 2.13) – AZD7422 (Evusheld); Bebtelovimab
June/July 2022	Combination therapy (chapter 3. 2.14) – see earlier version (V13_April 2021) for more details
June/July 2022	Update Solnatide (chapter 3. 2.15)
June/July 2022	Umifenovir (chapter 3. 2.16) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Inhaled corticosteroids (chapter 3. 2.17.1) – no changes
June/July 2022	Anakinra (chapter 3. 2.18) - see earlier version (V20_February and March 2022) for more details
June/July 2022	Colchicine (chapter 3. 2.19) – see earlier versions (V15_June 2021 and V18_October and November 2021) for more details
June/July 2022	Nafamostat (chapter 3. 2.20) – no changes
June/July 2022	Gimsilumab (chapter 3. 2.21) – no changes
June/July 2022	Canakinumab (chapter 3. 2.22) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Lenzilumab (chapter 3. 2.23) – no changes

June/July 2022	Vitamin D (chapter 3. 2.24) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Update Baricitinib (chapter 3. 2.25)
June/July 2022	Update Molnupiravir (chapter 3. 2.26)
June/July 2022	Ivermectin (chapter 3. 2.27) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Aspirin (chapter 3. 2.28) – see earlier version (V17_August and September 2021, and V19 December 2021/January 2022) for more details
June/July 2022	Aviptadil (RLF-100) (chapter 3. 2.29) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Dimethyl fumarate (chapter 3. 2.30) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Artesunate (chapter 3. 2.31) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Tofacitinib (chapter 3. 2.32) – no changes
June/July 2022	Fluvoxamine (chapter 3. 2.33) – see earlier version (V17_August and September 2021) for more details
June/July 2022	Update Nirmatrelvir (PF-07321332) and ritonavir – Paxlovid (chapter 3. 2.34)
June/July 2022	AT-527 (chapter 3.2.35) – no changes
June/July 2022	Plonmarlimab (TJM2) (chapter 3.2.36) – no changes
June/July 2022	Mavrilimumab (chapter 3.2.37) – no changes
June/July 2022	SAB-185 (chapter 3.2.38) – no changes
June/July 2022	Ensovibep (MP0420) (chapter 3.2.39) – no changes
June/July 2022	Bemcetinib (chapter 3.2.40) – no changes
June/July 2022	Update Y180 (chapter 3.2.41)

1 Background: policy question and methods

1.1 Policy Question

On March 30th 2020, a request was raised by the Austrian Ministry of Health (BMASGK), the Health Funds of the Regions and the Federation of Social Insurances to set up a Horizon Scanning system (HSS) for medicines and vaccines. The establishment of a HSS/ Horizon Scanning System for Covid-19 interventions has the intentions of

- a. informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and
- b. monitoring them over the next few months in order to support evidence-based purchasing, if necessary.

März 2020:
Österr. Politik empfiehlt
Aufbau von HSS
zu Covid-19

Information zu
*** Status F&E**
*** Evidenz-basierter**
Einkauf

1.2 Methodology

To respond to this request,

1. As a first step an inventory, based on international sources, is built.
2. As a second step, selective searches by means of searches in study registries are carried out for information on clinical studies in humans and the state of research.
3. This information forms the basis for “vignettes” (short descriptions) for those products that are already in an "advanced" stage.
4. Subsequently, the products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

mehrstufige Methodik

Bestandsaufnahme
selektive Suche
Vignetten
Monitoring

All work steps are conducted in close international (European) cooperation.

- Version 1 (V1, April 2020): inventory + vignettes for most advanced
- Version 2+: monthly monitoring and updates

**internationale/
europ. Zusammenarbeit**

Ongoing trials are reported in V1, April 2020 - V3, June 2020 of this Document and in the living documents - EUnetHTA (Covid-19 Rolling Collaborative Reviews: <https://eunetha.eu/rcr01-rcrxx/>).

From V4 July, 2020 of this HSS/ Horizon Scanning Document, only completed, terminated, withdrawn and suspended interventional clinical trials from ClinicalTrials.gov and EUdraCT registers are reported. From Version 8 November, 2020 only terminated, withdrawn and suspended interventional clinical trials are reported.

From V5, August 2020 of this HSS/ Horizon Scanning Document only the best available evidence will be presented in.

V1-V3: auch laufende
Studien - Verweis auf
EUnetHTA
ab V4: nur
abgeschlossene (oder
beendete)
Interventionsstudien aus
2 Studienregistern
ab V5: nur mehr best
verfügbare Evidenz

Table 1.2-1: International Sources

Primary sources	Link
WHO Drugs: Vaccines:	https://www.who.int/teams/blueprint/covid-19 https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1 https://www.who.int/who-documents-detail/covid-19-candidate-treatments https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines
Danish Medicine Agency Drugs: Vaccines:	https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~media/5B83D25935DF43A38FF823E24604AC36.ashx https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~media/3A4B7F16D0924DD8BD157BBE17BFED49.ashx
Pang et al. 2020 [1] Drugs: Vaccines:	https://www.mdpi.com/2077-0383/9/3/623 Table 5+6, Table 3+4
SPS HS-report (UK)	unpublished
Secondary sources	
VfA/ Verband Forschender Arzneimittelhersteller Drugs: Vaccines:	https://www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/therapeutische-medikamente-gegen-die-coronavirusinfektion-covid-19 https://www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/impfstoffe-zum-schutz-vor-coronavirus-2019-ncov
EMA/ European Medicines Agency Medicines:	https://www.ema.europa.eu/ https://www.ema.europa.eu/en/medicines/medicines-under-evaluation
FDA/US Food and Drug Administration	https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19
Trial Registries	
US National Library of Medicine European Union Drug Regulating Authorities Clinical Trials Database WHO International Clinical Trials Registry Platform TrialsTracker	https://clinicaltrials.gov/ https://eudract.ema.europa.eu/ https://www.who.int/ictrp/en/ http://Covid-19.trialstracker.net/
Up-to-date information on clinical trials and literature searching resources relating to COVID-19	
Cochrane COVID-19 Study Register 21/04.20	https://covid-19.cochrane.org/
Living mapping of research and a living systematic review	https://covid-nma.com/ https://covid-nma.com/dataviz/
Dynamic meta-analysis of evidences about drug efficacy and safety for COVID19 - meta/Evidence – COVID-19	http://metaevidence.org/COVID19.aspx
CORDITE (CORona Drug InTERactions database)	https://cordite.mathematik.uni-marburg.de/#/
Living listing of interventional clinical trials in Covid-19/2019-nCoV produced by the Anticancer Fund	http://www.redo-project.org/covid19db/ ; http://www.redo-project.org/covid19_db-summaries/
Global Coronavirus COVID-19 Clinical Trial Tracker	https://www.covid-trials.org/
LitCovid	https://www.ncbi.nlm.nih.gov/research/coronavirus/
UK NIHR Innovation Observatory NIHR COVID-19 Studies COVID-19 Therapeutics Dashboard COVID-19: a living systematic map of the evidence	https://www.nihr.ac.uk/covid-studies/ http://www.io.nihr.ac.uk/report/covid-19-therapeutics/ http://epi.ioe.ac.uk/cms/Default.aspx?tabid=3765
WHO COVID-19 Database new search interface	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov
COVID-evidence Database	https://covid-evidence.org/database
Medical Library Association – COVID-19 Literature search strategies	https://www.mlanet.org/page/covid-19-literature-searching
Centre of Evidence Based Dermatology (CEBD) - Coronavirus Dermatology Online Resource	https://www.nottingham.ac.uk/research/groups/cebd/resources/Coronavirus-resource/Coronavirushom
Ovid Expert Searches for COVID-19	http://tools.ovid.com/coronavirus/
EBSCO Covid-19 Portal Literature searching section of portal	https://covid-19.ebscomedical.com/research

Information portal	https://covid-19.ebscomedical.com/
NIH COVID-19 Treatment Guidelines. 2020.	https://covid19treatmentguidelines.nih.gov/introduction/
Tertiary sources	
NIPHNO	https://www.fhi.no/en/qk/systematic-reviews-hta/map/
INAHTA	http://www.inahta.org/covid-19-inahta-response/
EUnetHTA Covid-19 Rolling Collaborative Reviews (RCR)	https://eunethta.eu/rcr01-rcrx/

Several organisations and international teams of researchers are providing up-to-date information through living listing of interventional clinical trials in Covid-19/2019-nCoV and literature resources [2-4]. A short description of two of such databases is presented below.

Boutron et al., 2020 [5] are performing a living mapping of ongoing randomized trials, followed by living systematic reviews with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: the effectiveness of preventive interventions for COVID-19 and the effectiveness of treatment interventions for COVID-19 (Figure 1.2-1). As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

**“lebende” Dokumente mit
up-to-date Informationen**

**Kartierung von
laufenden RCTs**

**seit März 2022:
NMA nur mehr
Immunmodulatoren und
Antivirale Medikamente**

COVID-19 NMA

a living mapping of ongoing research.


▼ As of April 24, 2020...

The Covid-19 - living NMA initiative collected a number of 506 studies of treatments from the ICTRP. 278 of these trials are recruiting patients. Most of the studies are being conducted in Asia (264 trials) with the majority from China (151 trials). Other countries in Europe (160 trials) and North America (92 trials) are rapidly setting up new trials with the majority being conducted in multiple centers (194 trials).

Search

Ex: Dexamethasone, Spain, Assistance Publique Hôpitaux de Paris, LUCTA2019...

▼ Map



▼ HELP 📖

- Make your browser window as wide as possible for a 2-column display.
- Click on the map or any of the graphs to create filters on the data.
- All the filters are applied jointly, refining your selection.
- To select a Registration date, click and drag to create a range.
- At any moment you can click **Reset All** below to remove the filters.
- Click on the black arrows to open or close any section.
- For any questions or remarks, please contact us.

All trials selected (506) | [Reset All](#)


▼ Recruitment status

- ☒ Recruiting (278)
- ☒ Not recruiting (219)
- ☒ Completed (9)

▼ Registration date



▼ Study aim



▼ Disease severity



Figure 1.2-1: A living mapping of ongoing randomized trials, living systematic reviews with pairwise meta-analyses and network meta-analyses

Thorlund et al., 2020 [6] developed a COVID-19 clinical trials registry to collate all trials related to COVID-19: Global Coronavirus COVID-19 Clinical Trial Tracker. Data is pulled from the International Clinical Trials Registry Platform, including those from the Chinese Clinical Trial Registry, ClinicalTrials.gov, Clinical Research Information Service - Republic of Korea, EU Clinical Trials Register, ISRCTN, Iranian Registry of Clinical Trials, Japan Primary Registries Network, and German Clinical Trials Register (Figure 1.2-2). They also use content aggregator services, such as LitCovid, to ensure that their data acquisition strategy is complete [7].

Clinical Trial Tracker real-time dashboard




Figure 1.2-2: Global Coronavirus COVID-19 Clinical Trial Tracker - a real-time dashboard of clinical trials for COVID-19

1.3 Selection of Products for “Vignettes”

The following products have been selected for further investigation (searches in registry databases and description as “vignettes”) for the following reasons:

- most advanced in clinical research in humans
- most often discussed in clinical journals as potential candidates

Decision to stop further investigation will be based on modified EUnetHTA stopping rules, <https://eunetha.eu/covid-19-treatment/>: 1) the compound has a positive marketing authorization decision or 2) no clinical benefit: ≥ 2 RCTs OR treatment arms in platform trials (e.g., RECOVERY) with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered) OR ≥ 1 RCT with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered) AND stopped enrollment of participants to the treatment arm of interest in a platform trial (e.g., RECOVERY) because no evidence of beneficial effects.

**Vignetten zu Produkten,
in “fortgeschrittenen”
Stadien oder
häufig diskutiert/
publiziert**

**Regeln, wann das
Monitoring beendet wird,
folgen EUnetHTA**

The full inventory (list) can be found in Part 2 - Appendix A-1: vaccines, A-2, therapeutics, A3-EudraCT registry studies.

From January 2021 (v10) only vaccines for which the European Commission (EC) concluded contracts or exploratory talks with their manufactures, to build a diversified portfolio of COVID-19 vaccines for EU citizens, will be presented in detail.

From April 2021 (V13) focus will be also on COVID-19 vaccines which clinical trials are conducted in children, on vaccines effectiveness related to SARS-CoV-2 new variants as well as on COVID-19 intranasal vaccines in development.

From October-November 2021 (v18) onwards the reporting related to Vaccines is stopped according to a decision of the Austrian Ministry of Health.

**ab Jän 2021: nur
Impfstoffe, für die EC
Verträge abgeschlossen
hat**

**ab April 2021: Fokus auf
Impfungen für Kinder und
auf Wirksamkeit bei
unterschiedlichen
Mutationen**

**ab Okt/Nov 2021: nur
mehr Medikamente**

2 Results: Vaccines

The reader is referred to the earlier version (v17_August and September 2021) for more details on **Vaccines**.

Reporting related to Vaccines is stopped according to decision of the Austrian Ministry of Health.

**ab Okt/Nov 2021: nur
mehr Medikamente, keine
Impfungen**

3 Results: Therapeutics

On **May 5, 2021** the **European Commission** proposed **EU Strategy for the development and availability of COVID-19 therapeutics**, to support the development and availability of much-needed COVID-19 therapeutics, including for the treatment of 'long COVID'. This Strategy covers the full lifecycle of medicines: from research, development and manufacturing to procurement and deployment. It includes clear actions and targets in the research, development and innovation; access to and swift approval of clinical trials; scanning for candidate therapeutics; supply chains and delivery of medicine; regulatory flexibility; joint procurement and financing and international cooperation to make medicine available to all, https://ec.europa.eu/commission/presscorner/detail/en/IP_21_2201.

On **June 29, 2021** the EC announced that the EU Strategy on COVID-19 Therapeutics delivers its first outcome: the first portfolio of **five promising therapeutics identified that could soon be available** to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency (**combination of bamlanivimab and etesevimab; combination of casirivimab and imdevimab; regdanvimab; and sotrovimab**.) Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients (**baricitinib**), https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3299.

On **October 22, 2021** the EC established a portfolio of **10 potential COVID-19 therapeutics**. The list established is based on independent scientific advice, and focuses on COVID-19 treatment candidates that are likely to be authorised and therefore available on the European market soon. The list of ten is divided in three categories of treatments and will continue to evolve as new scientific evidence emerges: 1) **Antiviral monoclonal antibodies** that are most efficacious in the earliest stages of infection: Ronapreve, a **combination of two monoclonal antibodies casirivimab and imdevimab** from Regeneron pharmaceuticals and Roche; Xevudy (**sotrovimab**) from Vir Biotechnology and GlaxoSmithKline; Evusheld, a **combination of two monoclonal antibodies tixagevimab and cilgavimab** from AstraZeneca; 2) **Oral antivirals** for use as quickly as possible after the infection: **Molnupiravir** from Ridgeback Biotherapeutics and MSD; **PF-07321332** from Pfizer; **AT-527** from Atea Pharmaceuticals and Roche and 3) **Immunomodulators** to treat hospitalised patients: Actemra (**tocilizumab**) from Roche Holding; Kineret (**anakinra**) from Swedish Orphan Biovitrum; Olumiant (**baricitinib**) from Eli Lilly; **Lenzilumab** from Humanigen.

These therapeutics will bring treatment to patients across the EU as fast as possible provided that their safety and effectiveness has been confirmed by the European Medicines Agency, https://ec.europa.eu/commission/presscorner/detail/en/ip_21_5366.

Details of Report of the COVID-19 therapeutics subgroup - list of 10 - 22.10.2021. could be found on the website <https://ec.europa.eu/transparency/expert-groups-register/screen/meetings/consult?lang=en&meetingId=31115&fromExpertGroups=true>.

EU-Strategie:
Unterstützung bei
Medikamenten-
entwicklung entlang des
gesamten Lebenszyklus

öffentliche F&E

Ende Juni 2021:
EC verlautbart EU
Strategie für
Therapeutika – zentraler
Ankauf

5 Hoffnungsträger

Oktober 2021:
EC veröffentlicht Portfolio
von 10 Hoffnungsträgern

AIHTA war Mitglied der
EC-Kommission

Details zu den Produkten
auch in diesem Bericht

On June 7, 2022 EMA's Medicine Shortages Steering Group adopted the list of critical medicines for the COVID-19 health emergency. The published list contains all the approved vaccines and therapeutics: **dexamethasone-containing medicines**, **tixagevimab/cilgavimab** (Evusheld), **anakinra** (Kineret), **nirmatrelvir/ritonavir** (Paxlovid), **regdanvimab** (Regkirona), **tocilizumab** (RoActemra), **casirivimab/imdevimab** (Ronapreve), **remdesivir** (Veklury) and **sotrovimab** (Xevudy) in the European Union (EU) to prevent or treat COVID-19. It will be updated to reflect changes in the pandemic situation which may give rise to an increased risk of shortages of particular medicines, or following the authorisation of new medicines [8].

EMA Liste an knappen Arzneimitteln beinhaltet alle zugelassenen Medikamente

3.1 Current therapeutic management of patients with COVID-19 (outpatients and hospitalised patients): Summary

SARS-CoV-2 variants and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies and oral antivirals

In November 2021, the **Omicron (B.1.1.529) variant** was designated as the **new variant of concern (VOC)** and in January 2022 has become the dominant VOC globally: it includes numerous mutations in the spike protein. Omicron is comprised of several genetically related **sublineages**, including **BA.1**, **BA.2** and **BA.3**. Ongoing studies are evaluating the susceptibility of this VOC to the anti-SARS-CoV-2 mAbs. **This variant** is predicted to have **markedly reduced susceptibility to some anti-SARS-CoV-2 mAb products**, including **bamlanivimab plus etesevimab and casirivimab plus imdevimab**. **Sotrovimab** appears to **retain activity against this variant**. It has substantially **decreased in vitro activity against the Omicron BA.2 subvariant** that has recently become the dominant subvariant. Based on in vitro data, **bebtelovimab** is expected to have **activity against a broad range of SARS-CoV-2 variants**, including the **B.1.1.529 (Omicron) variant of concern (VOC)** and its **BA.1 and BA.2 sublineages**. The same is true for **BA.2.12.1** and **BA.4/BA.5 sublineages**. **Tixagevimab and cilgavimab in combination** retained full to nearly full neutralisation activity against pseudovirus and/or live virus SARS-CoV-2 variant strains: VLPs pseudotyped with the spike of **Omicron BA.2.12.1, BA.3, or BA.4/BA.5** showed **5-fold, 16-fold, and 33- to 65-fold reductions** in neutralizing activity, respectively.

seit November: Omicron

Einfluss auf Wirksamkeit von Antikörper-Therapien

These three new Omicron **sublineages BA.4, BA.5 and BA.2.12.1** have acquired a few additional mutations that may impact their characteristic: the number of cases and the number of countries reporting the detection of these three variants are rising. In some countries, the rise in cases has also led to a surge in hospitalizations and ICU admissions; however, the current evidence available does not indicate a change in severity associated with any of the three Omicron descendent lineages BA.2.12.1, BA.4 and BA.5.

3 Omikron Subtypen BA.4, BA.5, BA.2.12.1

keine Veränderung im Schweregrad

Currently, **nirmatrelvir** has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1 and BA.2. Several recently published laboratories studies found potential resistance-conferring mutations in MPRO: at positions 50, 166 and 167, as well as 144, 165, 172 and 192. The following MPRO amino acid substitutions were associated with reduced nirmatrelvir activity (≥ 3 -fold higher K_i values): G15S (4.4-fold), T135I (3.5-fold), S144A (91.9-fold),

Nirmatrelvir zeigt bis bislang gleichbleibende antivirale Wirkung

obwohl Laborstudien potentielle Resistenzen zeigt

H164N (6.4-fold), H172Y (233-fold), Q189K (65.4-fold), and D248E (3.7-fold), as well as Y54A (23.6-fold), F140A (39.0-fold), and E166A (33.4-fold).

The US COVID-19 Treatment Guidelines Panel on treatment of nonhospitalised patients (last update **May 13, 2022**)

The effectiveness of the different anti-SARS-CoV-2 mAb therapies varies dramatically depending on the circulating variant, and the role of each anti-SARS-CoV-2 mAb in the treatment of COVID-19 remains fluid. The Panel recommends using **bebtelovimab** 175 mg intravenous (IV) injection in patients aged ≥ 12 years as an alternative therapy **ONLY** when ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir are not available, feasible to use, or clinically appropriate (**CIII**). Treatment should be initiated as soon as possible and within 7 days of symptom onset. Because the Omicron VOC has become the dominant variant in the United States, the Panel **recommends against** using **bamlanivimab** **plus etesevimab, casirivimab plus imdevimab, or sotrovimab** for the treatment of COVID-19 (**AIII**).

This statement contains the Panel's recommendations for **treating nonhospitalised patients** using the currently available therapies. The Panel recommends one of the following:

Preferred therapies (listed in order of preference):

- **Ritonavir-boosted nirmatrelvir (Paxlovid) (AIIa)**
- **Remdesivir (BIIa)**

Alternative therapies (for use **ONLY** if none of the preferred therapies are available, feasible to use, or clinically appropriate, listed in alphabetical order):

- **Bebtelovimab 175 mg (CIII); or**
- **Molnupiravir 800 mg (CIIa)**

US COVID-19 Treatment Guidelines on prophylaxis (last update **April 29, 2022**)

- The Panel recommends using **tixagevimab 300 mg plus cilgavimab 300 mg** administered as 2 consecutive 3-mL intramuscular injections (**BIII**) as SARS-CoV-2 **pre-exposure prophylaxis (PrEP)** for adults and adolescents (aged ≥ 12 years and weighing ≥ 40 kg) who do not have SARS-CoV-2 infection, who have not been recently exposed to an individual with SARS-CoV-2 infection, **AND** who: Are moderately to severely immunocompromised and may have an inadequate immune response to COVID-19 vaccination; *or* Are not able to be fully vaccinated with any available COVID-19 vaccines due to a documented history of severe reactions to a COVID-19 vaccine or any of its components.

**April 2022:
US COVID-19 Treatment
Guidelines Panel
zur Behandlung
nicht-hospitalisierter
Patient*innen**

**Nirmatrelvir + ritonavir
(Paxlovid) (AIIa)
Remdesivir (BIIa)**

**geringere Präferenz
Bebtelovimab (CIII)
Molnupiravir (CIIa)**

**zur pre-Exposure
Prophylaxe bei schwer
immun-komprimierten
Pts:
Tixagevimab/ Cilgavimab
(Evusheld)**

- The FDA Emergency Use Authorization states that individuals who received tixagevimab 150 mg plus cilgavimab 150 mg should be given a second dose as soon as possible. The specific dose of tixagevimab plus cilgavimab that an individual should receive depends on the amount of time that has passed since the first dose was administered: If the initial dose was administered ≤ 3 months prior, the second dose should be tixagevimab 150 mg plus cilgavimab 150 mg. If the initial dose was administered > 3 months prior, the second dose should be tixagevimab 300 mg plus cilgavimab 300 mg.
- **Tixagevimab plus cilgavimab is not a substitute for COVID-19 vaccination and should not be used in unvaccinated individuals for whom COVID-19 vaccination is recommended and who are anticipated to have an adequate response.**
- If supplies of tixagevimab plus cilgavimab are limited, priority for use as PrEP should be given to those who are at the highest risk for severe COVID-19.

The Panel **recommends against** the use of **bamlanivimab plus etesevimab** and **casirivimab plus imdevimab** for **post-exposure prophylaxis (PEP)**, as the B.1.1.529 (**Omicron**) variant **and its subvariants**, which are not susceptible to these agents, are currently the predominant variant circulating in the United States (**AIII**).

Dexamethasone (and other systemic corticosteroids)

In **EU**, **dexamethasone** use is endorsed by **EMA** following referral procedure: it is **indicated in adults and adolescents (from 12 years of age and weighing at least 40 kg) who require supplemental oxygen therapy**. In all cases, the recommended dose in adults and adolescents is **6 milligrams once a day for up to 10 days**.

In current **WHO living guidance** the WHO panel made two recommendations: a **strong recommendation** (based on moderate certainty evidence) **for systemic** (i.e. intravenous or oral) **corticosteroid therapy** (e.g. 6 mg of dexamethasone orally or intravenously daily or 50 mg of hydrocortisone intravenously every 8 hours) for 7 to 10 days in **patients with severe and critical COVID-19**, and a **conditional recommendation** (based on low certainty evidence) **not to use corticosteroid therapy in patients with non-severe COVID-19**.

The **US COVID-19 Treatment Guidelines Panel** **recommends against** the use of **dexamethasone (AIIa)** or **other corticosteroids (AIII)** for the treatment of COVID-19 in **patients who do not require supplemental oxygen**.

In **patients who require supplemental oxygen** one of the following options for these patients is **recommended**: **Remdesivir** (e.g., for patients who require minimal supplemental oxygen) (**BIIa**); **Dexamethasone plus remdesivir** (e.g., for patients who require increasing amounts of oxygen) (**BIIb**); or **Dexamethasone** (when combination therapy with remdesivir cannot be used or is not available) (**BI**). If dexamethasone is not available, an alternative corticosteroid such as **prednisone**, **methylprednisolone**, or **hydrocortisone** can be used (**BIII**).

For **patients who require delivery of oxygen through a high-flow device or noninvasive ventilation** one of the following options for these patients is recommended: **Dexamethasone (AI)**; or **Dexamethasone plus remdesivir (BIII)**. For recently hospitalized patients (i.e., those within 3 days of hospital admission) who have rapidly increasing oxygen needs, and systemic

FDA EUA:
rasche Verabreichung von 2.Dosis

KEIN Ersatz für Impfung !

Empfehlung GEGEN Bamlanivimab/ Etesevimab sowie Casirivimab/ Imdevimab

als Post-Exposure Prophylaxe

derzeitige Therapien im Management von Covid-19 Patient*innen zugelassen:
Dexamethasone (und andere Kortikosteroide)

von WHO & US COVID-19 Treatment Guidelines Panel empfohlen für Pts mit Beatmung,

nicht aber für Pts ohne Beatmung

Therapieoptionen für invasiv und auch nicht-invasiv beatmete Pts

inflammation, add either **baricitinib (BIIa)** or **IV tocilizumab (BIIa)** (drugs are listed alphabetically and not in order of preference) to one of the two options above. If neither baricitinib nor IV tocilizumab is available or feasible to use, **tofacitinib** can be used **instead of baricitinib (BIIa)** or **IV sarilumab instead of IV tocilizumab (BIIa)**.

For patients who require Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation the Panel recommends the use of **dexamethasone** in hospitalized patients with COVID-19 who require invasive mechanical ventilation or ECMO (AI). The Panel recommends the use of **dexamethasone plus IV tocilizumab** for patients who are within 24 hours of admission to the ICU (BIIa). If IV tocilizumab is not available or feasible to use, IV **sarilumab can be used (BIIa)**.

Daily regimen of dexamethasone 6 mg once daily is equivalent to 160 mg of hydrocortisone, 40 mg of prednisone, and 32 mg of methylprednisolone.

Remdesivir (Veklury)

Remdesivir (Veklury) is an antiviral medicine for systemic use which received a **conditional marketing authorisation** in EU. It is **indicated** for the treatment of coronavirus disease 2019 (COVID-19) in **adults and adolescents** (aged 12 years and older with body weight at least 40 kg) with **pneumonia requiring supplemental oxygen**. On **December 17 2021** the CHMP recommended including the treatment of adults who do not require supplemental oxygen and who are **at increased risk of progressing to severe COVID-19** to its indication.

On June 11, 2021 **EMA** stated that PRAC has recommended a **change to the product information to include sinus bradycardia** as an **adverse reaction of unknown frequency** for this medicine.

The **FDA approved** remdesivir for use in **adult and pediatric patients 12 years of age and older** and weighing at least 40 kilograms (about 88 pounds) for the treatment of **COVID-19 requiring hospitalisation**.

On **January 21, 2022** **FDA** has **expanded** the approved indication for Veklury to include its use in **adults and pediatric patients** with positive results of direct SARS-CoV-2 viral testing, and who are **not hospitalised** and have **mild-to-moderate COVID-19**, and are at **high risk for progression to severe COVID-19, including hospitalisation or death**.

On **April 25, 2022** **FDA** **expanded** the approval of the COVID-19 treatment Veklury (remdesivir) to include **pediatric patients 28 days of age and older weighing at least 3 kilograms** (about 7 pounds) with positive results of direct SARS-CoV-2 viral testing, who are **hospitalised, or not hospitalised** and have **mild-to-moderate COVID-19** and are at **high risk for progression to severe COVID-19, including hospitalization or death**. This action makes Veklury the first approved COVID-19 treatment for children less than 12 years of age.

In the tenth version of the guideline, the **WHO living guideline (22 April 2022)** provided **conditional recommendation** for the **use of remdesivir** in patients with **non-severe COVID-19** at the **highest risk of hospitalisation**.

Tocilizumab und Sarilumab

EMA vorläufige Zulassung:
Remdesivir (Veklury)
Dez 2021:
Indikationsausweitung

PRAC: Sinusbradycardie

Jän 2022:
FDA- Indikationsausweitung:
mild-moderate Pts.
Kinder

The **US COVID-19 Treatment Guidelines Panel** issued new recommendations on remdesivir treatment for patients with COVID-19: There are insufficient data to recommend either for or against the routine use of remdesivir in hospitalised but does not require supplemental oxygen. For patients at high risk of disease progression, the use of remdesivir may be appropriate.

Remdesivir is recommended for use in hospitalised patients who require supplemental oxygen (BIIa); Dexamethasone plus remdesivir (e.g., for patient who required increasing amounts of supplemental oxygen) (BIII); **Dexamethasone** (e.g., when combination therapy with remdesivir cannot be used or is not available) (BI). For hospitalized patients with COVID-19 who require oxygen delivery through a high-flow device or, noninvasive ventilation use one of the following options: **Dexamethasone (AI); Dexamethasone plus remdesivir** (e.g., for patients who require increasing amounts of oxygen) (BIIb). For patients who were recently hospitalised with rapidly increasing oxygen needs and systemic inflammation: **Add either baricitinib (BIIa) or IV tocilizumab** to one of the two options above (BIIa). If neither baricitinib nor IV tocilizumab is available or feasible to use, **tofacitinib** can be used **instead of baricitinib (BIIa) or IV sarilumab instead of IV tocilizumab (BIIa).**

For hospitalised patients with COVID-19 who require invasive mechanical ventilation or extracorporeal membrane oxygenation: **Dexamethasone (AI).** For patients who are within 24 hours of administration to the ICU **dexamethasone plus tocilizumab (BIIa).** If IV tocilizumab is not available or not feasible to use IV **sarilumab** can be used (BIIa).

For the **US COVID-19 Treatment Guidelines Panel's** April 29, 2022 **outpatient treatment** recommendations, see the above subsection related to **SARS-CoV-2 variants and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies.**

Molnupiravir (Lagevrio)

On **November 19, 2021** CHMP has issued advice on the use of molnupiravir to **treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of developing severe COVID-19.** Lagevrio should be administered as soon as possible after diagnosis of COVID-19 and within 5 days of the start of symptoms. On **November 23, 2021,** EMA has **started evaluating as application for marketing authorisation.** On **December 14, 2021** EMA announced that it is reviewing **new data on effectiveness** of molnupiravir for the treatment of COVID-19.

On **December 23, 2021** FDA issued EUA, and **reissued on March 23, 2022** for molnupiravir for **the treatment of mild-to-moderate COVID-19 in certain adults** (with **positive results of direct SARS-CoV-2 viral testing,** and who are at **high risk for progression to severe COVID-19,** including hospitalization or death, and **for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate).**

For the **US COVID-19 Treatment Guidelines Panel's** April 29, 2022 **outpatient treatment** recommendations, see the above subsection related to **SARS-CoV-2 variants and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies.**

The **WHO living guideline** (3 March 2022) provided **conditional recommendation** to use molnupiravir in **non-severe COVID-19 patients** at

US COVID-19 Treatment Guidelines Panel:
insuffiziente Datenlage bei Pt ohne Sauerstoff
Hochrisiko Pt: ev. angemessen

Empfehlung:
Pts, die zusätzlich Sauerstoff benötigen, nicht aber für jene, die bereits künstlich beatmet werden

EMA: in rolling review für mild bis moderat erkrankte Erwachsene, die Risiko auf Krankheitsprogression haben

FDA: Notfallzulassung Dez. 2021 und erneuert März 2022: nur wenn andere Therapieoptionen nicht verfügbar sind

WHO: vorläufige Empfehlung für mild Erkrankte, aber mit hohem Risiko für Hospitalisierung

highest risk of hospitalisation (excluding pregnant and breastfeeding women, and children).

Nirmatrelvir (formerly PF-07321332) and ritonavir (Paxlovid)

On **January 27, 2022** EMA's human medicines committee (CHMP) has recommended granting a **conditional marketing authorisation** for the oral antiviral medicine Paxlovid (PF-07321332 / ritonavir) for the **treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe**. The **European Commission** authorised the COVID-19 treatment Paxlovid, following evaluation by EMA on **January 28, 2022**.

Jän. 2022
EMA: vorläufige
Zulassung von Paxlovid
für Hochrisiko-Pts.

On **December 22, 2021** FDA issued **EUA**, and **reissued** on **April 14, 2022** for Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the **treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients** (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with **positive results of direct SARS-CoV-2 testing**, and who are at **high risk for progression to severe COVID-19**, including hospitalization or death. It should be initiated as soon as possible after diagnosis of COVID-19 and **within five days of symptom onset**.

FDA: Notfallzulassung
Dez. 2021 und erneuert
April 2022:
Therapiebeginn innerhalb
von 5 Tagen nach
Symptomen

For the **US COVID-19 Treatment Guidelines** Panel's outpatient treatment recommendations, see the above subsection related to **SARS-CoV-2 variants and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies**.

The **WHO living guideline** (22 April 2022) provided **strong recommendation** for the **use of nirmatrelvir-ritonavir** in patients with **non-severe COVID-19** at the **highest risk of hospitalisation** and **conditional recommendation** against the use of **nirmatrelvir-ritonavir** in patients with **non-severe COVID-19** at a **low risk of hospitalisation**.

WHO Guideline: Paxlovid
NUR bei milder
Erkrankung für
Hochrisiko-Pts

Baricitinib (Olumiant)

The **FDA** recently issued revision to **Emergency Use Authorization (EUA)** for the distribution and emergency use of baricitinib to be used **alone for the treatment of COVID-19 in hospitalised adults and pediatric patients** two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

zugelassen nur in USA
(EUA): Baricitinib als
Kombinationstherapie mit
Remdesivir

In **May 2022**, **FDA** approved a **new indication** for baricitinib for the treatment of **COVID-19 in hospitalised adults** requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

EMA is evaluating an application to extend the use of baricitinib (Olumiant) to include treatment of COVID-19 in hospitalised patients from 10 years of age who require supplemental oxygen.

The **US COVID-19 Treatment Guidelines Panel** recommends using either **baricitinib (BIIa)** or **tocilizumab (BIIa)** in combination with **dexamethasone** alone or **dexamethasone plus remdesivir** for the treatment of COVID-19 patients who were recently hospitalised with rapidly increasing oxygen needs and systemic inflammation. If neither baricitinib nor IV tocilizumab is available or feasible to use, **tofacitinib** can be used **instead of baricitinib (BIIa)** or IV **sarilumab** instead of IV **tocilizumab (BIIa)**.

The Panel **recommends against** the use of **baricitinib** in combination with **tocilizumab** for the treatment of COVID-19 (AIII).

The Panel **recommends against** the use of **JAK inhibitors other than baricitinib or tofacitinib** for the treatment of COVID-19, except in a clinical trial (AIII).

The **WHO living guideline** (14 January 2022) provided **strong recommendation** to use baricitinib as an alternative to interleukin-6 (IL-6) receptor blockers, in combination with corticosteroids, in severe and critically ill COVID-19 patients.

Tofacitinib (Xeljanz)

See text above related to **US COVID-19 Treatment Guidelines Panel** on baricitinib.

The **WHO living guideline** (14 January 2022) provided **conditional recommendation against** the use of tofacitinib for treating severe and critical COVID-19.

Casirivimab and imdevimab (REGN-COV2, Ronapreve)

The **FDA** issued an **emergency use authorization (EUA)** for casirivimab and imdevimab (REGN-COV2) to be administered together for the **treatment of mild to moderate COVID-19 in adults and pediatric patients** (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are **at high risk for progressing to severe COVID-19**.

In **revision of EUA, July 2021** FDA has issued an **EUA** to permit the emergency use of the unapproved product, REGN-COV (casirivimab and imdevimab) co-formulated product and REGN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for **post-exposure prophylaxis of COVID-19** in individuals who are at **high risk for progression to severe COVID-19**, including hospitalization or death, and are:

- not fully vaccinated **or** who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications **and**

- have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Centers for Disease Control and Prevention (CDC)

US COVID-19 Treatment Guidelines Panel:
Empfehlung für Baricitinib oder Tocilizumab in Kombination mit Dexamethasone

Empfehlung gegen:
Baricitinib als Kombinationstherapie mit Tocilizumab sowie gegen andere JAK-Inhibitoren (als Baricitinib und Tofacitinib)

WHO: starke Empfehlung für Baricitinib bei schwerer/ kritischer Erkrankung

vgl. Text zu Baricitinib

WHO: vorläufige Empfehlung GEGEN Tofacitinib

FDA: EUA für mild bis moderat Erkrankte, die hohes Risiko auf Krankheitsprogression haben

Revision von EUA: auch für Post-Prophylaxe

or

- who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons).

As of **January 24, 2022** REGEN-COV is **not authorized** for **treatment** of mild to moderate COVID-19 in geographic regions **where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information such as variant susceptibility to this drug and regional variant frequency**. The same is true for **post-exposure prophylaxis** of COVID-19.

On **November 11, 2021** EMA's human medicines committee (CHMP) **has recommended authorising Ronapreve for treating COVID-19** in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who **do not require supplemental oxygen** and who are **at increased risk of their disease becoming severe**. Ronapreve can also be used for **preventing COVID-19** in adults and adolescents (from 12 years of age and weighing at least 40 kilograms). **Marketing authorisation is granted** by EC on **12 November 2021**.

The **WHO living guideline** (24 September 2021 and 3 March 2022) provided **conditional recommendation** to use casirivimab/imdevimab combination **in non-severe COVID-19 patients at the highest risk of severe disease** and conditional recommendation to use casirivimab/imdevimab combination **in severe and critically ill COVID-19 patients with seronegative status and where viral genotyping can confirm a susceptible SARS-CoV-2 variant (i.e. excluding omicron BA1)**.

For the **US COVID-19 Treatment Guidelines Panel's outpatient treatment recommendations**, see the above subsection related to **SARS-CoV-2 variants and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies**. The Panel **recommends against the use of bamlanivimab plus etesevimab and casirivimab plus imdevimab for post-exposure prophylaxis (PEP)**, as the B.1.1.529 (**Omicron**) variant, and **its subvariants**, which are not susceptible to these agents, are currently the predominant variant circulating in the United States (**AIII**).

Bamlanivimab in combination with etesevimab

On February 9, 2021 the **FDA** issued an **EUA** for **bamlanivimab and etesevimab administered together** for the treatment of **mild to moderate COVID-19** in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are **at high risk for progressing to severe COVID-19**, including hospitalization or death. Bamlanivimab and etesevimab are not authorized for use in states, territories, and US jurisdictions in which the combined frequency of variants resistant to bamlanivimab and etesevimab exceeds 5% (last revision of EUA August 2021). In the revised EUA on September 16, 2021 bamlanivimab and etesevimab administered together for **post-exposure prophylaxis (prevention)** for COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at **high risk for progression to severe COVID-19, including hospitalization or death**.

As of **January 24, 2022**, bamlanivimab and etesevimab are **not authorized** for **treatment** of mild to moderate COVID-19 in geographic regions **where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to**

Jän 2022: REGEN-COV: nur bei bestimmten Virus-Varianten

Nov 2021 EMA: Marktzulassung für mild bis moderat Erkrankte, die hohes Risiko auf Krankheitsprogression haben

WHO: Behandlung und Post-Exposure Prophylaxe nur bei bestimmten Virus-Varianten (nicht Omicron)

Feb 2021: zugelassen in USA (EUA) als Kombinationstherapie

Sept 2021 (EUA): auch für Post-Exposure Prophylaxe für Hochrisiko-Pts.

Nov 2021: EMA beendet Rolling Review,

Eli Lilly zieht Zulassungsantrag zurück

these drugs and regional variant frequency. The same is true for post-exposure prophylaxis of COVID-19.

On November 02, 2021 EMA has ended the rolling review of bamlanivimab and etesevimab, after the company Eli Lilly informed EMA that it was withdrawing from the process.

Sotrovimab (Xevudy)

On December 16 2021 CHMP has recommended authorisation of sotrovimab for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. Marketing authorisation is granted by EC on 17 December 2021.

On May 26, 2021 FDA issued EUA for sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalisation or death.

On April 05, 2022 FDA announced that sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 sub-variant.

For the US COVID-19 Treatment Guidelines Panel's December 30, 2021 outpatient treatment recommendations, see the above subsection related to SARS-CoV-2 variants and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies.

The WHO living guideline (14 January 2022) provided conditional recommendation to use sotrovimab for treating mild or moderate COVID-19 in patients who are at high risk of hospitalisation. This includes patients who are older, immunocompromised, having underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated.

Regdanvimab (Regkirona)

On November 11, 2021 EMA's human medicines committee (CHMP) has recommended authorising Regkirona (regdanvimab) to treat adults with COVID-19 who do not require supplemental oxygen therapy and who are at increased risk of progressing to severe COVID 19. Marketing authorisation is granted by EC on 12 November 2021.

AZD7442 – tixagevimab/cilgavimab combination (Evusheld)

On October 14, 2021 EMA's human medicines committee has started a rolling review of Evusheld (AZD7442), for the prevention of COVID-19 in adults and on March 15 2022 started evaluating the marketing authorisation application. On 23 March 2022 EMA recommended granting a marketing authorisation and on 30 March 2022 the EC authorised Evusheld for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg.

On December 8, 2021 the FDA issued an emergency use authorisation (EUA) for the Evusheld for the pre-exposure prophylaxis (prevention, PrEP) of COVID-19 in certain adults and pediatric individuals.

US COVID-19 Treatment Guidelines (last update April 29, 2022)

EMA Marktzulassung
Dez 2021 für mild bis
moderat Erkrankte,
die hohes Risiko auf
Krankheitsprogression
haben

FDA April 2022:
Sotrovimab nicht länger
zugelassen

WHO Jän 2022: vorläufige
Empfehlung

EMA Marktzulassung
Nov 2021 für mild bis
moderat Erkrankte,
die hohes Risiko auf
Krankheitsprogression
haben

EMA Zulassung März
2022:
Prä-Exposition
Prophylaxe

- The Panel recommends using **tixagevimab 300 mg plus cilgavimab 300 mg** administered as 2 consecutive 3-mL intramuscular injections (**BIII**) as SARS-CoV-2 **pre-exposure prophylaxis (PrEP)** for adults and adolescents (aged ≥ 12 years and weighing ≥ 40 kg) who do not have SARS-CoV-2 infection, who have not been recently exposed to an individual with SARS-CoV-2 infection, **AND** who: Are moderately to severely immunocompromised and may have an inadequate immune response to COVID-19 vaccination *or* Are not able to be fully vaccinated with any available COVID-19 vaccines due to a documented history of severe reactions to a COVID-19 vaccine or any of its components.
- The FDA Emergency Use Authorization states that individuals who received tixagevimab 150 mg plus cilgavimab 150 mg should be given a second dose as soon as possible. The specific dose of tixagevimab plus cilgavimab that an individual should receive depends on the amount of time that has passed since the first dose was administered: If the initial dose was administered ≤ 3 months prior, the second dose should be tixagevimab 150 mg plus cilgavimab 150 mg. If the initial dose was administered > 3 months prior, the second dose should be tixagevimab 300 mg plus cilgavimab 300 mg.
- **Tixagevimab plus cilgavimab is not a substitute for COVID-19 vaccination and should not be used in unvaccinated individuals for whom COVID-19 vaccination is recommended and who are anticipated to have an adequate response.**
- If supplies of tixagevimab plus cilgavimab are limited, priority for use as PrEP should be given to those who are at the highest risk for severe COVID-19.

The Panel **recommends against** the use of **bamlanivimab plus etesevimab** and **casirivimab plus imdevimab** for **post-exposure prophylaxis (PEP)**, as the B.1.1.529 (**Omicron**) variant and **its subvariants**, which are not susceptible to these agents, are currently the predominant variant circulating in the United States (**AIII**).

Bebtelovimab

On **February 11, 2022** the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of bebtelovimab for the treatment of **mild-to-moderate coronavirus disease 2019 (COVID-19)** in **adults and pediatric patients (12 years of age and older weighing at least 40 kg)**: with **positive results of direct SARS-CoV-2 viral testing**, and who are **at high risk for progression to severe COVID-19, including hospitalization or death**, and for whom **alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate**.

Bebtelovimab retains activity against the omicron variant and its BA.1 and BA.2 sublineages, as well as BA.2.12.1 and BA.4/BA.5.

The US COVID-19 Treatment Guidelines Panel (last update **May 13, 2022**)

The Panel recommends one of the following:

Preferred therapies (listed in order of preference):

- **Ritonavir-boosted nirmatrelvir (Paxlovid) (AIIa)**
- **Remdesivir (BIIIa)**

US COVID-19 Treatment Guidelines:

Pre-Exposure Prophylaxe:
Empfehlung für
Immunschwache und
nicht vollständig
Geimpfte

FDA EUA:
baldige Verabreichung
von 2. Dosis

KEIN Substitut für
Impfung !

Feb 2022: FDA EUA für
mild-moderat Erkrankte
mit hohem Risiko für
Progression, wenn
alternative Therapien
nicht verfügbar

auch gegen Omicron
wirksam

US COVID-19 Treatment Guidelines Panel

Bebtelovimab nur als
Alternative zu
Nirmatrelvir / ritonavir
Remdesivir

Alternative therapies (for use **ONLY** if none of the preferred therapies are available, feasible to use, or clinically appropriate, listed in alphabetical order):

- **Bebtelovimab 175 mg (CIII); or**
- **Molnupiravir 800 mg (CIIa)**

Convalescent plasma (CVP)

The **new** **EUA** **revision** in **December 2021** authorised the use of **high titer COVID-19 convalescent plasma** **only** in **outpatients** or **inpatients** with **COVID-19** who have **immunosuppressive disease** or who are **receiving immunosuppressive treatment**.

The **US COVID-19 Treatment Guidelines Panel** (last updated April 29, 2022

- **recommends against** the use of COVID-19 convalescent plasma that was collected prior to the emergence of the Omicron variant for the treatment of COVID-19 (**AIII**).
- The Panel **recommends against** the use of CCP for the treatment of COVID-19 in **hospitalised, immunocompetent patients (AI)**.
- There is **insufficient evidence** for the Panel to recommend **either for or against** the use of high-titer CCP that was collected after the emergence of Omicron for the **treatment of immunocompromised patients and nonhospitalised, immunocompetent patients** with COVID-19.

Current WHO living guidance (last updated December 6, 2021) on convalescent plasma for COVID-19 has a **strong recommendations against** administering convalescent plasma for the **treatment** of patients with **non-severe COVID-19**. It recommends **against** administering convalescent plasma for the **treatment** of patients with **severe or critical COVID-19** except in the **context of a clinical trial**.

Tocilizumab (RoActemra)

On **24 June 2021** **FDA** issued an **emergency use authorization (EUA)** for the drug Actemra (tocilizumab) for the treatment of **hospitalised adults and pediatric patients** (2 years of age and older) who are **receiving systemic corticosteroids** and **require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)**.

On **December 6 2021**, **CHMP** has recommended proposed **extension of indication** to include treatment of **hospitalised adult patients with severe COVID-19** who are already receiving treatment with corticosteroids and require extra oxygen or mechanical ventilation (breathing assisted by a machine) and **marketing authorisation** is granted by **EC** on **December 7, 2021**.

The **US COVID-19 Treatment Guidelines Panel** recommendations: For patients who were recently hospitalised with rapidly increasing oxygen needs and systemic inflammation: **Add** either **baricitinib (BIIa)** or **IV tocilizumab (BIIa)** to one of the two options, dexamethasone or dexamethasone plus remdesivir. If neither baricitinib nor IV tocilizumab is available or feasible to use, **tofacitinib** can be used **instead of baricitinib (BIIa)** or **IV sarilumab instead of IV tocilizumab (BIIa)**.

For hospitalised patients with COVID-19 who require invasive mechanical ventilation or extracorporeal membrane oxygenation: **Dexamethasone (AI)**. For patients who are within 24 hours of administration to the ICU

FDA-Revision der Zulassung von Reconvalezentenplasma: nur mit hohem Titer

US COVID-19 Treatment Guidelines und WHO : Empfehlung GEGEN CVP wegen insuffizienter Evidenz, nur in klinischen Studien

Juni 2021: FDA EUA Verwendung bei hospitalisierten Pts. mit nicht invasiver Beatmung

Dez 2021 EMA Indikationsausweitung/ Marktzulassung für hospitalisierte Pts mit nicht Beatmung

US COVID-19 Treatment Guidelines Panel: Empfehlung in Kombinaion mit Dexamethasone in einigen Patientengruppen,

ICU, beatmet, etc.

dexamethasone plus tocilizumab (BIIa). If IV tocilizumab is not available or not feasible to use IV **sarilumab** can be used (BIIa).

On July 6, 2021 the WHO recommends treatment with IL-6 receptor blockers (tocilizumab or sarilumab) for patients with severe or critical COVID-19 infection (strong recommendation). Corticosteroids have previously been strongly recommended in patients with severe and critical COVID-19, and WHO recommends patients meeting these severity criteria should now receive both corticosteroids and IL-6 receptor blockers.

Juli 2021: WHO empfiehlt Interleukin-6-Rezeptorblocker für Pts. mit schwere Erkrankung

Sarilumab (Kevzara)

See text above related to US COVID-19 Treatment Guidelines Panel and the WHO recommendations on tocilizumab.

vgl. Text zu Tocilizumab

Anakinra (Kineret)

On December 16, 2021, CHMP recommended adding the treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure (as determined by blood levels of a protein called suPAR, soluble urokinase plasminogen activator receptor, of at least 6 ng per ml), to its approved indications. Following evaluation by EMA, the EC authorised it use to treat COVID-19 on December 17, 2021.

Dez 2021: EMA Marktzulassung für Pts. mit Lungenentzündung und zusätzlichm Sauerstoffbedarf

Lopinavir + ritonavir, chloroquine and hydroxychloroquine

Lopinavir + ritonavir, chloroquine and hydroxychloroquine are **not effective** in treating COVID-19 patients.

keine Wirksamkeit

Favipiravir and Darunavir

The US COVID-19 Treatment Guidelines Panel **recommends against** using the **Lopinavir/ritonavir (AI)** or other **HIV protease inhibitors** for the treatment of COVID-19 in **hospitalised patients (AI)**.

US COVID-19 Treatment Guidelines Panel: Empfehlung GEGEN Behandlung mit:

They **recommends against** using the **Lopinavir/ritonavir (AI)** or other **HIV protease inhibitors** for the treatment of COVID-19 in **nonhospitalised patients (AIII)**.

Favipiravir, Darunavir

Ivermectin

Ivermectin

The US COVID-19 Treatment Guidelines Panel **recommends against** the use of ivermectin for the treatment of COVID-19, except in clinical trials (AIIa).

Colchicine

Colchicine

Canakinumab

The US COVID-19 Treatment Guidelines Panel based on negative results from RECOVERY trial **recommends against** the use of colchicine in **hospitalised patients (AI)**. The COVID-19 Treatment Guidelines Panel (the Panel) **recommends against** the use of **colchicine** for the treatment of **nonhospitalised patients** with COVID-19, except in a clinical trial (BIIa).

Interferone

Canakinumab

Aspirin

The US COVID-19 Treatment Guidelines Panel **recommends against** the use of **canakinumab** for the treatment of COVID-19, except in a clinical trial (BIIa).

Interferons

The **US COVID-19 Treatment Guidelines Panel recommends against** the use of **systemic interferon beta** for the treatment of hospitalised patients with COVID-19 (AI). The Panel **recommends against** the use of **interferon alfa** or **lambda** for the treatment of hospitalised patients with COVID-19, except in a clinical trial (AIIa). The Panel **recommends against** the use of **interferons** for the treatment of nonhospitalised patients with mild or moderate COVID-19, except in a clinical trial (AIIa).

Aspirin

The **US COVID-19 Treatment Guidelines Panel recommends against** the use of aspirin to prevent mortality or the need for organ support (AI).

Other pharmaceuticals listed in this document

Related to other pharmaceuticals listed in this document the **current evidence is uncertain or very uncertain** about their effect on different clinical outcomes in **COVID-19 patients**, or **not yet published in scientific journals** or **medicinal products are not yet in regulatory process**. Further RCTs are currently ongoing.

EMA is providing guidance to assist developers of potential COVID-19 medicines, to prepare for eventual applications for marketing authorisation. This includes scientific advice, as well as informal consultation with the COVID-19 EMA pandemic Task Force (COVID-ETF). The outcome of any consultation or advice from EMA is not binding on developers. COVID-19 medicines that have received EMA advice can be found at <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-research-development>.

**EMA scientific advice
für viele unterschiedliche
Medikamente**

3.2 Individual therapeutics

3.2.1 Remdesivir (Veklury®)

The reader is referred to the earlier version (V13_April and V18_October/November 2021) for more details on **remdesivir (Veklury)**.

On August 18, 2021 **EMA** published the clinical data supporting a **renewal** of the **conditional marketing authorisation** for Veklury (remdesivir). It is **indicated** for the treatment of coronavirus disease 2019 (**COVID-19**) in **adults and adolescents** (aged 12 years and older with body weight at least 40 kg) with **pneumonia requiring supplemental oxygen**. On **December 17, 2021** the **CHMP recommended extending the use** of remdesivir for the **treatment of adults who do not require supplemental oxygen** and who are at **increased risk of progressing to severe COVID-19** to its indication [9].

Details in V13_April

**Aug 2021: EMA-
Verlängerung der
konditionalen Zulassung
für Pts mit
Lungenentzündung und
zusätzlichem
Sauerstoffbedarf**

On **January 21, 2022** FDA has **expanded** the approved indication for Veklury to include its use in **adults and pediatric patients** (12 years of age and older who weigh at least 40 kilograms, which is about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, and who are **not hospitalised** and have **mild-to-moderate COVID-19**, and are at **high risk for progression to severe COVID-19, including hospitalisation or death** [10].

On **April 25, 2022** FDA **expanded** the **approval** of the COVID-19 treatment Veklury (remdesivir) to include **pediatric patients 28 days of age and older weighing at least 3 kilograms** (about 7 pounds) with positive results of direct SARS-CoV-2 viral testing, who are **hospitalised**, or **not hospitalised** and have **mild-to-moderate COVID-19** and are at **high risk for progression to severe COVID-19, including hospitalization or death**. Veklury becomes the first approved COVID-19 treatment for children less than 12 years of age [11].

The US COVID-19 Treatment Guidelines Panel (last update **May 13, 2022**)

This statement contains the Panel's recommendations for treating **nonhospitalised patients** using the currently available therapies. The Panel recommends one of the following [12]:

Preferred therapies (listed in order of preference):

- **Ritonavir-boosted nirmatrelvir (Paxlovid) (AIIa)**
- **Remdesivir (Veklury)(BIIa)**

Alternative therapies (for use **ONLY** if none of the preferred therapies are available, feasible to use, or clinically appropriate, listed in alphabetical order):

- **Bebtelovimab 175 mg (CIII); or**
- **Molnupiravir (Lagevrio) 800 mg (CIIa)**

The **WHO living guideline** (22 April 2022) provided **conditional recommendation** for the use of **remdesivir** in patients with **non-severe COVID-19** at the **highest risk of hospitalisation** [13].

Remdesivir in nonhospitalised patients

Gottlieb et al. 2021 published positive results from a randomized, double-blind, placebo-controlled trial (**PINETREE**, NCT04501952; EudraCT 2020-003510-12) involving **nonhospitalised patients** with Covid-19 who had symptom onset within the previous 7 days and who had at least one **risk factor for disease progression** (age ≥ 60 years, obesity, or certain coexisting medical conditions). Patients were randomly assigned to receive intravenous remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) or placebo. The primary efficacy end point was a composite of Covid-19-related hospitalisation or death from any cause by day 28. The primary safety end point was any adverse event. A secondary end point was a composite of a Covid-19-related medically attended visit or death from any cause by day 28. Among nonhospitalised patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalisation or death than placebo.

A total of 562 patients who underwent randomization and received at least one dose of remdesivir or placebo were included in the analyses: 279 patients in the remdesivir group and 283 in the placebo group. The most common coexisting conditions were diabetes mellitus (61.6%), obesity (55.2%), and hypertension (47.7%). Covid-19-related hospitalisation or death from any cause occurred in 2 patients (0.7%) in the remdesivir group and in 15 (5.3%) in the placebo group (hazard ratio, 0.13; 95% confidence interval [CI], 0.03

AIHTA | 2022

FDA Jän 2022:

Indikationsausweitung auch für nicht-hospitalisierte Pts. ohne Sauerstoffbedarf aber hohem Risiko, pädiatrische Pts.

US COVID-19 Treatment Guidelines Panel
Empfehlung für nicht-hospitalisierte Pts

präferiert:

Ritonavir-boosted nirmatrelvir (Paxlovid) und Remdesivir

Alternativen:

**Bebtelovimab
Molnupiravir**

PINETREE RCT

562 nicht-hospitalisierte Pts. mit Risiko zur Krankheits-Progression

Vorteil bei

Hospitalisierung/Tod oder Arztbesuchen

to 0.59; $p=0.008$). A total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a Covid-19–related medically attended visit by day 28 (hazard ratio, 0.19; 95% CI, 0.07 to 0.56). No patients had died by day 28. Adverse events occurred in 42.3% of the patients in the remdesivir group and in 46.3% of those in the placebo group [14].

Final results from the WHO Solidarity trial in hospitalised patients

WHO Solidarity Trial Consortium, 2022 published final results related to remdesivir treatment in hospitalised patients [15]. 8275 patients randomly allocated (1:1) either to remdesivir (ten daily infusions, unless discharged earlier) or to its control (allocated no study drug although remdesivir was locally available). Overall, 602 (14.5%) of 4146 patients assigned to remdesivir died versus 643 (15.6%) of 4129 assigned to control (mortality rate ratio [RR] 0.91 [95% CI 0.82–1.02], $p=0.12$). Of those already ventilated, 151 (42.1%) of 359 assigned to remdesivir died versus 134 (38.6%) of 347 assigned to control (RR 1.13 [0.89–1.42], $p=0.32$). Of those not ventilated but on oxygen, 14.6% assigned to remdesivir died versus 16.3% assigned to control (RR 0.87 [0.76–0.99], $p=0.03$). Of 1730 not on oxygen initially, 2.9% assigned to remdesivir died versus 3.8% assigned to control (RR 0.76 [0.46–1.28], $p=0.30$). Combining all those not ventilated initially, 11.9% assigned to remdesivir died versus 13.5% assigned to control (RR 0.86 [0.76–0.98], $p=0.02$) and 14.1% versus 15.7% progressed to ventilation (RR 0.88 [0.77–1.00], $p=0.04$). The non-prespecified composite outcome of death or progression to ventilation occurred in 19.6% assigned to remdesivir versus 22.5% assigned to control (RR 0.84 [0.75–0.93], $p=0.001$). Allocation to daily remdesivir infusions (vs open-label control) delayed discharge by about 1 day during the 10-day treatment period.

WHO Solidarity Trial:
8.275 Pts

Unterschiede bei
Mortalität:
14,5% vs. 15,6%

Mortalität unter bereits
künstlich Beatmeten:
42,1% vs. 38,6%

Mortalität unter nicht
künstlich Beatmeten:
14,6% vs. 16,3%

d.h. nur sehr kleine
Unterschiede

3.2.2 Lopinavir + Ritonavir (Kaletra®)

Due to the lack of effectiveness of lopinavir/ritonavir in treating adults hospitalised with COVID-19 patients and the decisions to stop enrolling participants to the lopinavir/ritonavir (Kaletra) arms of the RECOVERY, SOLIDARITY and DISCOVERY studies in adults hospitalized with COVID-19, our reporting related to lopinavir/ritonavir was stopped also.

wegen erwiesenem Mangel
an Wirksamkeit wurde
Beobachtung beendet

Last reporting V6/September 2020:

https://eprints.aihta.at/1234/50/Policy_Brief_002_Update_09.2020.pdf

3.2.3 Favipiravir (Avigan®)

The reader is referred to the earlier version (V15_June 2021) for more details on favipiravir treatment in hospitalised or nonhospitalised COVID-19 patients.

Beobachtung bis v15
(Juni)

The US COVID-19 Treatment Guidelines Panel (last update February 11, 2021) **recommends against** using the **Lopinavir/ritonavir (AI) or other HIV protease inhibitors** for the treatment of COVID-19 in **hospitalised patients (AI)**.

Empfehlungen des US
COVID-19 Treatment
Guidelines Panel GEGEN
jegliche HIV Protease
Inhibitoren

They **recommends against** using the **Lopinavir/ritonavir (AI) or other HIV protease inhibitors** for the treatment of COVID-19 in **nonhospitalised patients (AIII)** [12].

3.2.4 Darunavir

The reader is referred to the earlier version (V15_June 2021) for more details on darunavir treatment in hospitalised or nonhospitalised COVID-19 patients.

The US COVID-19 Treatment Guidelines Panel (last update February 11, 2021) **recommends against** using the **Lopinavir/ritonavir (AI) or other HIV protease inhibitors** for the treatment of COVID-19 in **hospitalised patients (AI)**.

They **recommends against** using the **Lopinavir/ritonavir (AI) or other HIV protease inhibitors** for the treatment of COVID-19 in **nonhospitalised patients (AIII)** [12].

Beobachtung bis v15 (Juni)

Empfehlungen des US COVID-19 Treatment Guidelines Panel GEGEN jegliche HIV Protease Inhibitoren

3.2.5 Chloroquine (Resochin®) and

3.2.6 Hydroxychloroquine (Plaquenil®)

Due to the lack of effectiveness of chloroquine and hydroxychloroquine in treating COVID-19 patients; in the light of serious adverse effects as well as the decisions to stop enrolling participants to the hydroxychloroquine arm of the RECOVERY and SOLIDARITY trials, the reporting related to these two pharmaceuticals was stopped also.

Last reporting V4/ July 2020:

https://eprints.aihta.at/1234/10/Policy_Brief_002_Update_07.2020.pdf

wegen erwiesenem Mangel an Wirksamkeit wurde Beobachtung beendet

3.2.7 Camostat Mesilate (Foipan®)

About the drug under consideration

Camostat Mesilate (Foipan®) is classified as a so-called serine protease inhibitor, blocking several pancreatic and plasmatic enzymes like trypsin, thrombin and plasmin [16]. Studies showed effects on the cell-entry mechanism of coronaviruses (e.g. SARS-CoV and SARS-CoV-2) in in-vitro human cells [17, 18] as well as in pathogenic mice-models [19] by inhibiting the enzyme Transmembrane protease, serine 2 (TMPRSS2).

Camostat Mesilate (Foipan®) ist not approved for any anti-viral use (FDA, EMA).

It is one of the drugs for which the German Federal Ministry of Health initiated centralized procurement in April 2020 for the treatment of infected and seriously ill COVID-19 patients in Germany (<https://www.abda.de>). Up to August 1, 2020, 35 to 60 Covid-19 patients have been treated with the

AIHTA | 2022

Protease-Inhibitor bei Entzündung der Bauchspeicheldrüse Zulassung: Japan, Südkorea

**nicht EMA, FDA
FDA: Orphan Drug
Designation seit 2011**

vom dt. BMG für schwere Erkrankungen zentral eingekauft

centrally procured medicinal product Foipan (Camostat) as part of an individual medical treatment. There was no obligation for the treating physicians to collect data in a registry [20].

Withdrawn, suspended or terminated studies

One withdrawn RCT was found (NCT04338906) related to combination therapy camostat + hydroxychloroquine because hydroxychloroquine not being standard of care anymore); no suspended or terminated studies were found in ClinicalTrials.gov and EUdRACT registers.

Results of publications

One scientific publication on a RCT of Camostat Mesilate (Foipan®) in **hospitalised** Covid-19 patients is currently identified. **Gunst et al. 2021** [21] published results from investigator-initiated, double-blind, randomized, placebo-controlled multicenter trial in patients hospitalised with confirmed SARS-CoV-2 infection (NCT04321096, EudRACT 2020-001200-42). Within 48 h of admission, 205 participants were randomly assigned in a 2:1 ratio to receive camostat mesilate 200 mg three times daily for 5 days or placebo. The primary outcome was time to discharge or clinical improvement measured as ≥ 2 points improvement on a 7-point ordinal scale. Other outcomes included 30-day mortality, safety and change in oropharyngeal viral load. 137 patients were assigned to receive camostat mesilate and 68 to placebo. Median time to clinical improvement was 5 days (interquartile range [IQR], 3 to 7) in the camostat group and 5 days (IQR, 2 to 10) in the placebo group ($p = 0.31$). The hazard ratio for 30-day mortality in the camostat compared with the placebo group was 0.82 (95% confidence interval [CI], 0.24 to 2.79; $p = 0.75$). The frequency of adverse events was similar in the two groups. Median change in viral load from baseline to day 5 in the camostat group was $-0.22 \log_{10}$ copies/mL ($p < 0.05$) and $-0.82 \log_{10}$ in the placebo group ($p < 0.05$).

One scientific publication on a RCT of Camostat Mesilate (Foipan®) in **non-hospitalised** Covid-19 patients is currently identified. **Chupp et al. 2022** [22] published as preprint results from phase 2, randomized double-blind, placebo-controlled trial in USA (NCT04353284). 70 **outpatients** were randomized to treatment of 7 days of oral camostat mesilate, 200 mg po four times a day, or placebo. The primary outcome was reduction of 4-day \log_{10} nasopharyngeal swab viral load by 0.5 \log_{10} compared to placebo. The main prespecified secondary outcome was reduction in symptom scores as measured by a quantitative Likert scale instrument, Flu-PRO-Plus modified to measure changes in smell/taste measured using FLUPRO-Plus. Participants receiving camostat had statistically significant lower quantitative symptom scores (FLU-Pro-Plus) at day 6, accelerated overall symptom resolution and notably improved taste/smell, and fatigue beginning at onset of intervention in the camostat mesilate group compared to placebo. Intention-to-treat analysis demonstrated that camostat mesilate was not associated with a reduction in 4-day \log_{10} NP viral load compared to placebo.

Kinoshita et al. 2022 [23] published as **preprint** negative results from RCT (CANDLE study) conducted in one-hundred and fifty-five **mild to moderate COVID-19 patients with or without symptoms**, in Japan. Camostat mesilate, administered at a dose of 600 mg qid for up to 14 days (a dose that was four to eight times higher than the clinical doses of camostat mesilate used in Japan for the acute symptoms of chronic pancreatitis and postoperative

in ClinicalTrials.gov and EUdRACT keine abgeschlossenen klinischen Studien registriert

1 Publikation zu RCT: kein Unterschied zwischen den Gruppen

Phase 2 RCT: 70 ambulante Pts.

kein Unterschied bei Viruslast (nach 4 Tagen)

CANDLE RCT (Japan) 155 Pts mild-moderat Erkrankte

kein Unterschied mit Placebo

reflux oesophagitis), was no more effective than placebo, based on upper airway viral clearance in patients with mild to moderate SARS-CoV-2 infection with or without symptoms. There were no differences between the study groups in terms of other efficacy endpoints. No additional safety concerns were identified beyond those already known for camostat mesilate.

On July 29, 2021 Manufacturer Daewoong Pharmaceutical Co., Ltd **announced** its **phase 2b** clinical trial results performed at 24 different clinical institutions in South Korea. Among 342 **mild COVID-19 patients**, 327 patients were administered with either camostat or a placebo. The primary endpoint aimed to assess the time taken to improve clinical symptoms with major secondary endpoints being treatment safety and rate of exacerbation. A total of seven clinical symptoms including fever, cough, shortness of breath, chills, muscle pain, headache, and sore throat were evaluated as modeled from various COVID-19 clinical trials. Symptoms were scored based on their severity (1-3) and was determined to be improved when a score of 0 (none) or 1 (mild) was reached and maintained for 24 hours. Concomitant uses of antipyretic analgesics were allowed for a conservative treatment. The analysis results demonstrated safety being confirmed in all patients receiving camostat. While varying medication adherence hindered statistical significant for the entire patient pool, a general trend of clinical symptom improvement was observed in the treatment group in seven days as opposed to eight days for the placebo group. None of the participants required advanced treatments including high-flow oxygen therapy. Among 175 medication-compliant patients (86 patients from the treatment group, 89 patients from the placebo group) who experienced at least one respiratory symptom indicative of exacerbation, statistically significant symptom improvement was observed on day 5 in the treatment group as opposed to the placebo group taking eight days to recover, suggesting a 40% faster recovery rate. A greater rate of 50% was reported to be statistically significant from seniors over the age of 50 who were at risk of developing severe COVID-19,

<https://www.biospace.com/article/releases/daewoong-pharmaceutical-announces-camostat-achieving-50-percent-faster-recovery-time-for-mild-covid-19-patients-over-age-of-50-in-topline-results-from-phase-2b-clinical-trial/>.

Hersteller
Kommunikation zu
klinischer Studie mit
342 mild erkrankten Pts.

raschere Gesundung
(-3 Tage)

3.2.8 APN01/ Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2)

Drug under consideration

APN01 (alunacedase alfa) is a recombinant human Angiotensin Converting Enzyme 2 (rhACE2) developed by Apeiron Biologics under Phase 2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension) [24], [25], [26].

The therapy with APN01 is currently not approved by the European Medicine Agency (EMA) and Food and Drug Administration (FDA) for COVID-19.

aus SARS-Forschung
hervorgegangen

keine Zulassung
1 Studie (Phase 2 RCT), vor
Rekrutierung

Withdrawn, suspended or terminated studies

One RCT number NCT04287686 is visible as withdrawn (without CDE Approval).

Results of publications

No relevant finished publications or finished trials assessing the efficacy and safety could be identified.

First results, related to a **phase 2/3 study** of hrsACE2 in 178 hospitalised patients with **severe COVID-19**, with primary composite outcome – All-cause mortality or invasive mechanical ventilation are recently announced (NCT04335136). Both groups, APN01 (n=88) and placebo (n=90), also additionally received standard of care (SOC). Patients received treatment for 7 days with follow-ups until day 28. The data showed that fewer patients treated with APN01 (n=9) died or received invasive ventilation compared to placebo (n=12), although statistical significance was not achieved due to the low total number of events. The data demonstrated a statistically significant improvement in mechanical ventilator-free days in alive patients and reduction in viral load in the group treated with APN01 compared to placebo. APN01 also demonstrated a positive impact on key biomarkers of the renin angiotensin system (RAS), demonstrating in vivo efficacy of the drug. Treatment with APN01 was safe and well tolerated and no drug-related severe adverse events were observed during the study.

In addition, APEIRON was invited to participate in the US **ACTIV-4d RAAS trial**, part of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), initiated and funded by the National Heart Lung and Blood Institute (NHLBI), part of the United States' National Institutes of Health (NIH). APN01 was prioritized for study by a broad panel of clinical trial experts through the Collaborative Network of Networks for Evaluating COVID19 Therapeutic Strategies (CONNECTS). The trial is anticipated to begin in Q2-2021, https://www.apeiron-biologics.com/wp-content/uploads/20210519_PR_APN01-development_ENG.pdf.

In parallel to the US clinical trial with APN01 as intravenous application, APEIRON is preparing a company-sponsored **phase 1** trial to evaluate drug delivery of APN01 through **inhalation** in order to target **all infected or at-risk patients earlier in the course of the disease**. Preliminary data from ongoing evaluations with inhalation of ACE2 based therapeutics show high efficacy in SARS-CoV-2 animal models. On October 12, 2021 APEIRON Biologics announced the start of this phase 1 trial: double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled APN01, https://www.apeiron-biologics.com/wp-content/uploads/20211012_APEIRON-Biologics_PR_Trial-Start-Inhalation-APN01_ENG.pdf.

3.2.9 Tocilizumab (Roactemra®)

The reader is referred to the earlier versions (V14_May 2021 and V18_October and November 2021) for more details on **tocilizumab (Roactemra)**.

in ClinicalTrials.gov and EUdraCT keine abgeschlossene, aber eine zurückgezogene Studie registriert

**Phase 2/3 RCT
178 Pt.
hospitalisiert,
schwere Erkrankung**

**besser bei
beatmungsfreien Tagen**

**APN01 in ACTIV-4
Plattform Studie
aufgenommen**

**Phase 1 Studie
Erprobung von APN01 als
Inhalation**

**Okt: Dosisfindungsstudie
40 Pts in Österreich**

Beobachtung bis v14 (Mai)

On 24 June 2021 FDA issued an **emergency use authorization (EUA)** for the drug Actemra (tocilizumab) for the treatment of **hospitalised adults and pediatric patients** (2 years of age and older) who are **receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)** [27] .

On December 6 2021, EMA's CHMP has **recommended extending of indication** of tocilizumab to include the **treatment of adults with COVID-19** who are **receiving systemic treatment with corticosteroids and require supplemental oxygen or mechanical ventilation**. Marketing authorisation is granted by EC on December 7, 2021 [28].

On July 6, 2021 the WHO recommends treatment with **IL-6 receptor blockers (tocilizumab or sarilumab)** for **patients with severe or critical COVID-19 infection (strong recommendation)**. Corticosteroids have previously been strongly recommended in patients with severe and critical COVID-19, and WHO recommends patients meeting these severity criteria should now receive both corticosteroids and IL-6 receptor blockers [29].

Juni 2021:
FDA EUA für
hospitalisierte Pts mit
nicht-invasiver Beatmung

Dez. 2021: EMA
Marktzulassung für Pts mit
Sauerstoff-/
Beatmungsbedarf

Juli 2021: WHO
Empfehlung Interleukin-
6-Rezeptorblocker für
schwer+ kritisch
Erkrankte

3.2.10 Sarilumab (Kevzara®)

Drug under consideration

Sarilumab (*Kevzara*) is a human monoclonal antibody that specifically binds to soluble and membrane-bound interleukin (IL)-6 receptors (IL-6R α), and inhibits IL-6-mediated signalling [30]. It is being investigated as a possible treatment for patients with moderate to severe or critical COVID-19. The therapy is currently not approved by the European Medicine Agency (EMA) and Food and Drug Administration (FDA) for COVID-19.

The **US COVID-19 Treatment Guidelines Panel** Statement (last update December 16, 2021) [169]: The Panel recommends **IV sarilumab** as an **alternative to IV tocilizumab only** when **IV tocilizumab is not available or not feasible to use**, in hospitalised patients who require supplemental oxygen, high-flow oxygen, noninvasive ventilation (NIV), or mechanical ventilation (**BIIa**).

On July 6, 2021 the WHO recommends treatment with **IL-6 receptor blockers (tocilizumab or sarilumab)** for **patients with severe or critical COVID-19 infection (strong recommendation)**. Corticosteroids have previously been strongly recommended in patients with severe and critical COVID-19, and WHO recommends patients meeting these severity criteria should now receive both corticosteroids and IL-6 receptor blockers [29].

The prospective and living network meta-analyses showed that in severely or critically ill patients, administering these drugs reduce the odds of death by 13%, compared to standard care: will be 15 fewer deaths per thousand patients, and as many as 28 fewer deaths for every thousand critically ill patients. The odds of mechanical ventilation among severe and critical patients are reduced by 28%, compared with standard care. This translates to 23 fewer patients out of a thousand needing mechanical ventilation [31].

Interleukin-6-
Rezeptorblocker

US COVID-19 Treatment
Guidelines Panel (Aug)
Sarilumab als Alternative
zu Tocilizumab

Juli 2021: WHO
Empfehlung Interleukin-
6-Rezeptorblocker für
schwer+ kritisch
Erkrankte

Network Metaanalyse
RR Tod -13%
RR künstliche Beatmung -
28%

Withdrawn, suspended or terminated studies

One RCT found as suspended, NCT04341870 - CORIMUNO-VIRO Trial (DSMB recommendation (futility)). One RCT found as terminated, NCT04322773 (TOCIVID) in Denmark, due to changed clinical conditions and too few patients available).

Results of publications

On July 03, 2020 in press release related to sarilumab RCT conducted in US, <https://www.clinicaltrialsarena.com/news/kevezara-us-covid19-trial-data/>, Sanofi and Regeneron Pharmaceuticals have reported that this phase III clinical trial of sarilumab, compared 400mg dose of the drug plus best supportive care to best supportive care alone, failed to meet its primary and key secondary endpoints in 194 **critically ill Covid-19 patients** who required mechanical ventilation in the US. In the primary analysis arm, adverse events were reported in 80% of patients treated with sarilumab and 77% of those on placebo. Serious adverse events in at least 3% of patients, more frequent among sarilumab patients, were multi-organ dysfunction syndrome and hypotension. Based on the data, the companies have halted this US-based trial, including a second cohort of patients who were on a higher 800mg dose of the drug. The trial being conducted outside of the US was continuing, in hospitalised patients with severe and critical Covid-19 using a different dosing regimen, with published **negative results** in March 2021 by **Lescure et al.** (NCT04327388, EudraCT 2020-001162-12)[32] 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), **sarilumab 200 mg** (n=159 [38%]), or **sarilumab 400 mg** (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12.0 days [95% CI 9.0 to 15.0]) and sarilumab 200 mg (10.0 days [9.0 to 12.0]; hazard ratio [HR] 1.03 [95% CI 0.75 to 1.40]; log-rank p=0.96) or sarilumab 400 mg (10.0 days [9.0 to 13.0]; HR 1.14 [95% CI 0.84 to 1.54]; log-rank p=0.34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference -1.7 [-9.3 to 5.8]; p=0.63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0.2 [-6.9 to 7.4]; p=0.85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8.9% [95% CI -7.7 to 25.5]; p=0.25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group.

As already described in Tocilizumab Section above, **Gordon et al. 2021 [33]**(REMAP-CAP, NCT02735707) published **preliminary report** as preprint, and then in scientific journal [34], with **positive results** related to IL-6 receptor antagonist, tocilizumab and sarilumab, to improve outcome, including survival, in **critical COVID-19 patients** who were randomised to receive either tocilizumab (8mg/kg) or **sarilumab (400mg)** or standard care (control). At the time of full analysis 353 patients had been assigned to tocilizumab, 48 to sarilumab and 402 to control. Median organ support-free days were 11 (IQR 0, 16) sarilumab and 0 (IQR -1, 15) for control. Relative to control, median adjusted odds ratio was 1.76 (95%CrI 1.17, 2.91) for sarilumab, compared with control. Hospital mortality was 22.2% (10/45) for sarilumab and 35.8% (142/397) for control. All secondary outcomes and

Juli 2020: Pressemeldung zu RCT mit 194 Pts

kein Unterschied mehr SAE in Sarilumab Gruppe

Publikation der Ergebnisse März 2021:

keine Unterschiede, negative Ergebnisse

REMAP-CAP Studienarm 48 Pts.

Vorteile bei Spitalmortalität, 90-Tages Überleben, Zeit bis zur Intensivmedizin Spitalsentlassung klinische Verbesserung

analyses supported efficacy of these IL-6 receptor antagonists. There were no serious adverse events in the sarilumab group.

Derde et al. 2021 published **final report** as **preprint** [35] from above mentioned **REMAP-CAP RCT (NCT02735707)**: Adult participants with **critical COVID-19** were randomized to receive **tocilizumab, sarilumab, anakinra, or standard care (control)**. In addition, a small group (n=21) of participants were randomized to interferon- β 1a. The primary outcome was an ordinal scale combining in-hospital mortality (assigned -1) and days free of organ support to day 21. The trial used a Bayesian statistical model with pre-defined triggers for superiority, equivalence or futility. Statistical triggers for equivalence between tocilizumab and sarilumab; and for inferiority of anakinra to the other active interventions were met at a planned adaptive analysis. Of the 2274 critically ill participants enrolled, 972 were assigned to tocilizumab, **485 to sarilumab 400 mg as a single intravenous infusion**, 378 to anakinra and **418 to control**. Median organ support-free days were 7 (interquartile range [IQR] -1, 16), 9 (IQR -1, 17), 0 (IQR -1, 15) and 0 (IQR -1, 15) for tocilizumab, sarilumab, anakinra and control, respectively. Median adjusted odds ratios were 1.46 (95%CrI 1.13, 1.87), 1.50 (95%CrI 1.13, 2.00), and 0.99 (95%CrI 0.74, 1.35) for tocilizumab, sarilumab and anakinra, yielding 99.8%, 99.8% and 46.6% posterior probabilities of superiority, respectively, compared to control. Median adjusted odds ratios for hospital survival were 1.42 (95%CrI 1.05, 1.93), 1.51 (95%CrI 1.06, 2.20) and 0.97 (95%CrI 0.66, 1.40) for tocilizumab, sarilumab and anakinra respectively, compared to control, yielding 98.8%, 98.8% and 43.6% posterior probabilities of superiority, respectively, compared to control. All treatments appeared safe. In critical COVID-19, tocilizumab and sarilumab are similarly effective at improving survival and reducing duration of organ support. Anakinra is not effective in this population.

Sivapalasingam et al. 2021 [36] published as **preprint** results from adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab **200 mg or 400 mg** in adults **hospitalised** with Covid-19 **requiring supplemental oxygen and/or assisted ventilation (NCT04315298)**. The **phase 3** primary analysis population (cohort 1) was patients with **critical Covid-19** receiving mechanical ventilation (MV) randomized to sarilumab 400 mg or placebo. The primary end point for phase 3 was the proportion of patients with ≥ 1 -point improvement in clinical status from baseline to day 22. 457 and 1365 patients were randomized and treated in phases 2 and 3, respectively. Among phase 3 critical patients receiving MV (n=289; 34.3% on corticosteroids), the proportion with ≥ 1 -point improvement in clinical status (alive not receiving MV) at day 22 was 43.2% in sarilumab 400 mg and 35.5% in placebo (risk difference [RD] +7.5%; 95% confidence interval [CI], -7.4 to 21.3; p=0.3261), representing a relative risk improvement of 21.7%. Day 29 all-cause mortality was 36.4% in sarilumab 400 mg versus 41.9% in placebo (RD -5.5%; 95% CI, -20.2 to 8.7; relative risk reduction 13.3%). In post hoc analyses pooling phase 2 and 3 critical patients receiving MV, the hazard ratio (HR) for death in sarilumab 400 mg compared with placebo was 0.76 (95% CI, 0.51 to 1.13) overall, improving to 0.49 (95% CI, 0.25 to 0.94) in patients receiving corticosteroids at baseline.

Plattform Studie:

REMAP-CAP

2.274 kritisch Erkrankte

**Tocilizumab & Sarilumab
gleichermaßen wirksam
bei Überleben und Dauer
der Unterstützung bei
Beatmung**

Phase 2/3 RCT

457 Pts phase 2

1.365 Pts Phase 3

**geringfügig bessere
Ergebnisse**

The **CORIMUNO-19 Collaborative group, 2021** [37] published negative results from multicentric, open-label, Bayesian randomised, adaptive, **phase 2/3** clinical trial **CORIMUNO-SARI-1 (NCT04324073)**, nested within the CORIMUNO-19 cohort, to test a superiority hypothesis. Patients 18 years or older **hospitalised** with COVID-19 in six French centres, **requiring at least 3L/min of oxygen but without ventilation assistance and a WHO Clinical Progression Scale [CPS] score of 5** were enrolled. 148 patients were randomly assigned (1:1) via a web-based system, according to a randomisation list stratified on centre and with blocks randomly selected among 2 and 4, to receive usual care plus 400 mg of sarilumab intravenously on day 1 and on day 3 if clinically indicated (sarilumab group, n=68) or usual care alone (usual care group, n=80). Primary outcomes were the proportion of patients with WHO-CPS scores greater than 5 on the 10-point scale on day 4 and survival without invasive or non-invasive ventilation at day 14. 18 (26%) of 68 patients in the sarilumab group had a WHO-CPS score greater than 5 at day 4 versus 20 (26%) of 76 in the usual care group (median posterior absolute risk difference 0.2%; 90% credible interval [CrI] -11.7 to 12.2), with a posterior probability of absolute risk difference greater than 0 of 48.9%. At day 14, 25 (37%) patients in the sarilumab and 26 (34%) patients in the usual care group needed ventilation or died, (median posterior hazard ratio [HR] 1.10; 90% CrI 0.69–1.74) with a posterior probability HR greater than 1 of 3.4%. Serious adverse events occurred in 27 (40%) patients in the sarilumab group and 28 (37%) patients in the usual care group (p=0.73). Sarilumab treatment did not improve early outcomes in patients with moderate-to-severe COVID-19 pneumonia.

Merchante et al. 2021 [38] published negative results from **phase 2**, open-label, RCT of hospitalised patients with COVID-19 pneumonia and interleukin (IL)-6 levels ≥ 40 pg/mL and/or D-dimer > 1500 ng/mL (**SARICOR, EudraCT 2020-001531-27; NCT04357860**). Participants were randomized (1:1:1) to receive SOC (control group), SOC plus a single subcutaneous dose of sarilumab 200 mg (Sarilumab-200) or SOC plus a single subcutaneous dose of sarilumab 400 mg (Sarilumab-400). The primary outcome variable was the development of acute respiratory distress syndrome (ARDS) requiring high-flow nasal oxygenation (HFNO), non-invasive mechanical ventilation (NIMV) or invasive mechanical ventilation (IMV) at day 28. One-hundred and fifteen participants (control group, n=39; Sarilumab-200, n=37; Sarilumab-400, n=39) were included. At randomization, 104 (90%) patients had supplemental oxygen and 103 (90%) received corticosteroids. Eleven (28%) patients in the control group, ten (27%) in Sarilumab-200 and five (13%) in Sarilumab-400 developed the primary outcome (hazard ratio [95% CI] of Sarilumab-400 vs control group: 0.41 [0.14–1.18]; p=0.09). Seven (6%) patients died: three in the control group and four in Sarilumab-200. There were no deaths in Sarilumab-400 (p=0.079, log-rank test for comparisons with the control group).

Sancho-Lopez et al. 2021 [39] published negative results from **phase 3**, RCT (**SARTRE, EudraCT 2020-002037-15**), in which 201 patients underwent randomization: 99 patients in the sarilumab group and 102 patients in the control group. The rate of patients progressing to severe respiratory failure (Brescia-COVID scale score C 3) up to day 15 was 16.16% in the Sarilumab group versus 15.69% in the control group (RR 1.03; 95% CI 0.48–2.20). No relevant safety issues were identified. Authors concluded that in hospitalised patients with Covid-19 pneumonia, who were under standard oxygen therapy and who presented analytical inflammatory parameters, an early therapeutic intervention with sarilumab plus standard of care (including

CORIMUNO-19
Phase 2/3
148 hospitalisierte Pts.

kein Unterschied
zwischen den Gruppen bei
Mortalität und
Nebenwirkungen

kein Vorteil von
Sarilumab

Phase 2 RCT
115 hospitalisierte Pts

kein Unterschied
zwischen den Gruppen bei
akutem Lungenversagen

kein Vorteil von
Sarilumab

SARTRE Phase 3 RCT
201 hospitalisierte Pts.

kein Unterschied
zwischen den Gruppen bei
akutem Lungenversagen

kein Vorteil von
Sarilumab

corticosteroids) was not shown to be more effective than current standard of care alone.

Branch-Elliman et al. 2022 [40] published negative results from pragmatic, embedded, adaptive trial to measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added to an evolving standard of care (SOC), for clinical management of inpatients with moderate to severe COVID-19 disease (**NCT04359901**).

Hospitalized patients with clinical criteria for moderate to severe COVID-19 but not requiring mechanical ventilation, and a diagnostic test positive for SARS-CoV-2 were randomized to sarilumab, 200 or 400 mg subcutaneous injection or standard of care (SOC). The primary outcome was intubation or death within 14 days of randomization. All data were extracted remotely from the electronic health record (EHR). Among 162 eligible patients, 53 consented, and 50 were evaluated for the primary endpoint of intubation or death. This occurred in 5/20 and 1/30 of participants in the sarilumab and SOC arms respectively, with the majority occurring in the initial 9 participants (3/4 in the sarilumab and 1/5 in the SOC) before the sarilumab dose was increased to 400 mg and before remdesivir and dexamethasone were widely adopted. After interim review, the unblinded Data Monitoring Committee recommended that the study be stopped due to concern for safety: a high probability that rates of intubation or death were higher with addition of sarilumab to SOC (92.6%), and a very low probability (3.4%) that sarilumab would be found to be superior.

Garcia-Vicuna et al. 2022 [41] published negative results from open label RCT (**SARCOVID, NCT04357808**) conducted in hospitalised moderate to severe COVID-19 patients in Spain. Participants were randomly assigned to receive sarilumab, a single 400 mg dose in two 200 mg subcutaneous injections, added to standard care or standard care, in a 2:1 proportion. Primary endpoints included 30-day mortality, mean change in clinical status at day 7 scored in a 7-category ordinal scale ranging from death (category 1) to discharge (category 7), and duration of hospitalisation. A total of 30 patients underwent randomization: 20 to sarilumab and 10 to standard care. At day 30, 2/20 (10%) patients died in the sarilumab arm vs. none (0/10) in standard care (Log HR 15.11, SE 22.64; $p = 0.54$). At day 7, no significant differences were observed in the median change in clinical status (2 [0–3]) vs. 3 [0–3], $p = 0.32$). Median time to discharge (days) was similar (7 [6–11] vs. 6 [4–12]; HR 0.65, SE 0.26; $p = 0.27$). No significant differences were detected in the rate of progression to invasive and noninvasive mechanical ventilation.

Summary of findings Table 3.2-1 related to RCTs mentioned above can be found below (last update 01/07/2022, https://covid-nma.com/living_data/index.php?allcomp#comparisons_div). In summary, evidence is uncertain or very uncertain about the effect of sarilumab on further outcomes: evidence is uncertain or very uncertain on sarilumab compared to standard care to All-cause mortality D28 (RR 1.06, 95% CI 0.86 to 1.30, 9 RCTs, very low certainty of evidence); as well as on outcome All-cause mortality D60 (RR 0.95, 95% CI 0.84 to 1.07, 6 RCTs, low certainty of evidence); evidence is uncertain or very uncertain on WHO progression score (level 7 or above) (RR 1.10, 95% CI 0.90 to 1.33, 5 RCTs, very low certainty of evidence), Clinical improvement D28 (RR 0.99, 95% CI 0.94 to 1.05, 7 RCTs, low certainty of evidence), AEs (RR 1.10, 95% CI 1.01 to 1.19, 5 RCTs, low certainty of evidence), and very uncertain on SAEs (RR 1.09,

Adaptive RCT
162 hospitalisierte Pts

kein Vorteil von
Sarilumab vs. SoC,
Nachteil:
Nebenwirkungen

SARCOVID
30 Pts (Spanien)

kein Unterschied

SoF von RCTs:
(sehr) unsichere Evidenz
zu Sarilumab zu allen
Endpunkten

95% CI 0.97 to 1.21, 6 RCTs, very low certainty of evidence), compared to standard care for hospitalised COVID-19 patients.

Table 3.2-1: Summary of findings table on Sarilumab compared to Standard Care for Hospitalised COVID-19

Sarilumab compared to Standard Care for Hospitalised COVID-19 (last update 01/07/2022), details on https://covid-nma.com/living_data/index.php?allcomp#comparisons_div

Patient or population: Hospitalised (Moderate/Severe/Critical COVID-19)

Setting: Worldwide

Intervention: Sarilumab

Comparison: Standard Care

Outcome	Anticipated absolute effects (95% CI) ^a		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with Standard treatment	Risk with Sarilumab				
All-cause mortality D28	224 per 1000	238 per 1000	RR: 1.06 (0.86 - 1.30)	3305 (9 RCTs) ^b	⊕○○○ VERY LOW ^h	Absolute effect (95% CI) 13 more per 1000 (from 31 fewer to 67 more)
All-cause mortality D60	294 per 1000	279 per 1000	RR: 0.95 (0.84 - 1.07)	3379 (6 RCTs) ^c	⊕⊕○○ LOW ⁱ	Absolute effect (95% CI) 15 fewer per 1000 (from 47 fewer to 21 more)
Clinical improvement D28	643 per 1000	637 per 1000	RR: 0.99 (0.94 - 1.05)	2425 (7 RCTs) ^d	⊕⊕○○ LOW ^j	Absolute effect (95% CI) 6 fewer per 1000 (from 39 fewer to 32 more)
WHO progression score (level 7 or above) D28	250 per 1000	275 per 1000	RR: 1.10 (0.90 - 1.33)	886 (5 RCTs) ^e	⊕○○○ VERY LOW ^k	Absolute effect (95% CI) 25 more per 1000 (from 25 fewer to 83 more)
Number of patients with any adverse event	491 per 1000	540 per 1000	RR: 1.10 (1.01 - 1.19)	2647 (5 RCTs) ^f	⊕⊕○○ LOW ^l	Absolute effect (95% CI) 49 more per 1000 (from 5 more to 93 more)
Number of patients with serious adverse events	243 per 1000	265 per 1000	RR: 1.09 (0.97 - 1.21)	2936 (6 RCTs) ^g	⊕○○○ VERY LOW ^m	Absolute effect (95% CI) 22 more per 1000 (from 7 fewer to 51 more)

CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect; **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Explanations: aThe risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI); b Sancho-Lopez A, 2021; Branch-Elliman W, 2022; Garcia-Vicuna R, 2022; Merchante N, 2021; Mariette X, 2021; Sivapalasingam S, 2021 (phase 2 and 3); Lescure FX, 2021; Hermine O, 2022; Gordon AC, 2021; c Garcia-Vicuna R, 2022; CORIMUNO-SARI-1, 2021; Sivapalasingam S, 2021 (phase 2 and 3) Lescure FX, 2021; Hermine O, 2022; Derde L, 2021; d Sancho-Lopez A, 2021; Brach Elliman W, 2022; Garcia-Vicuna R, 2022; Merchante N, 2021; Mariette X, 2021; ; Sivapalasingam S, 2022 (phase 2 and 3); Hermine O, 2022; e Sancho-Lopez A, 2021; Branch-Elliman W, 2022; Garcia-Vicuna R, 2022; Mariette X, 2021; Sivapalasingam S, 2022; f Sacho-Lopez A, 2021;Mariette X, 2021; Sivapalasingam S, 2021 (phase 2 and 3); Lescure FX, 2021; Hermine O, 2022; g Garcia-Vicuna R, 2022; CORIMUNO-SARI-1, 2021; Sivapalasingam S, 2021 (phase and 3); Lescure FX, 2021; Hermine O, 2022; Gordon AC, 2021; h Risk of bias: serious Imprecision: Very serious Imprecision downgraded by 2 level: due to wide confidence interval consistent with the possibility for benefit and the possibility for harm low number of participants; i Imprecision: Very seriousImprecision downgraded by 2 level: due to wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of; j Risk of bias: Serious Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviation from intended intervention, missing data, outcome measurement and selection of the reported results Imprecision: Serious due to low number of participants; k Risk of bias: serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants; l Risk of bias: Serious. Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, missing data, outcome measurement, and selection of reported results Imprecision: Serious due to low number of participants; m Risk of bias: Serious Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviation from intended intervention, missing data and outcome measurement Imprecision: Very serious Imprecision downgraded by 2 level: due to wide confidence interval consistent with the possibility for no effect and the possibility for harm and low number of participants.

3.2.11 Interferon beta 1a (SNG001) (Rebif®, Avonex®) and Interferon beta 1b (Betaferon®, Extavia®)

The reader is referred to the earlier version (V18_October and November 2021) for more details on **interferons**.

The **US COVID-19 Treatment Guidelines Panel** (last update December 16, 2021) [42] **recommends against** the use of **systemic interferon beta** for the treatment of **hospitalised patients** with COVID-19 (**AI**). The Panel **recommends against** the use of **interferon alfa** or **lambda** for the treatment of **hospitalised patients** with COVID-19, except in a clinical trial (**AIa**). The Panel **recommends against** the use of **interferons** for the treatment of **nonhospitalised patients** with mild or moderate COVID-19, except in a clinical trial (**AIa**).

Empfehlung des US COVID-19 Treatment Guidelines Panel GEGEN INF-Therapie, nur in klinischen Studien

3.2.12 Convalescent plasma (CVP) transfusion

The reader is referred to the earlier version (V15_June 2021) for more details on Convalescent plasma treatment in COVID-19 patients.

On August 23, 2020 the FDA issued an **emergency use authorization (EUA)** for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients [43]. On **February 4 2021**, FDA announced that this **EUA** is **being revised** to authorize **only the use of high titer COVID-19 convalescent plasma**, for the treatment of **hospitalized patients** with COVID-19, **early in the disease course** and those hospitalized with **impaired humoral immunity**. The use of low titer COVID-19 convalescent plasma is no longer authorized under this EUA. The **new EUA revision** in **December 2021** authorised the use of **high titer COVID-19 convalescent plasma only in outpatients or inpatients with COVID-19** who have **immunosuppressive disease** or who are **receiving immunosuppressive treatment** [44].

FDA im August 2020: Emergency UseAuthorization (EUA)

EUA Revision CVP nur mit hohem Titer und nur für immunsupprimierte Pts.

The **US COVID-19 Treatment Guidelines Panel** (last update April 29, 2022)

- **Recommends against** the use of COVID-19 convalescent plasma that was collected prior to the emergence of the Omicron variant for the treatment of COVID-19 (**AIID**).
- The Panel **recommends against** the use of CCP for the treatment of COVID-19 in hospitalized, immunocompetent patients (**AI**).
- There is insufficient evidence for the Panel to recommend either for or against the use of high-titer CCP that was collected after the emergence of Omicron for the treatment of immunocompromised patients and nonhospitalized, immunocompetent patients with COVID-19.

US NIH COVID-19 Treatment Guidelines und WHO:

April 2022 Empfehlung GEGEN CVP

Current WHO living guidance (last updated December 6, 2021) on convalescent plasma for COVID-19 has a **strong recommendations against** administering convalescent plasma for the **treatment of patients with non-severe COVID-19**. It recommends **against** administering convalescent plasma for the **treatment of patients with severe or critical COVID-19 except in the context of a clinical trial** [45].

3.2.13 Plasma derived medicinal products

Neutralizing monoclonal antibodies

As Marovich et al. 2020 [46] stated, **neutralizing monoclonal antibodies** to SARS-CoV-2 have the potential to be used for both prevention and treatment of infection. They can help to guide vaccine design and development as well. The main target of SARS-CoV-2 neutralizing monoclonal antibodies is the surface spike glycoprotein that mediates viral entry into host cells. Some products will include of a combination of 2 monoclonal antibodies targeting different sites on the spike protein. Due to long half-life of most monoclonal antibodies (approximately 3 weeks for IgG1), a single infusion should be sufficient. A potential limitation of monoclonal antibodies for treatment of COVID-19 is the unknown bioavailability of passively infused IgG in tissues affected by the disease, especially the lungs, which serve as a key target of SARS-CoV-2 infection. Due to the effect of viral diversity it will be important to monitor for the emergence of resistant viral mutations under selective pressure of monoclonal antibody treatment.

Possible disease enhancement include antibody-mediated enhancement of viral entry and replication in target cells (Fc-bearing monocytes or macrophages) and virus-antibody immune complexes and the associated cytokine release [46].

SARS-CoV-2 variants and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies

In laboratory studies, some SARS-CoV-2 variants that harbor certain mutations have markedly reduced susceptibility to a number of the authorized anti-SARS-CoV-2 mAbs. The clinical relevance of reduced in vitro susceptibility of select variants to anti-SARS-CoV-2 mAbs is under investigation.

In **November 2021**, the **Omicron (B.1.1.529) variant** was designated as the **new variant of concern (VOC)** and in January 2022 has become the dominant VOC globally: it includes numerous mutations in the spike protein. Omicron is comprised of several genetically related sublineages, including BA.1, BA.2 and BA.3 [47, 48]. Ongoing studies are evaluating the susceptibility of this VOC to the anti-SARS-CoV-2 mAbs. This variant is predicted to have **markedly reduced susceptibility to some anti-SARS-CoV-2 mAb products**, including **bamlanivimab plus etesevimab** and **casirivimab plus imdevimab**.

Sotrovimab has substantially **decreased in vitro activity against** the Omicron **BA.2 subvariant** that has recently become the dominant subvariant. Based on in vitro data, **bebtelovimab** is expected to have **activity against a broad range of SARS-CoV-2 variants**, including the **B.1.1.529 (Omicron) variant of concern (VOC)** and its **BA.1 and BA.2 sublineages**. The same is true for Omicron subvariants **BA.2.12.1** and **BA.4/BA.5 sublineages**.

Tixagevimab and cilgavimab in combination retained full to nearly full neutralisation activity against pseudovirus and/or live virus SARS-CoV-2 variant strains: VLPs pseudotyped with the spike of **Omicron BA.2.12.1**, **BA.3**, or **BA.4/BA.5** showed **5-fold, 16-fold, and 33- to 65-fold reductions** in neutralizing activity, respectively.

**neutralisierende
monoklonale Antikörper:
Prävention und
Behandlung**

**Halbwertszeit bis
3 Wochen von Vorteil**

**Nachteil: unbekannte
Bioverfügbarkeit der
infundierten Antikörper**

**Wirksamkeit von
Antikörper Therapien bei
Virus-Varianten:
Laborstudien**

**Omicron-Variante:
stark reduzierte
Wirksamkeit
bamlanivimab +
etesevimab und
casirivimab plus
imdevimab**

**reduzierte Wirksamkeit
gegen Omikron BA.2:
Sotrovimab
nicht so bei Bebtelovimab**

**Tixagevimab and
cilgavimab (Evusheld)**

These three new Omicron **sublineages BA.4, BA.5 and BA.2.12.1** have acquired a few additional mutations that may impact their characteristic: the number of cases and the number of countries reporting the detection of these three variants are rising [49]. As of June 29, 2022 the Omicron VOC remains the dominant variant circulating globally, accounting for 94% of sequences reported in the past 30 days. BA.5 and BA.4 lineages continue to rise in prevalence globally. Among Omicron sequences, as of epidemiological week 24 (13 to 19 June 2022) BA.2 represents 25%, while BA.2.12.1 represents 11%, BA.4 represents 12%, and BA.5 represents 43%. BA.4 and BA.5 have a constellation of genetic mutations that differ from BA.2, including a shared mutation at S:L452 which has been associated with higher transmissibility. In some countries, the rise in cases has also led to a surge in hospitalizations and ICU admissions; however, the current evidence available does not indicate a change in severity associated with any of the three Omicron descendent lineages BA.2.12.1, BA.4 and BA.5. [50, 51].

Ongoing population-based genomic surveillance of the types and proportions of circulating SARS-CoV-2 variants, as well as studies on the susceptibility of different variants to available anti-SARS-CoV-2 mAbs, will be important in defining the utility of specific mAbs in the future [52].

The US COVID-19 Treatment Guidelines Panel (last update **May 13, 2022**)

The effectiveness of the different anti-SARS-CoV-2 mAb therapies varies dramatically depending on the circulating variant, and the role of each anti-SARS-CoV-2 mAb in the treatment of COVID-19 remains fluid. The Panel recommends using **bebtelovimab** 175 mg intravenous (IV) injection in patients aged ≥ 12 years as an alternative therapy **ONLY** when ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir are not available, feasible to use, or clinically appropriate (**CIII**). Treatment should be initiated as soon as possible and within 7 days of symptom onset. Because the Omicron VOC has become the dominant variant in the United States, the Panel **recommends against** using **bamlanivimab** **plus etesevimab, casirivimab plus imdevimab, or sotrovimab** for the treatment of COVID-19 (**AIII**).

This statement contains the Panel's recommendations for treating **nonhospitalised patients** using the currently available therapies. The Panel recommends one of the following [12]:

Preferred therapies (listed in order of preference):

- Ritonavir-boosted **nirmatrelvir (Paxlovid)** (**AIIa**)
- **Remdesivir** (**BIIa**)

Alternative therapies (for use **ONLY** if none of the preferred therapies are available, feasible to use, or clinically appropriate, listed in alphabetical order):

- **Bebtelovimab 175 mg** (**CIII**); *or*
- **Molnupiravir 800 mg** (**CIIa**)

Omicron Subtypen BA.4, BA.5, BA.2.12.1

keine Anzeichen von veränderten Schweregraden

US COVID-19 Treatment Guidelines Panel Empfehlung (nach Präferenzen)

**Nirmatrelvir/ ritonavir
Remdesivir**

**(nur als) Alternativen:
Bebtelovimab
Molnupiravir**

Sotrovimab nur in Regionen, in denen Omicron BA.2 nicht dominant ist

3.2.13.1.1 REGN-COV2 - combination of two monoclonal antibodies casirivimab/imdevimab (REGN10933 and REGN10987, Ronapreve)

The reader is referred to the earlier version (V18_October and November 2021) for more details on **casirivimab and imdevimab combination (Ronapreve)**.

EMA-Marktzulassung im Nov 2021

Marketing authorisation for COVID-19 granted in EU on November 12, 2021.

In US, **FDA** stated that **due to the high frequency of the Omicron variant**, REGEN-COV is **not currently authorized** in any U.S. region. Therefore, REGEN-COV may not be administered for treatment or post-exposure prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency.

FDA: NICHT für Omikron zugelassen

RECOVERY Collaborative Group published results from the **RECOVERY trial** NCT04381936, ISRCTN 50189673) - a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. In **patients admitted to hospital** with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab **reduced 28-day mortality in patients who were seronegative** (and therefore had not mounted their own humoral immune response) **at baseline but not in those who were seropositive at baseline**. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio 0.79, 95% CI 0.69–0.91; p=0.0009). There were no deaths attributed to the treatment, or meaningful between-group differences in the pre-specified safety outcomes of cause-specific mortality, cardiac arrhythmia, thrombosis, or major bleeding events. Serious adverse reactions reported in seven (<1%) participants were believed by the local investigator to be related to treatment with casirivimab and imdevimab [53].

**RECOVERY
4.839 Pts.**

**Reduktion der 28-Tage
Mortalität nur bei sero-
negativen Pts.**

3.2.13.1.2 LY-CoV555 - neutralizing IgG1 monoclonal antibody (bamlanivimab) and LY-CoV016 - recombinant fully human monoclonal neutralizing antibody (etesevimab)

The reader is referred to the earlier version (V17_August and September 2021) for more details on **bamlanivimab and etesevimab**.

Verweis auf v17

Our reporting on bamlanivimab and etesevimab was stopped because on November 02, 2021 **EMA has ended the rolling review of bamlanivimab and etesevimab**, developed by Eli Lilly Netherlands BV, **after the company informed EMA that it was withdrawing from the process** [54].

**da Antrag auf
Marktzulassung
zurückgezogen wurde:
Ende des Monitoring hier**

3.2.13.1.4 AZD7442 - combination of two monoclonal antibodies (tixagevimab AZD8895 + cilgavimab AZD1061) - Evusheld

The reader is referred to the earlier version (V21_April and May 2022) for more details on **tixagevimab + cilgavimab** (Evusheld).

On **30 March 2022** the EC authorised Evusheld for the **pre-exposure prophylaxis** of COVID-19 in **adults and adolescents aged 12 years and older weighing at least 40 kg**.

In US, the FDA issued EUA for **emergency use** as **pre-exposure prophylaxis for prevention of COVID-19 in adults and pediatric individuals** (12 years of age and older weighing at least 40 kg), who **are not currently infected with SARS-CoV-2** and who **have not had a known recent exposure** to an individual infected with SARS-CoV-2 and who **have moderate to severe immune compromise** due to a medical condition or receipt of immunosuppressive medications or treatments and **may not mount an adequate immune response to COVID-19 vaccination or for whom vaccination with any available COVID-19 vaccine**, according to the approved or authorized schedule, is **not recommended due to a history of severe adverse reaction** (e.g., severe allergic reaction) to a **COVID-19 vaccine(s) and/or COVID-19 vaccine component(s)**. Evusheld is not authorized for individuals for the treatment of COVID-19 or for post-exposure prevention of COVID-19 [55]. In FDA **revised EUA** from **June 2022** [56] related to repeat dose: 300 mg of tixagevimab and 300 mg of cilgavimab every 6 months. Repeat dosing should be timed from the date of the most recent Evusheld dose.

The **neutralizing activity** of tixagevimab and cilgavimab in combination was tested against pseudotyped VLPs and/or authentic **SARS-CoV-2 variant** strains harboring all spike substitutions.

Tixagevimab and cilgavimab in combination retained full to nearly full neutralisation activity against pseudovirus and/or live virus SARS-CoV-2 variant strains harbouring all spike substitutions identified in Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) Delta (B.1.617.2) and Delta [+K417N] (AY.1/AY.2), and Omicron (BA.2) variants of concern. Pseudotyped VLPs expressing spike protein and authentic SARS-CoV-2 Omicron BA.1 variant (B.1.1.529) and Omicron BA.1.1 (B.1.1.529 [+R346K]) showed reduced susceptibility to tixagevimab and cilgavimab in combination (132 to 183-fold and 424-fold respectively). VLPs pseudotyped with the spike of Omicron BA.2.12.1, BA.3, or BA.4/BA.5 showed 5-fold, 16-fold, and 33- to 65-fold reductions in neutralizing activity, respectively [56].

US COVID-19 Treatment Guidelines (last update **April 29, 2022**)

AZD7442 Kombination aus 2 monoklonalen Antikörpern
Vanderbilt University/ AstraZeneca – Evusheld

März 2022: EMA Zulassung für Prä-Expositionsprophylaxe

Wirksamkeit gegen Virus-Varianten

AZD7442 Kombinationstherapie:

reduzierte Wirksamkeit nur bei Omikron BA.1 und BA.1.1

- The Panel recommends using **tixagevimab 300 mg plus cilgavimab 300 mg** administered as 2 consecutive 3-mL intramuscular injections (**BIII**) as SARS-CoV-2 **pre-exposure prophylaxis (PrEP)** for adults and adolescents (aged ≥ 12 years and weighing ≥ 40 kg) who do not have SARS-CoV-2 infection, who have not been recently exposed to an individual with SARS-CoV-2 infection, **AND** who: Are moderately to severely immunocompromised and may have an inadequate immune response to COVID-19 vaccination *or* Are not able to be fully vaccinated with any available COVID-19 vaccines due to a documented history of severe reactions to a COVID-19 vaccine or any of its components
- The FDA Emergency Use Authorization states that individuals who received tixagevimab 150 mg plus cilgavimab 150 mg should be given a second dose as soon as possible. The specific dose of tixagevimab plus cilgavimab that an individual should receive depends on the amount of time that has passed since the first dose was administered: If the initial dose was administered ≤ 3 months prior, the second dose should be tixagevimab 150 mg plus cilgavimab 150 mg. If the initial dose was administered > 3 months prior, the second dose should be tixagevimab 300 mg plus cilgavimab 300 mg.
- **Tixagevimab plus cilgavimab is not a substitute for COVID-19 vaccination and should not be used in unvaccinated individuals for whom COVID-19 vaccination is recommended and who are anticipated to have an adequate response.**
- If supplies of tixagevimab plus cilgavimab are limited, priority for use as PrEP should be given to those who are at the highest risk for severe COVID-19.

The Panel **recommends against** the use of **bamlanivimab plus etesevimab** and **casirivimab plus imdevimab** for post-exposure prophylaxis (PEP), as the B.1.1.529 (**Omicron**) variant and **its subvariants**, which are not susceptible to these agents, are currently the predominant variant circulating in the United States (**AIII**) [12].

Results of publications

In addition to one publication from RCTs related to AZD7442 (**PROVENT** - NCT04625725, **phase 3** trial, in **pre-exposure prophylaxis**), there is one new publication from **phase 3** RCTs related to AZD7442 (**TACKLE** RCT, NCT04723394, for **early outpatient treatment**).

The results from **TACKLE** trial are now published by **Montgomery et al. 2022** [57]. **TACKLE** is an ongoing, randomised, double-blind, phase 3 placebo-controlled study conducted at 95 sites in the USA, Latin America, Europe, and Japan. Eligible participants were **non-hospitalised adults** aged 18 years or older with a laboratory-confirmed SARS-CoV-2 infection (determined by RT-PCR or an antigen test) from any respiratory tract specimen collected 3 days or less before enrolment and who had not received a COVID-19 vaccination. A WHO Clinical Progression Scale score from more than 1 to less than 4 was required for inclusion and participants had to receive the study drug 7 days or less from self-reported onset of mild to moderate COVID-19 symptoms or measured fever. Participants were randomly assigned (1:1) to receive either a single tixagevimab–cilgavimab 600 mg dose (two consecutive 3 mL intramuscular injections, one each of 300 mg tixagevimab and 300 mg cilgavimab) or placebo. 1014 participants

US COVID-19 Treatment Guidelines:

Empfehlung für Pre-Exposur Prophylaxe Immunschwache und nicht vollständig Geimpfte

FDA EUA: baldige Verabreichung einer 2. Dosis

KEIN Ersatz für Impfung !

2 RCTs: PROVENT zur Prä-Expositionsprophylaxe

TACKLE zur frühen ambulanten Behandlung

1.014 Pts (USA, Europa) ARR 4,5%

1/3 in beiden Gruppen hat Nebenwirkungen

were enrolled, of whom 910 were randomly assigned to a treatment group (456 to receive tixagevimab–cilgavimab and 454 to receive placebo). The mean age of participants was 46.1 years (SD 15.2). Severe COVID-19 or death occurred in 18 (4%) of 407 participants in the tixagevimab–cilgavimab group versus 37 (9%) of 415 participants in the placebo group (relative risk reduction 50.5% [95% CI 14.6–71.3]; $p=0.0096$). The absolute risk reduction was 4.5% (95% CI 1.1–8.0; $p<0.0001$). Adverse events occurred in 132 (29%) of 452 participants in the tixagevimab–cilgavimab group and 163 (36%) of 451 participants in the placebo group, and were mostly of mild or moderate severity. There were three COVID-19-reported deaths in the tixagevimab–cilgavimab group and six in the placebo group.

The AZD7442 was well tolerated in both above mentioned trials.

3.2.13.2 Sotrovimab (VIR-7831 monoclonal antibody, Xevudy)

The reader is referred to the earlier version (V19_December 2021/January 2022) for more details on **sotrovimab (Xevudy)**.

Marketing authorisation in EU is granted by EC on 17 December 2021.

On **April 05, 2022 FDA** announced that sotrovimab is **no longer authorized** to treat COVID-19 in any U.S. region **due to increases** in the proportion of COVID-19 cases caused by the **Omicron BA.2 sub-variant** [58].

The **WHO living guideline** (14 January 2022) provided **conditional recommendation** to **use** sotrovimab for treating **mild or moderate COVID-19** in patients who are at **high risk of hospitalisation**. This includes patients who are older, immunocompromised, having underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated [13].

**Verweis auf v19
monoklonaler Antikörper
EMA-Zulassung:
Dez 2021
FDA April 2022: nicht
mehr zugelassen bei
Omicron**

**WHO: vorläufige
Empfehlung**

3.2.13.3 Regdanvimab (CT-P59, Regkirona)

The reader is referred to the earlier version (V18_October and November 2021) for more details on **regdanvimab (Regkirona)**.

Marketing authorisation for COVID-19 granted **in EU** on **November 12, 2021**.

**monoklonaler Antikörper
Veweis auf v18**

3.2.13.4 Bebtelovimab

Bebtelovimab, manufactured by Eli Lilly and Company, is a recombinant neutralizing human IgG1κ monoclonal antibody (mAb) to the spike protein of SARS-CoV-2 and is unmodified in the Fc region. Bebtelovimab binds the spike protein with a dissociation constant $K_D = 0.046$ to 0.075 nM and blocks spike protein attachment to the human ACE2 receptor with an IC_{50} value of 0.39 nM (0.056 mcg/mL).

On **February 11, 2022** the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of bebtelovimab for the treatment of **mild-to-moderate coronavirus disease 2019 (COVID-19)** in **adults and pediatric patients (12 years of age and older weighing at least 40 kg)**: with **positive results of direct SARS-CoV-2 viral testing**, and who are at **high risk for progression to severe COVID-19, including hospitalization or death**, and for whom **alternative COVID-19 treatment options approved or authorized by FDA are not accessible or**

monoklonaler Antikörper

**Feb 2022:
FDA: EUA für mild-
moderat Erkrankte mit
hohem Risiko für
Progression**

bislang keine Resistenzen

clinically appropriate. Bebtelovimab (175 mg) must be administered as a single intravenous injection [59].

Bebtelovimab is currently authorized in all U.S. regions until further notice by the Agency.

In revised June 2022 EUA, bebtelovimab retains activity to Omicron subvariants BA.2.12.1 and BA.4/BA.5 [60].

Pseudotyped VLP assessment using the full-length spike genes from different variant lineages indicate that bebtelovimab retains activity (<5-fold reduction) against the Alpha (B.1.1.7, UK origin), Beta (B.1.351, South Africa origin), Gamma (P.1, Brazil origin), Delta (B.1.617.2, India origin), Delta [+K417N] (AY.1/AY.2, India origin), Epsilon (B.1.427/B.1.429, California origin), Iota (B.1.526, New York origin), Kappa (B.1.617.1, India origin), Lambda (C.37, Peru origin), Omicron (B.1.1.529/BA.1, South Africa origin), Omicron [+R346K] (BA.1.1), and Omicron BA.2 variant lineages, BA.2.12.1 as well as BA.4 and BA.5 [60]. The Mu (B.1.621, Colombia origin) variant showed a reduction in susceptibility to bebtelovimab of 5.3-fold (Table 3.2-2.)

Wirksamkeit bei unterschiedlichen Virus-Varianten

wirksam bei Omicron

Table 3.2-2: Bebtelovimab Pseudotyped Virus-Like Particle Neutralization Data for SARS-CoV-2 Spike Protein Variants

Lineage with Spike Protein Substitution	Key substitutions tested	Fold reduction in susceptibility
Alpha - B.1.1.7 (UK origin)	N501Y	No change
Beta - B.1.351 (South Africa origin)	K417N, E484K, N501Y	No change
Gamma - P.1 (Brazil origin)	K417T + E484K + N501Y	No change
Delta - B.1.617.2/AY.3	L452R+T478K	No change
Delta plus - AY.1/AY.2f	K417N+L452R+T478K	No change
Epsilon - B.1.427/B.1.429 (California origin)	L452R	No change
Iota - B.1.526 (New York origin)	E484K	No change
Kappa/no designation - B.1.617.1/B.1.617.3 (India)	L452R+E484Q	No change
Lambda - C.37 (Peru)	L452Q, F490S	No change
Mu - B.1.621 (Colombia)	R346K, E484K, N501Y	5.3
Omicron - B.1.1.529/BA.1 (South Africa)	G339D+S371L+S373P+S375F+K417N+N440K+G446S+S477N+T478K+E484A+Q493R+G496S+Q489R+N501Y+Y505H	No change
Omicron - BA.1.1 (South Africa)	G339D+R346K+S371L+S373P+S375F+K417N+N440K+G446S+S477N+T478K+E484A+Q493R+G496S+Q498R+N501Y+Y505H	No change
Omicron - BA.2 (South Africa)	G339D+S371F+S373P+S375F+T376A+D405N+R408S+K417N+N440K+S477N+T478K+E484A+Q493R+Q498R+N501Y+Y505H	No change
Omicron - BA.2.12.1 (USA)	BA.2 + L452Q	No change
Omicron - BA.4/BA.5 (South Africa)	G339D+S371F+S373P+S375F+T376A+D405N+R408S+K417N+N440K+L452R+S477N+T478K+E484A+F486V+Q498R+N501Y+Y505H	No change

No change: <5-fold reduction in susceptibility; Source: [59] [60]

The US COVID-19 Treatment Guidelines Panel of nonhospitalised patients (last update May 13, 2022)

The Panel recommends one of the following [12]:

Preferred therapies (listed in order of preference):

- **Ritonavir-boosted nirmatrelvir (Paxlovid) (AIIa)**
- **Remdesivir (BIIa)**

Alternative therapies (for use ONLY if none of the preferred therapies are available, feasible to use, or clinically appropriate, listed in alphabetical order):

- **Bebtelovimab 175 mg (CIII); or**
- **Molnupiravir 800 mg (CIIa)**

Results of publications

There is one publication-from a RCT-related to bebtelovimab (as preprint).

According to FDA, the data supporting above mentioned EUA for treatment of mild-to-moderate COVID-19 are primarily based on analyses of data from the **phase 2 portion** of the **BLAZE-4 trial (NCT04634409)** that **enrolled both low risk and high risk subjects**. This trial, now published as preprint by **Dougan et al. 2022 [61]** evaluated the clinical efficacy data from subjects receiving **175 mg bebtelovimab alone and together with 700 mg bamlanivimab and 1,400 mg of etesevimab**. BLAZE-4 is a phase 1/2, randomized, single-dose clinical trial evaluating treatment of subjects with mild-to-moderate COVID-19 (subjects with COVID-19 symptoms who are not hospitalized). Efficacy of bebtelovimab (BEB), alone and together with bamlanivimab and etesevimab (BAM+ETE), was evaluated in low risk adults (i.e., those not at high-risk to progress to severe COVID-19) in a randomized part of the trial which included a placebo control arm. Low risk adults were randomized with a 1:1:1 ratio. High-risk adults and pediatric subjects (12 years of age and older weighing at least 40 kg) received open-label active treatments. One cohort of high risk subjects was randomized with 2:1 ratio. Another cohort of high risk subject was enrolled with no randomization. The trial enrolled subjects who were not hospitalized and had 1 or more COVID19 symptoms that were at least mild in severity. Treatment was initiated within 3 days of obtaining the clinical sample for the first positive SARS-CoV-2 viral infection determination. BLAZE-4 was conducted prior to the emergence of the Omicron variant. No subject in BLAZE-4 was infected with virus of the Omicron lineage or sub-lineages. The majority of participants in the trial were infected with Delta (49.8%) and Alpha (28.6%). The placebo-controlled portion of the trial enrolled 380 low-risk patients (i.e., patients without risk factors for progression to severe COVID-19 illness). Patients in this part of the trial were randomized to receive a single infusion of bebtelovimab alone, bebtelovimab with other monoclonal antibodies or a placebo. Treatment with bebtelovimab resulted in a reduction in time to sustained symptom resolution compared to placebo. Reduction in viral load relative to placebo was also seen on Day 5 after treatment.

US COVID-19 Treatment Guidelines Panel Empfehlungen

Bebtelovimab nur, wenn keine Alternative

1 Publikation

laut FDA basiert EUA auf Phase 2 Auswertungen von BLAZE-4

nicht-hospitalisierte Pts.,mild erkrankt (ohne Risiko für Progression) sowie Hoch-risiko Pts.

Pts mit Delta + Alpha erkrankt, nicht Omikron

In another part of the trial involving mostly **high-risk individuals** (i.e. patients with risk factors for progression to severe COVID-19 illness), **150 patients** were randomized to receive a single infusion of bebtelovimab alone or a single infusion of bebtelovimab with other monoclonal antibodies. An **additional 176 high-risk patients received bebtelovimab with other monoclonal antibodies in an open-label treatment arm**. Viral load-area under the curve analysis from baseline to Day 11 showed statistically significant reductions for patients treated with BEB ($p=0.006$) and BEB+BAM+ETE ($p=0.043$) compared to patients who received placebo. Time to sustained symptom resolution was reduced by a median of 2 days for patients treated with BEB (6 days; $p=0.003$) and 1 day for patients treated with BEB+BAM+ETE (7 days; $p=0.289$) compared to placebo (8 days). The rates of COVID-19 related hospitalization and death through Day 29 seen in those who received bebtelovimab alone or with other monoclonal antibodies were generally lower than the placebo rate reported in prior trials of other monoclonal antibodies in high risk patients.

Conclusions are limited as these data are from different trials that were conducted when different viral variants were circulating and baseline risk factors varied. Clinical data were similar for bebtelovimab alone as compared to the combination of bebtelovimab with other monoclonal antibodies.

Possible **side effects** of bebtelovimab include itching, rash, infusion-related reactions, nausea and vomiting. Serious and unexpected adverse events including hypersensitivity, anaphylaxis and infusion-related reactions have been observed with other SARS-CoV2 monoclonal antibodies and could occur with bebtelovimab. In addition, clinical worsening following administration of other SARS-CoV-2 monoclonal antibody treatment has been reported and therefore is possible with bebtelovimab. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19 [59, 62].

weitere Teilstudie mit 176 Pts.

Beb Kombinationstherapie

Schlussfolgerungen sind begrenzt, da Ergebnisse aus verschiedenen Studien stammen und Pts unterschiedliche Virus-Varianten hatten

auch die Daten zu Nebenwirkungen sind mehr Annahmen als Fakten

3.2.14 Combination therapy – triple combination of interferon beta-1b, lopinavir–ritonavir and ribavirin vs. lopinavir–ritonavir or other triple combination of interferons

The reader is referred to the earlier version (V13_April) for more details on **Combination therapy** related to **interferon beta-1b, lopinavir and ribavirin or other triple combination of interferons**.

Details in v13_April

3.2.15 Solnatide

About the treatment under consideration

The therapeutic molecule solnatide (INN) has been designed by APEPTICO (a privately-held biotechnology company from Vienna/Austria) for the therapeutic treatment of patients with Acute Respiratory Distress Syndrome (ARDS) and various forms of life-threatening Pulmonary Oedema (PPO). Solnatide is a synthetic peptide of less than 20 amino acids applied directly in the lower airways in the form of a liquid aerosol, aims to accelerate the

Medikament gegen akutes Atemnotsyndrom

Verabreichung: Inhalation

dissolution of alveolar oedema and reduce barrier damage caused by Covid-19 in the lungs.

In April 2020, solnatide has been approved for Compassionate Use by the Austrian Federal Office for Safety in Health Care (BASG) for the treatment of patients infected by the novel coronavirus SARS-CoV-2 and subsequently developing severe pulmonary dysfunction (severe COVID-19), as well as by the Italian Medicines Agency and the Ethics Committee of the National Institute for Infectious Diseases (Lazzaro Spallanzani-Rome), within the compassionate use program of drugs undergoing clinical trials for the treatment of COVID-19 patients suffering from pulmonary oedema and acute respiratory distress syndrome.

APEPTICO Forschung und Entwicklung GmbH has signed, together with the “solnatide consortium”, the Grant Agreement ID: 101003595 with the European Commission to accelerate the process of making APEPTICO’s proprietary investigational medicinal product (IMP) solnatide available for medical treatment of patients severely affected by the novel coronavirus 2019 (SARS-CoV-2) disease, COVID-19; the Grant Agreement was made available via the Horizon2020 programme “Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic” (https://ec.europa.eu/commission/presscorner/detail/en/ip_20_386). Project started on 1 April 2020 and will end on 31 December 2021. The main goal of the H2020 SOLNATIDE project is to demonstrate safety, tolerability and clinical efficacy of solnatide in treatment of COVID-19 patients.

One ongoing randomised, double-blind, placebo controlled, parallel assignment trial with aim to assess efficacy and safety of 7 days orally inhaled 100 mg solnatide to treat pulmonary permeability oedema of 40 SARS-Cov-2 positive patients with moderate-to-severe ARDS is registered in EUdRACT register (EudraCT number 2020-001244-26), <https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001244-26/AT> [63].

On **May 30, 2022** APEPTICO Forschung und Entwicklung GmbH **announced** that the **mechanism of action of solnatide**, a possible treatment for pulmonary oedema, has been disclosed by an international network of scientists from Austria, Spain and the United States. The collaborators propose a model to describe how the solnatide peptide may interact with the cytoplasmic C-terminal domain of the ENaC- α subunit via electrostatic complementarity. The sodium channel ENaC is responsible for the removal of pulmonary liquid in life-threatening conditions such as COVID19-associated and non-COVID ARDS, file:///C:/Users/mirja/OneDrive/Radna%20povr%C5%A1ina/MH%20for%20AIHTA_2022/MH%20for%20AIHTA_June%20July%202022/Press%20Release%20APEPTICO_2022-05-30.pdf

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies related to solnatide in COVID-19 patients were found in ClinicalTrials.gov and EUdRACT registers [63].

Results of publications

No publications related to the RCTs of solnatide in COVID-19 patients were found [63].

April: BASG, AIFA lassen Solnatide für “Compassionate Use” zu

EC-Grant seit April für Covid-19 bis Dezember 2021

1 laufender RCT mit 40 moderat bis schwer Covid-19 Erkrankten

Pressemeldung, dass Wirkmechanismus erkannt wurde

ClinicalTrials.gov & EUdRACT: keine klinischen Studien registriert,

keine Publikation von RCT

3.2.16 Umifenovir (Arbidol®)

The reader is referred to the earlier version (V17_August and September 2021) for more details on **umifenovir (Arbidol)**.

Verweis auf v17

3.2.17 Dexamethasone and other corticosteroids

The reader is referred to the earlier version (V13_April) for more details on **dexamethasone and other systemic corticosteroids** (except for inhaled corticosteroids).

Details in v13

3.2.17.1 Inhaled corticosteroids: Budesonide

About the drug under consideration

Budesonide is a type of medicine known as a steroid (also called a corticosteroid). Inhaled budesonide is a medicine used for asthma and chronic obstructive pulmonary disease (COPD).

Budesonid: Glucocorticoid zum Inhalieren bei COPD

On May 27, 2021 **EMA** issued **advice to healthcare professionals** that there is currently **insufficient evidence** that inhaled corticosteroids are beneficial for people with COVID-19 [64].

EMA: insuffiziente Datenlage

The US COVID-19 Treatment Guidelines Panel (last update **December 16, 2021**)

US COVID-19 Treatment Guidelines Panel: insuffiziente Evidenz für nicht-hospitalisierte und für hospitalisierte Pts

For **nonhospitalised** patients with COVID-19: there is **insufficient evidence** for the Panel to recommend **either for or against** the use of **inhaled corticosteroids** for the treatment of COVID-19. For **hospitalised** patients with COVID-19: there is **insufficient evidence** for the Panel to recommend **either for or against** the use of **inhaled corticosteroids** for the treatment of COVID-19 [12].

Results of publications

On April 9th the results of an open-label, parallel-group, phase 2, randomised controlled trial (Steroids in COVID-19; **STOIC**, NCT04416399) of inhaled budesonide, compared with usual care, in adults within 7 days of the onset of **mild COVID-19** symptoms was published [65]. From July 16 to Dec 9, 2020, 146 participants were randomly assigned—73 to usual care and 73 to budesonide. The number needed to treat with inhaled budesonide to reduce COVID-19 deterioration was eight. Clinical recovery was 1 day shorter in the budesonide group compared with the usual care group (median 7 days [95% CI 6 to 9] in the budesonide group vs 8 days [7 to 11] in the usual care group; log-rank test $p=0.007$). The mean proportion of days with a fever in the first 14 days was lower in the budesonide group (2%, SD 6) than the usual care group (8%, SD 18; Wilcoxon test $p=0.051$) and the proportion of participants with at least 1 day of fever was lower in the budesonide group when compared with the usual care group. As-needed antipyretic medication was required for fewer proportion of days in the budesonide group compared with the usual care group (27% [IQR 0–50] vs 50% [15–71]; $p=0.025$) Fewer participants randomly assigned to budesonide had persistent symptoms at days 14 and 28 compared with participants

**Phase 2 RCT (STOIC)
167 Pts.
milde Erkrankung**

**NNT 8
-1 Tag weniger lang krank**

**weniger andauerende
Symptome unter
Budesonid**

receiving usual care (difference in proportions 0.204, 95% CI 0.075 to 0.334; $p=0.003$). Budesonide was safe, with only five (7%) participants reporting self-limiting adverse events.

On April 12th a pre-print of an interim analyses from the **PRINCIPLE** trial (ISRCTN86534580) was published [66]. On August 10, 2021 results are published in scientific article [67]. PRINCIPLE is a multicentre, open-label, multi-arm, randomised, controlled, adaptive platform trial done remotely from a central trial site and at primary care centres in the UK. Eligible participants in **outpatient setting** were aged 65 years or older or 50 years or older with comorbidities, and unwell for up to 14 days with suspected COVID-19 but not admitted to hospital. Participants were randomly assigned to usual care, usual care plus inhaled budesonide (800 µg twice daily for 14 days), or usual care plus other interventions, and followed up for 28 days. Participants were aware of group assignment. The coprimary endpoints are time to first self-reported recovery and hospital admission or death related to COVID-19, within 28 days. The primary analysis population included all eligible SARS-CoV-2-positive participants randomly assigned to budesonide, usual care, and other interventions, from the start of the platform trial until the budesonide group was closed. 4700 participants were randomly assigned to budesonide ($n=1073$), usual care alone ($n=1988$), or other treatments ($n=1639$). The primary analysis model includes 2530 SARS-CoV-2-positive participants, with 787 in the budesonide group, 1069 in the usual care group, and 974 receiving other treatments. There was a benefit in time to first self-reported recovery of an estimated 2.94 days (95% Bayesian credible interval [BCI] 1.19 to 5.12) in the budesonide group versus the usual care group (11.8 days [95% BCI 10.0 to 14.1] vs 14.7 days [12.3 to 18.0]; hazard ratio 1.21 [95% BCI 1.08 to 1.36]). For the hospital admission or death outcome, the estimated rate was 6.8% (95% BCI 4.1 to 10.2) in the budesonide group versus 8.8% (5.5 to 12.7) in the usual care group (estimated absolute difference 2.0% [95% BCI -0.2 to 4.5]; odds ratio 0.75 [95% BCI 0.55 to 1.03]). Two participants in the budesonide group and four in the usual care group had serious adverse events (hospital admissions unrelated to COVID-19). Inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or deaths (although results did not meet the superiority threshold), in people with COVID-19 in the community who are at higher risk of complications.

Summary of findings related to **inhaled budesonide compared to standard care** for COVID-19 patients in **outpatient setting**, related to 2 RCTs mentioned above, is presented in Summary of findings Table 3.2-3 below. Inhaled budesonide may decrease number of hospitalisation ((RR 0.71, 95% CI 0.54 to 0.93, 1 RCT, low certainty of evidence). The evidence is very uncertain about the effect of inhaled budesonide on outcomes: All-cause mortality D28 (RR 0.83, 95% CI 0.34 to 2.03, 1 RCT, very low certainty of evidence); WHO progression score (level 7 or above) D28 (RR 1.06, 95% CI 0.58 to 1.91, 1 RCT, very low certainty of evidence) and serious Adverse events (RR 5.23, 95% CI 0.25 to 108.86, 1 RCT, very low certainty of evidence).

**RCT Interim Auswertung
PRINCIPLE
4.663 Pts.,
davon 751 mit Budesonid
frühzeitiger Abbruch**

**Verkürzung der Zeit der
Erkrankung um
ca 3 Tage**

**geringe Effekte auf
Hospitalisierung/ Tod**

**SoF von 2 RCTs
ev. Reduktion der
Hospitalisierungen**

Table 3.2-3: Summary of findings table, on **budesonide vs standard care** (2 RCTs: Ramakrishnan, Yu)**Budesonide compared to Standard Care for Mild COVID-19** (last update 30/08/2021)**Patient or population:** Mild COVID-19**Setting:** Worldwide Outpatients**Intervention:** Budesonide**Comparison:** Standard Care

Outcome	Anticipated absolute effects (95% CI) ^a		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with Standard treatment/Placebo	Risk with Budesonide				
All-cause mortality D28	10 per 1000	8 per 1000	RR: 0.83 (0.34 - 2.03)	2060 (1 RCT) ^b	OOO⊕ VERY LOW ^c	Absolute effect (95% CI) 2 fewer per 1000 (from 7 fewer to 10 more)
Clinical improvement D28	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported
WHO progression score (level 7 or above) D28	20 per 1000	21 per 1000	RR: 1.06 (0.58 - 1.91)	2060 (1 RCT) ^b	OOO⊕ VERY LOW ^c	Absolute effect (95% CI) 1 more per 1000 (from 9 fewer to 18 more)
Hospitalisation or death	105 per 1000	75 per 1000	RR: 0.71 (0.54 - 1.93)	2060 (1 RCT) ^b	OO⊕⊕ LOW ^d	Absolute effect (95% CI) 31 fewer per 1000 (from 48 fewer to 7 more)
Number of patients with adverse events	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported
Number of patients with serious adverse events	0 per 1000	0 per 1000	RR: 5.23 (0.25 - 108.86)	2112 (1 RCT) ^b	OOO⊕ VERY LOW ^e	Absolute effect (95% CI) Zero events in both groups

a The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) ^b Yu, 2021
c Risk of bias: Serious. Risk of bias downgraded by 1 level: some concerns deviation from intended intervention and missing data Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants ^d Risk of bias: Serious Risk of bias downgraded by 1 level: some concerns regarding deviation from intended intervention and missing data Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. ^e Risk of bias: Serious. Risk of bias downgraded by 1 level: some concerns deviation from intended intervention, missing data and outcome measurement Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants

3.2.18 Anakinra (Kineret®)

The reader is referred to the earlier version (V20_February and March2022) for more details on anakinra (Kineret).

On December 17, 2021 the EC authorised it use to treat COVID-19, in adult patients with pneumonia who are at risk of developing severe respiratory failure.

Verweis auf v20
Anakinret von EMA
zugelassen für Hochrisiko-
Pts mit Lungentzündung

3.2.19 Colchicine

The reader is referred to the earlier version (V15_June 2021 and V18_October/November 2021) for more details on colchicine treatment in hospitalised and nonhospitalised COVID-19 patients.

The US COVID-19 Treatment Guidelines Panel (update December 16, 2021), based on negative results from RECOVERY trial **recommends against** the use of colchicine in **hospitalised patients (AI)**. The COVID-19 Treatment Guidelines Panel (the Panel) **recommends against** the use of **colchicine** for the treatment of **nonhospitalised patients** with COVID-19, except in a clinical trial (BIIa) [12].

Verweis auf v18

US COVID-19 Treatment
Guidelines Panel:
Empfehlung GEGEN
Colchicine bei
hospitalisierten oder nicht-
hospitalisierten Pts.

3.2.20 Nafamostat (Futhan©)

The reader is referred to the earlier version (V17_August and September 2021) for more details on nafamostat (Futhan).

Zhuravel et al. 2021 [68] published results from a **phase 2** open-label, randomised, multicentre, controlled trial (NCT04623021) that evaluated nafamostat (4.8 mg/kg/ day) plus standard-of-care (SOC) in **hospitalised patients with COVID-19 pneumonia** (i.e., those requiring nasal high-flow oxygen therapy and/or non-invasive mechanical ventilation). The primary outcome was the time to clinical improvement. Key secondary outcomes included the time to recovery, rates of recovery and National Early Warning Score (NEWS). A total of 104 patients, mean age 58.6 years were enrolled in 13 clinical centres in Russia between 25/9/2020 and 14/11/2020 and randomised to nafamostat plus SOC (n=53) or SOC alone (n=51).

There was no significant difference in time to clinical improvement (primary endpoint) between the nafamostat and SOC groups (median 11 [interquartile range (IQR) 9 to 14] vs 11 [IQR 9 to 14] days; Rate Ratio [RR; the ratio for clinical improvement], 1.00; 95% CI, 0.65 to 1.57; p=0.953). In 36 patients with baseline NEWS ≥ 7 (high-risk COVID-19 patients requiring oxygen treatment), nafamostat was superior to SOC alone in median time to clinical improvement (11 vs 14 days; RR, 2.89; 95% CI, 1.17 to 7.14; p=0.012). Patients receiving nafamostat in this subgroup had a significantly higher recovery rate compared with SOC alone (61.1% (11/18) vs 11.1 % (2/18) by Day 11, p=0.002). The 28-day mortality was 1.9% (1/52) for nafamostat and 8.0% (4/50) for SOC (95% CI, -17.0 to 3.4; p=0.155). No case of COVID-19 related serious adverse events leading to death was recorded in the patients receiving nafamostat.

Details in v17

Phase 2 (Russland)
104 hospitalisierte Pts.
mit Lungenentzündung
und Bedarf an nicht-
invasiver Beatmung

wirksam (Mortalität) nur
in Subgruppe an Pts. mit
Bedarf an Sauerstoff

3.2.21 Gimsilumab

About the drug under consideration

Gimsilumab is a fully human monoclonal antibody that acts on granulocyte-macrophage colony-stimulating factor (GM-CSF) [1]; it is manufactured by Roivant Sciences Ltd. /Altasciences. Gimsilumab – ATC-code not assigned yet. Gimsilumab belongs to anti-inflammatories, antirheumatics, monoclonal antibodies drug class and has no approval for any indication by EMA or FDA yet.

**monoklonaler Antikörper
in Entwicklung**

**EMA/ FDA: keine
Zulassung**

The **US COVID-19 Treatment Guidelines Panel** (update March 24, 2022):

- There is **insufficient evidence** for the COVID-19 Treatment Guidelines Panel to **recommend either for or against the use** of GM-CSF inhibitors for the treatment of hospitalised patients with COVID-19.

**US COVID-19 Treatment
Guidelines Panel:
insuffiziente Evidenz**

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated interventional studies were found on gimsilumab in ClinicalTrials.gov and EudraCT registers.

**keine abgeschlossenen,
abgebrochenen Studien**

Results of publications

There are published negative results, as scientific article in press, by **Criner et al. 2022**, from one **phase 2 RCT** related to effectiveness and safety of gimsilumab for Covid-19 treatment (**BREATHE, NCT04351243**); results are also posted in ClinicalTrials.gov register. Pre-specified subgroup analysis is published also as abstract. BREATHE was a double-blind, randomized, placebo-controlled trial at 21 US locations. Patients were randomized 1:1 to receive two doses of IV gimsilumab or placebo one week apart. The study included **hospitalised COVID-19 patients with hyperinflammation** (CRP ≥ 50 mg/L or ferritin $\geq 1,000$ ng/mL) **and pre-ARDS lung injury or ARDS**. The primary endpoint was all-cause mortality at day 43, and key secondary outcomes assessed ventilator use and hospitalisation length. 225 patients were randomized and dosed. 41 patients were invasively ventilated at baseline. Steroid use and baseline characteristics were generally balanced across study arms in this subgroup. Enrollment was halted early for futility based on an interim analysis. Gimsilumab did not improve mortality or other key clinical outcomes in patients with COVID-19 pneumonia and evidence of systemic inflammation. Overall mortality rates at 24 weeks were similar across the treatment arms. The key secondary endpoints demonstrated no significant differences between groups. Despite high background use of corticosteroids and anticoagulants, adverse events were generally balanced between treatment groups [69].

**Phase 2 RCT: BREATHE
225 hospitalisierte Pts.**

**Studie wird abgebrochen
wegen negativen
Ergebnissen**

3.2.22 Canakinumab

The reader is referred to the earlier version (V17_August and September 2021) for more details on **canakinumab**.

Verweis auf v17

The **US COVID-19 Treatment Guidelines Panel** (update October 19, 2021), **recommends against** the use of **canakinumab** for the treatment of COVID-19, except in a clinical trial (BIIa).

US COVID-19 Treatment Guidelines Panel:
Empfehlung GEGEN Canakinumab

3.2.23 Lenzilumab

About the drug under consideration

Lenzilumab is a first-in-class Humaneered® recombinant monoclonal antibody targeting human GM-CSF, with potential immunomodulatory activity, high binding affinity in the picomolar range, 94% homology to human germline, and has low immunogenicity. Following intravenous administration, lenzilumab binds to and neutralizes GM-CSF, preventing GM-CSF binding to its receptor, thereby preventing GM-CSF-mediated signaling to myeloid progenitor cells. The inhibition of GM-CSF signaling may be beneficial in improving the hyperinflammation-related lung damage in the most severe cases of COVID-19. This blockade can be achieved through antagonism of the GM-CSF receptor or the direct binding of circulating GM-CSF [70, 71].

Lenzilumab is not authorised in Covid-19 patients (EMA, FDA). FDA has approved the administration of lenzilumab for COVID-19 patients under individual patient emergency IND applications to patients under the company's compassionate use program.

The **US COVID-19 Treatment Guidelines Panel** (update March 24, 2022):

- There is **insufficient evidence** for the COVID-19 Treatment Guidelines Panel to **recommend either for or against the use** of GM-CSF inhibitors for the treatment of hospitalised patients with COVID-19.

monoklonaler Antikörper

**für keine Indikation
bislang zugelassen**

**FDA: für Einzelanwendungen im Notfall –
compassionate use zur
Verhinderung von akutem
Lungenversagen**

US COVID-19 Treatment Guidelines Panel:
insuffiziente Evidenz

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated interventional studies were found on lenzilumab in ClinicalTrials.gov and EUdRACT registers.

Lenzilumab was selected for investigation within **ACTIV-5**, as a concomitant therapy with remdesivir compared with remdesivir alone. The study began in October 2020 and was comprised of 200 adult hospitalised patients who need medical care for COVID-19 pneumonia and randomized (1:1) to the treatment groups. Patients receive a loading dose of 200-mg intravenous (IV) remdesivir on day 1 followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized. Lenzilumab (or placebo) is administered at 600-mg IV lenzilumab infusion every 8 hours starting on Day 1 for a total of 3 doses. On July 30, 2021 Humanigen announced that NIH has advanced the ACTIV-5/BET-B study to a **phase 2/3** study and modified the primary endpoint to survival without ventilation ("SWOV"), the same endpoint used in the Phase 3 LIVE-AIR study. The amended ACTIV-5/BET-B study now includes 400 patients overall. Up to sixty US sites will be participating in the study, https://s28.q4cdn.com/539885110/files/doc_news/NIH-Advances-ACTIV-5BET-B-Trial-Evaluating-Lenzilumab-from-a-Phase-2-Exploratory-Study-to-a-Phase-23-Study-for-the-Treatment-of-COVID-CML3P.pdf.

**ACTIV-5 RCT: laufend
200 hospitalisierte Pts**

Results of publications

Currently, results from one RCT were published as preprint, and then in scientific journal, related to effectiveness and safety of lenzilumab for Covid-19. **Temesgen et al. 2021** [72] [73] published results from **LIVE-AIR phase 3** randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lenzilumab to assess the potential for lenzilumab to improve the likelihood of ventilator-free survival (referred to herein as survival without ventilation, SWOV), beyond standard supportive care, in hospitalised subjects with severe COVID-19 (NCT04351152). Subjects with COVID-19 (n=520), ≥ 18 years, and $\leq 94\%$ oxygen saturation on room air and/or requiring supplemental oxygen, but not invasive mechanical ventilation, were randomized to receive lenzilumab (600 mg, n=261) or placebo (n=259) via three intravenous infusions administered 8 hours apart. Subjects were followed through Day 28 following treatment. Baseline demographics were comparable between the two treatment groups: male, 64.7%; mean age, 60.5 years; mean BMI, 32.5 kg/m²; mean CRP, 98.36 mg/L; CRP was <150 mg/L in 77.9% of subjects. The most common comorbidities were obesity (55.1%), diabetes (53.4%), chronic kidney disease (14.0%), and coronary artery disease (13.6%). Subjects received steroids (93.7%), remdesivir (72.4%), or both (69.1%). Survival without invasive mechanical ventilation to day 28 was achieved in 198 (84%; 95% CI 79–89) participants in the lenzilumab group and in 190 (78%; 72–83) patients in the placebo group, and the likelihood of survival was greater with lenzilumab than placebo (hazard ratio 1.54; 95% CI 1.02–2.32; p=0.040). 68 (27%) of 255 patients in the lenzilumab group and 84 (33%) of 257 patients in the placebo group experienced at least one adverse event that was at least grade 3 in severity based on CTCAE criteria. The most common treatment-emergent adverse events of grade 3 or higher were related to respiratory disorders (26%) and cardiac disorders (6%) and none led to death. Authors concluded that lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with COVID-19, with a safety profile similar to that of placebo. The added value of lenzilumab beyond other immunomodulators used to treat COVID-19 alongside steroids remains unknown [73].

**Phase 3 RCT
LIVE-AIR
520 Pts
mit schwerer Erkrankung**

**bessere klinische
Ergebnisse in der
Lenzilumab-Gruppe**

On **September 08, 2021** Humanigen announced the U.S. **FDA** has **declined** its request for **emergency use authorization** of lenzilumab to treat newly hospitalized COVID-19 patients. In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19, https://s28.q4cdn.com/539885110/files/doc_news/FDA-has-declined-Humanigens-Emergency-Use-Authorization-EUA-Request-for-Lenzilumab-in-Hospitalized-COVID-19-Patients-2021.pdf. NIH's ACTIV-5/BET-B study is expected to provide further data that may support a new EUA request.

**Sept 2021: FDA lehnt für
Lenzilumab EUA ab**

3.2.24 Vitamin D

The reader is referred to the earlier version (V17_August and September 2021) for more details on **Vitamin D**.

Verweis auf v17

3.2.25 Baricitinib (Olumiant)

About the drug under consideration

Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Baricitinib (Olumiant) is indicated in EU for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs and for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy [74, 75].

Baricitinib (Olumiant) has not been approved by the European Medicines Agency (EMA). On November 19, 2020, the U.S. Food and Drug Administration (FDA) issued an **Emergency Use Authorization (EUA)** for the distribution and emergency use of baricitinib to be used **in combination with remdesivir in hospitalised adult and pediatric patients two years of age or older** with suspected or laboratory confirmed COVID-19 **who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)** [76].

On **July 28, 2021** the FDA issued **revision to EUA** for the distribution and emergency use of **baricitinib to be used alone for the treatment of COVID-19 in hospitalised adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)** [77]. The EUA for baricitinib no longer requires baricitinib be used in combination with remdesivir. The use of baricitinib in combination with remdesivir is not contraindicated under the terms and conditions of this authorization. In **May 2022**, FDA approved a **new indication for baricitinib for the treatment of COVID-19 in hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)** [78].

On **April 29, 2021** EMA starts **evaluating an application to extend the use of baricitinib (Olumiant) to include treatment of COVID-19 in hospitalised patients from 10 years of age who require supplemental oxygen** [79].

The **US COVID-19 Treatment Guidelines Panel** (last update December 16, 2021), recommends using either **baricitinib (BIIa)** or **tocilizumab (BIIa)** (listed alphabetically) in combination with **dexamethasone** alone or **dexamethasone plus remdesivir** for the treatment of COVID-19 patients who were recently hospitalised with rapidly increasing oxygen needs and systemic inflammation [12]. The Panel recommends **tofacitinib** as an alternative to **baricitinib** only when baricitinib is not available or not feasible to use (BIIa).

The Panel **recommends against** the use of **baricitinib** in combination with **tocilizumab** for the treatment of COVID-19 (AIII). Because both baricitinib and tocilizumab are potent immunosuppressants, there is the potential for an additive risk of infection [12].

The **WHO living guideline** (14 January 2022) provided **strong recommendation** to use baricitinib as an **alternative to interleukin-6 (IL-6)**

Januskinase-Inhibitor

Baricitinib (Olumiant) in EU für moderate bis schwere rheumatoide Arthritis zugelassen

EMA: keine Zulassung für covid-19

FDA Zulassung (EUA) als Kombinationstherapie mit Remdesivir hospitalisierte Pts mit Bedarf zur Beatmung

FDA Zulassung:

auch als Monotherapie möglich

US COVID-19 Treatment Guidelines Panel: Empfehlung für Kombinationstherapie mit Dexamethasone in hospitalisierten Pts., die Sauerstoff brauchen

Empfehlung gegen eine Kombinationstherapie Baricitinib + Tocilizumab

WHO: starke Empfehlung für Baricitinib

receptor blockers, in combination with corticosteroids, in severe and critically ill COVID-19 patients [13].

Withdrawn, suspended or terminated studies

One withdrawn (NCT04340232, could not make FDA required changes), no suspended and one terminated RCTs (NCT04373044, after the release of results of ACTT-2 trial) were found on baricitinib in ClinicalTrials.gov and EUdRACT registers. There are several ongoing RCTs, evaluating baricitinib alone or in combination with other pharmaceuticals in Covid-19 hospitalised patients. One is the RECOVERY (Randomised Evaluation of COvid-19 thERapY) trial, led by the University of Oxford [80].

mehrere laufende Studien

Results of publications: Baricitinib in combination with remdesivir

On December 11, 2020, **Kalil et al.** [81] published results from the Adaptive COVID-19 Treatment Trial (**ACTT-2**) (**NCT04401579**), multicentre, double-blind, randomised, placebo-controlled trial evaluating **baricitinib plus remdesivir with remdesivir alone** in **hospitalised adults** with Covid-19 in eight countries. Effectiveness and safety data summary, related to three outcomes (All-cause mortality; Number of patients with AEs and Number of patients with SAEs), can be found in the **Summary of Findings** Table 3.2-4. High certainty evidence from one published RCT, ACTT-2 trial, showed that baricitinib in combination with remdesivir does not reduce All-cause mortality, and does not increase the number of patients with any adverse events as well as the number of patients with serious adverse events (high certainty of evidence). Combination of baricitinib and remdesivir significantly reduced median time to recovery in hospitalised COVID-19 patients from eight days to seven days, compared to remdesivir treatment alone. Patients who required high-flow oxygen or non-invasive ventilation during hospitalisation appeared to have had the largest benefit: their median time to recovery was shortened from eighteen days to ten days. Participants' conditions at day 15 was significantly improved when they received the two therapeutics combined. The incidence of progression to death or non-invasive or invasive ventilation was statistically significant lower in the combination of baricitinib and remdesivir vs remdesivir alone, as was the incidence of progression to death or invasive ventilation [82]: Risk ratio (95% CI) for outcome WHO progression score level 7 or above D14-28 is 0.59 (0.44 to 0.80) (COVID-NMA Meta-analysis, https://covid-nma.com/living_data/index.php?allcomp#comparisons_div). New Summary of finding table and certainty of evidence will be provided in the next versions of this report, https://covid-nma.com/living_data/index.php?allcomp#comparisons_div.

**RCT, ACTT-2
hospitalisierte Pts
Kombinationstherapie +
Remdesivir**

**keine Reduktion der
Gesamtmortalität
aber Reduktion der Zeit
zur Erholung um 1 Tag**

**Pts. mit nicht-invasiver
Beatmung: größter
Nutzen**

**Reduktion der Zeit zur
Erholung um 8 Tage (statt
18, nur 10 Tage)**

Results of publications: Baricitinib monotherapy (in addition to standard care)

On May 3, 2021 **Marconi et al.** [83] published as **pre-print** and on September 3, 2021 in **scientific journal** [84], results from phase 3, global, double-blind, randomized, placebo-controlled trial **COV-BARRIER** (**NCT04421027**). 1525 **hospitalised adults** with COVID-19 **receiving standard of care (SOC)** were randomly assigned (1:1) to once-daily **baricitinib 4-mg** (n=764) or **placebo** (n=761) for up to 14 days. **SOC included systemic corticosteroids in ~79% of participants (dexamethasone ~90%)**. The primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28. A key secondary

**Phase 3 RCT
COV-BARRIER
1.525 hospitalisierte Pts
bessere Ergebnisse bei**

**28-Tage und
Gesamtmortalität mit
Baricitinib**

endpoint was all-cause mortality by day 28. All-cause mortality by day 60 was an exploratory endpoint. 27.8% of participants receiving baricitinib vs 30.5% receiving placebo progressed (primary endpoint, odds ratio 0.85, 95% CI 0.67-1.08; $p=0.18$). The 28-day all-cause mortality was 8% ($n=62$) for baricitinib and 13% ($n=100$) for placebo (hazard ratio [HR] 0.57 [95% CI 0.41–0.78]; nominal $p=0.0018$), a 38.2% relative reduction in mortality; one additional death was prevented per 20 baricitinib-treated participants. Reduction in mortality was seen for all pre-specified subgroups of baseline severity (most pronounced for participants on high-flow oxygen/non-invasive ventilation at baseline [17.5%, baricitinib vs 29.4%, placebo; HR 0.52, 95% CI 0.33-0.80; nominal $p=0.007$]).

The 60-day all-cause mortality was 10% ($n=79$) for baricitinib and 15% ($n=116$) for placebo (HR 0.62 [95% CI 0.47–0.83]; $p=0.0050$). The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups.

On August 3, 2021 Eli Lilly and Company announced results from an additional cohort of 101 adult critical COVID-19 patients from the above mentioned COV-BARRIER trial. The results are posted in preprint article by Ely et al. 2021 [85] and in February 2022 published in scientific article [86]. In this sub-study, in patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who received baricitinib plus standard of care (baseline systemic corticosteroid use in 86% of participants) all-cause mortality at day 28 was significantly reduced (39.2% vs 58.0%; hazard ratio [HR]=0.54 [95%CI 0.31–0.96]; $p=0.030$). One additional death was prevented for every six baricitinib-treated participants. Significant reduction in 60-day mortality was also observed (45.1% vs 62.0%; HR=0.56 [95%CI 0.33–0.97]; $p=0.027$). Baricitinib-treated participants showed numerically more ventilator-free days (8.1 vs 5.5 days, $p=0.21$) and spent over 2 days less in the hospital than placebo-treated participants (23.7 vs 26.1 days, $p=0.050$). These findings are consistent with the reduction in mortality observed in the overall COV-BARRIER patient population. By Day 28, the frequency of adverse events, serious adverse events and serious infections were similar in the baricitinib group (88%, 50% and 44%, respectively) compared to placebo (95.9%, 71.4% and 53.1%, respectively). Venous thromboembolic events were reported in 6% of patients treated with baricitinib and 6.1% of patients treated with placebo. No new safety signals were identified [85, 87].

Results from RECOVERY trial are published as preprint [88]: in hospitalised patients with COVID-19, baricitinib significantly reduced the risk of death. Eligible and consenting patients ($n=8156$) were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was conducted that included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. At randomisation, 95% of patients were receiving corticosteroids and 23% receiving tocilizumab (with planned use within the next 24 hours recorded for a further 9%). Overall, 513 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0.87; 95%

Nebenwirkungen

Hersteller Kommunikation

Pts mit kritischer Erkrankung in COV-BARRIER

28-Tage und 60-Tage Mortalität geringer

RECOVERY RCT 8.156 Pts Mortalität 12% vs. 14% SoC

RECOVERY + 9 weitere RCTs zeigen ein 20%ige RRR

CI 0.77-0.98; $p=0.026$). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of 8 previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths) in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0.57; 95% CI 0.45-0.72). Including the results from RECOVERY into an updated meta-analysis of all 9 completed trials (involving 11,888 randomised patients and 1484 deaths) allocation to baricitinib or other JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0.80; 95% CI 0.71-0.89; $p<0.001$). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no excess of thrombosis, or other safety outcomes.

Summary of Findings Table 3.2-5 related to these 3 articles mentioned above, can be found below. In Summary, baricitinib probably reduces All-cause mortality at Day28 (RR 0.75, 95% CI 0.58 to 0.98, moderate certainty of evidence) and All-cause mortality at Day60 (RR 0.69, 95% CI 0.56 to 0.86, moderate certainty of evidence) compared to placebo. Baricitinib decreases WHO progression score level 7 or above (RR 0.87, 95% CI 0.78 to 0.97, high certainty of evidence) and increases clinical improvement (RR 1.02, 95% CI 1.00 to 1.05, high certainty of evidence).

Baricitinib probably does not increase Adverse events (RR 0.96, 95% CI 0.88 to 1.05, moderate certainty of evidence) and Serious adverse events (RR 0.77, 95% CI 0.64 to 0.94, moderate certainty of evidence).

Wolfe et al. 2022 [89] published results from randomised, double-blind, double placebo-controlled trial (NCT04640168), from 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), and Japan (one site). **Hospitalised adults** (≥ 18 years) with COVID-19 who required supplemental oxygen administered by low-flow (≤ 15 L/min), high-flow (>15 L/min), or non-invasive mechanical ventilation modalities who met the study eligibility criteria (male or nonpregnant female adults ≥ 18 years old with laboratory-confirmed SARS-CoV-2 infection) were enrolled in the study. Patients were randomly assigned (1:1) to receive either baricitinib, remdesivir, and placebo, or dexamethasone, remdesivir, and placebo using a permuted block design. Randomisation was stratified by study site and baseline ordinal score at enrolment. All patients received **remdesivir** (≤ 10 days) **and either baricitinib** (or matching oral placebo) for a maximum of 14 days **or dexamethasone** (or matching intravenous placebo) for a maximum of 10 days. The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population. Safety analyses were done in the as-treated population, comprising all participants who received one dose of the study drug. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (49%) to dexamethasone plus remdesivir plus placebo. The mean age of the patients was 58.3 years (SD 14.0) and 590 (58%) of 1010 patients were male.

SoF: ev. geringere 28-Tage und 60-Tage Mortalität, weitere Endpunkte sehr unsicher

**Wolfe 2022
RCT (USA, ...)
1.010 hospitalisierte Pts
mit Bedarf nach nicht-
invasiver Beatmung**

**baricitinib, remdesivir +
placebo, or
dexamethasone,
remdesivir + placebo**

Mechanical ventilation-free survival by day 29 was similar between the study groups (Kaplan-Meier estimates of 87·0% [95% CI 83·7 to 89·6] in the baricitinib plus remdesivir plus placebo group and 87·6% [84·2 to 90·3] in the dexamethasone plus remdesivir plus placebo group; risk difference 0·6 [95% CI -3·6 to 4·8]; $p=0·91$). The odds ratio for improved status in the dexamethasone plus remdesivir plus placebo group compared with the baricitinib plus remdesivir plus placebo group was 1·01 (95% CI 0·80 to 1·27). At least one adverse event occurred in 149 (30%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 179 (37%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·5% [1·6 to 13·3]; $p=0·014$). 21 (4%) of 503 patients in the baricitinib plus remdesivir plus placebo group had at least one treatment-related adverse event versus 49 (10%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 6·0% [2·8 to 9·3]; $p=0·00041$). Severe or life-threatening grade 3 or 4 adverse events occurred in 143 (28%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 174 (36%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·7% [1·8 to 13·4]; $p=0·012$). Authors concluded that in hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or noninvasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events. A more individually tailored choice of immunomodulation now appears possible, where side-effect profile, ease of administration, cost, and patient comorbidities can all be considered.

Karamitsakos et al. 2022 [90] published as preprint results from randomized controlled trial (NCT05082714), on 251 patients with COVID-19 and $\text{PaO}_2/\text{FiO}_2 < 200$ to receive either **tocilizumab** ($n=126$) or **baricitinib** ($n=125$) plus standard of care. The primary outcome was mechanical ventilation or death by day 28. Secondary outcomes included time to hospital discharge by day 28 and change in WHO progression scale at day 10. Baricitinib was non-inferior to tocilizumab for the primary composite outcome of mechanical ventilation or death by day 28 (HR 0.83, 95% CI: 0.56 to 1.21, $p=0.001$ for non-inferiority). Baricitinib was non-inferior to tocilizumab for the time to hospital discharge within 28 days (discharged alive- tocilizumab: 52.4% vs baricitinib: 58.4%; HR 0.85, (95% CI: 0.61 to 1.18), $p< 0.001$ for non-inferiority). There was no significant difference between baricitinib and tocilizumab arm in the change in WHO scale at day 10 [0.0 (95% CI: 0.0 to 0.0) vs 0.0 (95% CI: 0.0 to 1.0), $p=0.83$]. Authors concluded that baricitinib was non-inferior to tocilizumab with regards to the composite outcome of mechanical ventilation or death by day 28 and the time to discharge by day 28 in patients with severe COVID-19. Cost-effectiveness should be taken into account to avoid a dramatic upswing in health system budgets.

**ähnliche Ergebnisse bei
beatmungsfreiem
Überleben**

**Dexamethason jedoch mit
deutlich mehr
unerwünschten
Ereignissen verbunden**

**Karamitsakos 2022
RCT, 251 Pts
tocilizumab or baricitinib**

kein Unterschied

Table 3.2-4: Summary of findings table, on **baricitinib + remdesivir** (1 RCT: Kalil 2020)**Question:** Should Baricitinib-Remdesivir compared to Standard treatment (placebo/remdesivir) be used for COVID-19 patients?**Setting:** Inpatient

Outcome	Anticipated absolute effects (95% CI)		Relative effect (95% CI)	Absolute effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with placebo+remdesivir	Risk with baricitinib+remdesivir					
All-cause mortality	71 per 1000	46 per 1000	RR 0.65 (0.40 to 1.07)	25 fewer per 1.000 (from 43 fewer to 5 more)	1033 (1 RCT) ^a	⊕⊕⊕⊕ HIGH	Baricitinib in combination with remdesivir does not reduce All-cause mortality
Number of patients with any adverse event	432 per 1000	367 per 1000	RR 0.85 (0.73 to 0.99)	65 fewer per 1.000 (from 117 fewer to 4 fewer)	1016 (1 RCT) ^a	⊕⊕⊕⊕ HIGH	Baricitinib in combination with remdesivir reduces the risk of AE
Number of patients with serious adverse events	210 per 1000	159 per 1000	RR 0.76 (0.59 to 0.99)	50 fewer per 1.000 (from 86 fewer to 2 fewer)	1013 (1 RCT) ^a	⊕⊕⊕⊕ HIGH	Baricitinib in combination with remdesivir reduces the risk of serious AE

Source: ref Cruciani F., De Crescenzo F., Vecchi S., Saulle R., Mitrova Z., Amato L., et al. Should Baricitinib-Remdesivir compared to Standard treatment (placebo/remdesivir) be used for COVID-19 patients?. 2020.

^a ref Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine. 2020. 10.1056/NEJMoa2031994. **Abbreviations:** RR=Risk ratio; CI=Confidence interval; AE=Adverse event; SAE=Serious adverse event

Table 3.2-5: Summary of findings table, on **baricitinib monotherapy vs placebo in hospitalised COVID-19 patients** (Marconi 2021, Ely 2021, RECOVERY trial 2022)Baricitinib vs Placebo in Hospitalised patients, last update 29/03/2022, details on https://covid-nma.com/living_data/index.php?allcomp#comparisons_div**Patient or population:** COVID-19 patients **Setting:** Worldwide **Intervention:** Baricitinib **Comparison:** Placebo

Outcome	Anticipated absolute effects (95% CI) ^a		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with Placebo	Risk with Baricitinib				
All-cause mortality D28	140 per 1000	105 per 1000	RR: 0.75 (0.58 - 0.98)	9782 (3 RCTs)	⊕⊕⊕○ MODERATE	Absolute effect (95% CI) 35 fewer per 1000 (from 59 fewer to 3 fewer)
All-cause mortality D60	181 per 1000	125 per 1000	RR: 0.69 (0.56 - 0.86)	1626 (2 RCTs)	⊕⊕⊕○ MODERATE	Absolute effect (95% CI) 56 fewer per 1000 (from 80 fewer to 25 fewer)
Clinical improvement D28	777 per 1000	792 per 1000	RR: 1.02 (1.00 - 1.05)	9782 (3 RCTs)	⊕⊕⊕⊕ HIGH	Absolute effect (95% CI) 16 more per 1000 (from 0 fewer to 39 more)
WHO progression score (level 7 or above) D28	173 per 1000	150 per 1000	RR: 0.87 (0.78 - 0.97)	9782 (3 RCTs)	⊕⊕⊕⊕ HIGH	22 fewer per 1000 (from 38 fewer to 5 fewer)
Number of patients with any adverse event	470 per 1000	451 per 1000	RR: 0.96 (0.88 - 1.05)	1626 (2 RCTs)	⊕⊕⊕○ MODERATE	Absolute effect (95% CI) 19 fewer per 1000 (from 56 fewer to 23 more)
Number of patients with serious adverse events	210 per 100	161 per 1000	RR: 0.77 (0.64 - 0.94)	1626 (2 RCTs)	⊕⊕⊕○ MODERATE	Absolute effect (95% CI) 48 fewer per 1000 (from 75 fewer to 13 fewer)

3.2.26 Molnupiravir (Lagevrio)

About the drug under consideration

Molnupiravir is the orally available pro-drug of the nucleoside analogue N4-hydroxycytidine (NHC), which has shown potent anti-influenza virus activity in mice, guinea pigs, ferrets and human airway epithelium organoids. Animal study in ferrets showed that therapeutic treatment of infected animals with molnupiravir (MK-4482/EIDD-2801) twice a day significantly reduced the SARS-CoV-2 load in the upper respiratory tract and completely suppressed spread to untreated contact animals [91, 92].

Molnupiravir attacks the same viral enzyme as Gilead's Remdesivir, but it can be taken orally. This would allow an administration at home and, therefore, earlier in the course of the disease. According to Ridgeback Biotherapeutics, molnupiravir has an extremely high barrier to resistance. According to Merck Sharp & Dohme/ MSD, molnupiravir is aimed at the treatment of Covid-19 in patients hospitalised due to mild, moderate or severe disease, and non-hospitalized patients with mild or moderate disease [92].

Molnupiravir is not approved by the European Medicines Agency (EMA) or the American Food and Drug Administration (FDA) [92].

On **October 25, 2021** EMA's human medicines committee (CHMP) has started a **rolling review of molnupiravir** (also known as MK 4482 or Lagevrio), developed by Merck Sharp & Dohme in collaboration with Ridgeback Biotherapeutics for the **treatment of COVID-19 in adults** [93].

On **November 19, 2021** CHMP has **issued advice** on the use of molnupiravir to **treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of developing severe COVID-19**. Lagevrio should be administered as soon as possible after diagnosis of COVID-19 and within 5 days of the start of symptoms. On **November 23, 2021**, EMA has **started evaluating as application for marketing authorisation**. On **December 14, 2021** EMA announced that it is reviewing **new data on effectiveness** of molnupiravir for the treatment of COVID-19 [94].

On **December 23, 2021** FDA issued **EUA** for molnupiravir for the treatment of **mild-to-moderate** coronavirus disease (COVID-19) in **adults with positive results of direct SARS-CoV-2 viral testing**, and who are at **high risk for progression to severe COVID-19**, including hospitalisation or death, and **for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate**. It should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth. It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because benefit of treatment has not been observed in people when treatment started after hospitalisation due to COVID-19. Molnupiravir is a medication that works by introducing errors into the SARS-CoV-2 virus' genetic code, which prevents the virus from further replicating. It is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules [95].

**antivirales Medikament
ähnlich Remdesivir
aber orale Verabreichung**

**frühere Verabreichung zu
Hause daher möglich**

**hospitalisierte, aber auch
milde und moderate
Erkrankung**

**weder von EMA noch FDA
zugelassen**

**Okt 2021: EMA beginnt
Rolling Review**

**EMA: für mild bis moderat
Erkrankte mit hohem
Risiko auf Progression,
innerhalb der ersten 5
Tage nach
Krankheitsbeginn
einzunehmen**

**FDA: EUA, aber nur für Pts,
die keinen Zugang zu
anderen zugelassenen
Medikamenten haben**

**nicht: für Prä- oder
PostExpositionen
Prophylaxe**

The US COVID-19 Treatment Guidelines Panel (last update May 13, 2022)

This statement contains the Panel's recommendations for treating these **nonhospitalised patients** using the currently available therapies. The Panel recommends one of the following [12]:

Preferred therapies (listed in order of preference):

- Ritonavir-boosted nirmatrelvir (Paxlovid) (AIIa)
- Remdesivir (BIIa)

Alternative therapies (for use ONLY if none of the preferred therapies are available, feasible to use, or clinically appropriate, listed in alphabetical order):

- Bebtelovimab 175 mg (CIII); *or*
- Molnupiravir 800 mg (CIIa)

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated interventional studies were found on molnupiravir in ClinicalTrials.gov and EudraCT registers.

On September 01, 2021 Merck and Ridgeback Biotherapeutics announced the initiation of the **phase 3 MOVE-AHEAD** (NCT04939428) clinical trial to evaluate molnupiravir for the **prevention** of COVID-19 infection. The global study is enrolling individuals who are at least 18 years of age and reside in the same household as someone with laboratory-confirmed SARS-CoV-2 infection with symptoms. The trial will enroll approximately 1332 participants who will be randomized to receive either molnupiravir (800 mg) or placebo orally every 12 hours for five days. The primary endpoints of the trial include percentage of participants with COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14, percentage of participants with an adverse event and percentage of participants who discontinued study intervention due to an adverse event, <https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-pivotal-phase-3-move-ahead-study-evaluating-molnupiravir-for-post-exposure-prophylaxis-of-covid-19-infection/>.

Molnupiravir is now being evaluated in the **UK Panoramic trial**, coordinated by Oxford University (<https://www.panoramictrial.org/>). The inclusion criteria and primary efficacy endpoint are similar to the Move-Out trial, with two exceptions: Panoramic includes mainly vaccinated patients, and is being conducted during the Omicron wave, whereas Move-Out included only unvaccinated patients and was conducted in 2021, when previous variants led to more severe disease [96].

Results of publications

There are one published phase 2a RCT (as preprint [97]) related to effectiveness and safety of molnupiravir for Covid-19 (NCT04405570); one published phase 2 component of MOVE-OUT (NCT04575597) RCT [98], one published phase 2/3 RCT in hospitalised patients (NCT04575584, MOVE-IN) [99], and one published phase 3 component of MOVE-OUT (NCT04575597) trial [100]

US COVID-19 Treatment Guidelines Panel: Empfehlungen für ambulante, nicht-hospitalisierte Pts. (in Rangreihung nach Präferenz)

Molnupiravir nur als Alternative, wenn andere Therapien nicht verfügbar sind

Sept 2021: Phase 3 MOVE-AHEAD mit 1.332 Pts gestartet

PANORAMIC trial läuft mit geimpften Pts.

4 Publikationen

In June 2021, results from **phase 2a** randomized, double-blind, placebo-controlled trial (NCT04405570) to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of molnupiravir (EIDD-2801/MK-4482) are published as **preprint** and then in **scientific article** by **Fisher et al. 2021** [97, 101] Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days. Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 ($p=0.02$). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo ($p=0.03$). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo ($p=0.01$). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups. Four serious adverse events occurred and resulted in hospitalization, comprising one (1.6%) participant administered placebo who had hypoxia, two (3.2%) participants administered 400 mg molnupiravir (cerebrovascular accident and decreased oxygen saturation), and one (1.8%) participant administered 800 mg molnupiravir who had acute respiratory failure. Treatment was discontinued in all 4 participants.

Based on a planned interim analysis of data from the phase 2, dose-finding portion (Part 1) of two ongoing placebo-controlled phase 2/3 trials evaluating molnupiravir administered twice a day for five days in outpatients (NCT04575597, MOVE-OUT) [98] and hospitalised patients (NCT04575584, MOVE-IN) with COVID-19, and from a previously completed phase 2a dose-ranging study in outpatients, the decision has been made to proceed with the phase 3 portion (Part 2) of MOVE-OUT in outpatients with COVID-19, evaluating the 800 mg dose of molnupiravir twice daily. The **phase 2** component of **MOVE-OUT**, which results are published by **Caraco et al. 2021**, randomly assigned 302 participants to treatment 1:1:1:1 to receive **200, 400, or 800mg of molnupiravir or placebo twice daily for 5 days**. Of 225 participants in the combined molnupiravir group, 7 (3.1%) were hospitalised or died, compared with 4 of 74 participants (5.4%) in the placebo group. Subgroup analyses suggested lower incidences of hospitalisation and/or death in the molnupiravir versus placebo groups in participants older than 60 years of age, those with increased risk for severe illness, those with symptom onset up to (and including) 5 days before randomization, and those with both symptom onset up to (and including) 5 days before randomization and increased risk for severe illness [98].

Data from **MOVE-IN** published by **Arribas et al. 2021**, indicate that molnupiravir is unlikely to demonstrate a clinical benefit in hospitalised patients, who generally had a longer duration of symptoms prior to study entry; therefore, the decision has been made not to proceed to phase 3. A 5-day course of molnupiravir up to 800 mg twice daily was not associated with dose-limiting side effects or adverse events. Median time to sustained recovery was 9 days in all groups, with similar day 29 recovery rates ranging from 81.5% to 85.2% [99].

Phase 2a RCT 202 Pts.

**deutlich raschere
Reduktion der Virulslast
unter Molnupiravir**

Phase 2 (Dosisfindung) + Phase 2/3 MOVE-OUT 302 ambulante Pts.

**geringere
Hospitalisierungen
3,1% vs 5,4%**

MOVE-IN hospitalisierte Pts

keine Wirksamkeit

Jayk Bernal et al. 2021 published results from the **phase 3 MOVE-OUT trial** (NCT04575597): a total of 1433 **unvaccinated** participants underwent randomization; 716 were assigned to receive **800 mg of molnupiravir** and 717 to receive placebo, **twice daily for 5 days**. The superiority of molnupiravir was demonstrated at the interim analysis; the risk of hospitalization for any cause or death through day 29 was lower with molnupiravir (28 of 385 participants [7.3%]) than with placebo (53 of 377 [14.1%]) (difference, -6.8 percentage points; 95% confidence interval, -11.3 to -2.4; $p=0.001$). In the analysis of all participants who had undergone randomization, the percentage of participants who were hospitalized or died through day 29 was lower in the molnupiravir group than in the placebo group (6.8% [48 of 709] vs. 9.7% [68 of 699]; difference, -3.0 percentage points; 95% confidence interval, -5.9 to -0.1). Results of subgroup analyses were largely consistent with these overall results; in some subgroups, such as patients with evidence of previous SARS-CoV-2 infection, those with low baseline viral load, and those with diabetes, the point estimate for the difference favored placebo. One death was reported in the molnupiravir group and 9 were reported in the placebo group through day 29. Adverse events were reported in 216 of 710 participants (30.4%) in the molnupiravir group and 231 of 701 (33.0%) in the placebo group [100].

Johnson et al. 2022 [102] published results from **secondary analysis** of this randomized, double-blind, placebo-controlled phase 3 component of MOVE-OUT. Participants receiving molnupiravir showed faster normalization of CRP and Spo2, with improvements observed on day 3 of therapy, compared with placebo. Molnupiravir-treated participants had a decreased need for respiratory interventions versus placebo-treated participants (relative risk reduction [RRR], 34.3% [95% CI, 4.3% to 54.9%]), with similar findings in participants who were hospitalized after randomization (RRR, 21.3% [CI, 0.2% to 38.0%]). Hospitalised participants who received molnupiravir were discharged a median of 3 days before those who received placebo. Acute care visits (7.2% vs. 10.6%; RRR, 32.1% [CI, 4.4% to 51.7%]) and COVID-19-related acute care visits (6.6% vs. 10.0%; RRR, 33.8% [CI, 5.6% to 53.6%]) were less frequent in molnupiravir versus placebo treated participants.

Koudinya Tippabhotla et al. 2022 [103] published as preprint positive results from phase 3, randomized, open-label, parallel-group study in 1220 patients with laboratory-confirmed (RT-PCR positive) SARS-CoV-2 infection across 16 centres in India. 7.3% (90/1220) patients were with one risk factor (i.e. hypertension, diabetes mellitus, obesity, hypothyroidism, hyperthyroidism) presenting a risk for progression to severe COVID-19 (Clinical Trials Registry of India, CTRI/2021/07/034588). **Non-hospitalized adults with mild COVID-19** were randomized to receive either molnupiravir 800 mg (200 mg x 4 capsules administered orally every 12 hours for 5 days) with SOC or SOC alone and followed up at day 5 (end of treatment, and days 10, 14 and 28. Standard of care was provided as per the clinical guidance for management of adult COVID-19 patients by the Government of India or as per the Investigator's discretion.

The primary endpoint was the rate of hospitalisation of patients from randomization till day 14. Secondary endpoints included rate of hospitalisation of patients from randomization up to day 28; clinical improvement (2-point decrease in 11-point WHO Clinical Progression Scale) at days 5, 10, and 14; SARS-CoV-2 RT-PCR negativity at the end of treatment; and mortality rate at day 14 and day 28. 1220 patients were randomly assigned to receive molnupiravir + SOC (n=610) or SOC alone

Phase 3 von MOVE-OUT
1.433 ungeimpfte
ambulante Pts.

geringere
Hospitalisierungen
(oder Tod)
6,8% vs 9,7%

Sekundäranalyse von
MOVE-OUT

RRR 34,4% bei
repiratorischen
Interventionen und
Ambulanzbesuchen

RCT, Phase 3
1.220 Pts. (Indien)
nicht-hospitalisierte Pts.

frühere Genesung
(10 vs. 14 Tage) mit
Molnupiravir

keine SAE

(n=610) and considered for the intent-to-treat (ITT) analysis. No patient met the hospitalisation-defined criteria during the 14-day duration as well as till day 28. Clinical improvement was observed significantly earlier in patients of molnupiravir + SOC group as compared to the SOC alone group at the end of treatment day 5 (29.0% vs 5.6%), and further at day 10 (67.4% vs 31.6%) and day 14 (89.0% vs 79.5%) in the ITT population ($p < 0.001$ for all). The median time to clinical improvement was 10 days in molnupiravir + SOC group vs. 14 days in SOC alone group ($p < 0.001$). Significantly higher proportion of patients in the molnupiravir + SOC group were associated with RT-PCR negativity as compared to SOC alone at day 5 (81.5% vs. 17.4%), day 10 (89.8% vs. 46.4%), and day 14 (93.1% vs 83.1%) ($p < 0.0001$ for all). Mean viral load at day 5 was 4.8 in the molnupiravir + SOC vs. 21.8 in the SOC alone group ($p < 0.001$). There were no serious adverse events or deaths reported in the study till day 28.

Summary of Findings Table 3.2-6 related to 4 RCTs mentioned above in outpatients (Caraco, 2021; Jayk Bernal, 2021; Fischer, 2021; Koudinya Tippabhotla 2022) can be found below. In Summary, molnupiravir probably reduce all-cause mortality at Day28 (RR 0.19, 95% CI 0.04 to 0.86, moderate certainty of evidence) compared to standard care/placebo. The same is true for the outcomes of hospitalisation or death (RR 0.68, 95% CI 0.50 to 0.94, moderate certainty of evidence). Evidence is very uncertain on viral negative conversion D7 (RR 1.97, 95% CI 0.76 to 5.10, very low certainty of evidence). Molnupiravir probably does not increase adverse events (RR 0.94, 95% CI 0.83 to 1.06, moderate certainty of evidence) compared to standard care/placebo. Evidence is uncertain on Serious adverse events (RR 0.75, 95% CI 0.53 to 1.05, low certainty of evidence).

**SoF von 4 RCTs:
ev. Reduktion der
Hospitalisierungen
(32%RRR),
28-Tages Mortalität**

Table 3.2-6: Summary of findings table, on **molnupiravir vs standard care/placebo** (4 RCTs: Caraco, 2021; Jayk Bernal, 2021; Fischer, 2021; Koudinya Tippabhotla 2022)**Molnupiravir compared to Standard Care/Placebo for Mild COVID-19 – Outpatients** (last update 27/04/2022)**Patient or population:** Mild COVID-19 - Outpatients**Setting:** Worldwide**Intervention:** Molnupiravir**Comparison:** Standard Care/Placebo

Outcome	Anticipated absolute effects (95% CI) ^a		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with Standard treatment/Placebo	Risk with Molnupiravir				
All-cause mortality D28	8 per 1000	1 per 1000	RR: 0.19 (0.04 - 0.86)	2920 (4 RCTs) ^b	⊕⊕⊕○ MODERATE ^c	Absolute effect (95% CI) 6 fewer per 1000 (from 7 fewer to 1 fewer)
Clinical improvement D28	795 per 1000	890 per 1000	RR: 1.12 (1.07 - 1.18)	1220 (1 RCT)	⊕⊕○○ LOW ⁱ	Absolute effect (95% CI) 95 more per 1000 (from 56 more to 143 more)
WHO progression score (level 7 or above) D28	0 per 1000	0 per 1000	RR: (-)	1220 (1 RCT)	⊕○○○ VERY LOW ^m	Zero events in both groups
Hospitalisation or death	61 per 1000	41 per 1000	RR: 0.68 (0.50 - 0.94)	2803 (3 RCTs) ^d	⊕⊕⊕○ MODERATE ^e	Absolute effect (95% CI) 19 fewer per 1000 (from 30 fewer to 4 fewer)
Viral negative conversion D7	96 per 1000	190 per 1000	RR: 1.97 (0.76 - 5.10)	2770 (3 RCTs) ^f	⊕○○○ VERY LOW ^g	Absolute effect (95% CI) 94 more per 1000 (from 23 fewer to 396 more)
Number of patients with adverse events	245 per 1000	230 per 1000	RR: 0.94 (0.83 - 1.06)	2920 (4 RCTs) ^h	⊕⊕⊕○ MODERATE ⁱ	Absolute effect (95% CI) 15 fewer per 1000 (from 42 fewer to 15 more)
Number of patients with serious adverse events	49 per 1000	37 per 1000	RR: 0.75 (0.53 - 1.05)	2920 (4 RCTs) ^j	○○⊕⊕ LOW ^k	Absolute effect (95% CI) 12 fewer per 1000 (from 23 fewer to 2 more)

a The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI); b Caraco Y, 2021; Jayk Bernal A, 2021; Fischer W, 2021; Koudinya Tippabhotla 2022; c Imprecision: Serious due to low number of participants; d Caraco Y, 2021; Jayk Bernal A, 2021; Koudinya Tippabhotla 2022; e Imprecision: Serious due to low number of participants; f Jayk Bernal A, 2021; Fische W, 2021; Koudinya Tippabhotla 2022; g Risk of bias: Very serious Risk of bias downgraded by 2 levels: some concerns or high risk regarding missing data, and selection of the reported results Imprecision: Serious due to low number of participants h Caraco Y, 2021; Jayk Bernal A, 2021; Fischer W, 2021; Koudinya Tippabhotla 2022; i Imprecision: Serious due to low number of participants; j Caraco Y, 2021; Jayk Bernal A, 2021; Fischer W, 2021; Koudinya Tippabhotla 2022; k Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for no effect and low number of participants; l Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious due to low number of participants; m Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious no events in both groups and low number of participants

3.2.27 Ivermectin

The reader is referred to the earlier versions (V15_June 2021 and V17_August and September 2021) for more details on ivermectin treatment in COVID-19 patients.

The **US COVID-19 Treatment Guidelines Panel** Statement (April 29, 2021) [42] [12] is: the Panel now **recommends against** the use of ivermectin for the treatment of COVID-19, except in clinical trials (**AIIa**).

The **WHO Therapeutics and COVID-19 living guideline** [104, 105] includes a **recommendation not to use ivermectin except in the context of a clinical trial**. Such recommendation is based on the living systematic review and network meta-analysis (NMA) that pooled data from 16 randomized controlled trials (RCTs) with 2407 participants, including both inpatients and outpatients with COVID-19. The effects of ivermectin on mortality, need for invasive mechanical ventilation, hospital admission, duration of hospitalization and time to viral clearance all remain very uncertain (all very low certainty evidence). The uncertainty results from important concerns related to risk of bias in the included studies, and imprecision from a very low number of events and, in some cases, wide confidence intervals (CIs) in pooled estimates. Ivermectin may increase the risk of serious adverse events (SAEs) leading to drug discontinuation (odds ratio [OR] 3.07; 95% CI: 0.77–12.09; low certainty evidence) and may have little or no impact on time to clinical improvement (mean difference [MD] 0.5 fewer days; 95% CI: 1.7 fewer days to 1.1 more days; low certainty evidence). There was no credible subgroup effect based on dose. Subgroup analyses were not performed examining between-study differences in age or illness severity as per our pre-defined decision to limit subgroup analysis to within-study comparisons.

Verweis auf v15

**US COVID-19 Treatment Guidelines Panel:
Empfehlung GEGEN
Ivermectin**

**WHO Therapeutics and COVID-19 living guideline
(basierend auf NMA von
16 RCTs):**

**Empfehlung GEGEN
Ivermectin (außer in klin.
Studien)**

3.2.28 Aspirin

The reader is referred to the earlier version (V17_August and September 2021) for more details on **Aspirin**.

The **US COVID-19 Treatment Guidelines Panel** Statement (February 24, 2022) [12]: The Panel **recommends against** the use of aspirin to prevent mortality or the need for organ support (**AI**). The Panel recommends that anticoagulant or antiplatelet therapy not be used to prevent arterial thrombosis outside of the usual standard of care for patients without COVID-19 (**AIII**).

The **final results** were published from **RECOVERY** trial. 7351 patients were randomly allocated (1:1) to receive aspirin and 7541 patients to receive usual care alone. Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) of 7541 patients allocated to usual care died within 28 days (rate ratio 0.96, 95% CI 0.89–1.04; $p=0.35$). Consistent results were seen in all prespecified subgroups of patients. Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median 8 days, IQR 5 to >28, *vs* 9 days, IQR 5 to >28) and a higher proportion were discharged from hospital alive within 28 days (75% *vs* 74%; rate ratio 1.06, 95% CI 1.02–1.10; $p=0.0062$). Among patients not on invasive mechanical ventilation at

Verweis auf v17

**US COVID-19 Treatment Guidelines Panel:
Empfehlung GEGEN
Aspirin**

**RECOVERY
7.351 hospitalisierte Pts**

**keine Unterschiede, kein
Vorteil von Aspirin**

baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (21% vs 22%; risk ratio 0.96, 95% CI 0.90–1.03; p=0.23). Aspirin use was associated with a reduction in thrombotic events (4.6% vs 5.3%; absolute reduction 0.6%, SE 0.4%) and an increase in major bleeding events (1.6% vs 1.0%; absolute increase 0.6%, SE 0.2%) [106].

3.2.29 Aviptadil (Zysami)

The reader is referred to the earlier version (V17_August and September 2021) for more details on **aviptadil (Zysami)**.

Verweis auf v17

3.2.30 Dimethyl fumarate

The reader is referred to the earlier version (V17_August and September 2021) for more details on **dimethyl fumarate**.

Verweis auf v17

3.2.31 Artesunate

The reader is referred to the earlier version (V17_August and September 2021) for more details on **artesunate**.

Verweis auf v17

3.2.32 Tofacitinib (Xeljanz)

About the drug under consideration

Tofacitinib is a potent, selective inhibitor of the JAK family. In enzymatic assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent TyK2. In human cells, tofacitinib preferentially inhibits signalling by heterodimeric cytokine receptors that associate with JAK3 and/or JAK1 with functional selectivity over cytokine receptors that signal via pairs of JAK2. Inhibition of JAK1 and JAK3 by tofacitinib attenuates signalling of interleukins (IL-2, -4, -6, -7, -9, -15, -21) and type I and type II interferons, which will result in modulation of the immune and inflammatory response [107].

JAK-Inhibitor

Acting on multiple critical pathways of the inflammatory cascade tofacitinib may ameliorate progressive, inflammation-driven lung injury in hospitalised patients with Covid-19.

Tofacitinib is not authorised in Covid-19 patients (EMA, FDA).

ev. Verbesserung der entzündungsbedingten Lungenschädigung bei hospitalisierten Patient*innen

The **US COVID-19 Treatment Guidelines Panel** Statement (August 25, 2021) [12] is: the Panel recommends **tofacitinib** as an **alternative** to **baricitinib** only when baricitinib is not available or not feasible to use (**BIIa**) for recently hospitalised patients with rapidly increasing oxygen

US COVID-19 Treatment Guidelines Panel Statement – Alternative zu Baricitinib

needs and systemic inflammation (see Section on baricitinib).

The **WHO living guideline (14 January 2022)** provided **conditional recommendation against** the use of tofacitinib for treating severe and critical COVID-19 [13].

**WHO: vorläufige
Empfehlung GEGEN
Tofacitinib**

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies were found for tofacitinib in COVID-19 patients.

Results of publications

Guimaraes et al. 2021 [108] published results from **STOP-COVID RCT (NCT04469114)**, on **hospitalised adults** with Covid-19 pneumonia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hospital discharge. The primary outcome was the occurrence of death or respiratory failure through day 28 as assessed with the use of an eight level ordinal scale (with scores ranging from 1 to 8 and higher scores indicating a worse condition). All-cause mortality and safety were also assessed. A total of 289 patients underwent randomization at 15 sites in Brazil. Overall, 89.3% of the patients received glucocorticoids during hospitalisation. The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; $p=0.04$). Death from any cause through day 28 occurred in 2.8% of the patients in the tofacitinib group and in 5.5% of those in the placebo group (hazard ratio, 0.49; 95% CI, 0.15 to 1.63). The proportional odds of having a worse score on the eight-level ordinal scale with tofacitinib, as compared with placebo, was 0.60 (95% CI, 0.36 to 1.00) at day 14 and 0.54 (95% CI, 0.27 to 1.06) at day 28. Serious adverse events occurred in 20 patients (14.1%) in the tofacitinib group and in 17 (12.0%) in the placebo group. Among the adverse events of special interest, deep-vein thrombosis, acute myocardial infarction, ventricular tachycardia, and myocarditis occurred in 1 patient each in the tofacitinib group; hemorrhagic stroke and cardiogenic shock occurred in 1 patient each in the placebo group. The incidence of serious infection was 3.5% in the tofacitinib group and 4.2% in the placebo group. Adverse events other than death that led to the discontinuation of the trial regimen occurred in 11.3% of the patients in the tofacitinib group and in 3.5% of those in the placebo group; the most common such events were an increase in aminotransferase levels (in 4.2% of the patients in the tofacitinib group and in 0.7% of those in the placebo group) and lymphopenia (in 2.8% and 1.4%, respectively).

**RCT
STOP-COVID
289 hospitalisierte Pts.**

**bessere Ergebnisse bei
Überleben und
Atemwegsversagen**

Nebenwirkungen

Murugesan et al. 2021 [109] published results from an open-labeled randomized control study on tofacitinib, in addition to the standard of care (SOC) in **hospitalised adults with mild to moderate COVID-19 pneumonia**. Patients ($n=100$) with COVID 19 pneumonia were randomly assigned to either control ($n=50$) (SOC treatment alone) or to study groups ($n=50$) receiving tofacitinib in addition. The study group received tofacitinib for 14 days irrespective of the discharge status and was followed up to 28 days. There was a greater relative reduction in levels of important markers of inflammation in the tofacitinib group than in the control group (CRP: 78% vs 45%; Ferritin: 15% vs 10%; D. Dimer: 37% vs 15%) although there were

**RCT
150 hospitalisierte Pts mit
milder-moderater
Lungenentzündung**

**kein Unterschied bei
Dauer der
Hospitalisierung oder bei
Bedarf zu Beatmung**

no differences in duration of hospitalisations or oxygen requirement. Tofacitinib, 10 mg was well-tolerated and was devoid of any serious adverse event.

Summary of Findings Table 3.2-7 (last update 09/03/2022) related to above two mentioned RCTs can be found below. In summary, evidence is uncertain about outcomes All-cause mortality D28 (RR 0.50, 95% CI 0.16 to 1.64, low certainty of evidence), Clinical improvement D28 (RR 1.05, 95% CI 0.97 to 1.12, low certainty of evidence), Adverse events (RR 1.16, 95% CI 0.77 to 1.76, low certainty of evidence) and Serious adverse events (RR 1.18, 95% CI 0.65 to 2.17, low certainty of evidence). Evidence is very uncertain about WHO progression score (level 7 or above) D28 (RR 0.42, 95% CI 0.15 to 1.16, very low certainty of evidence).

SoF von 2 RCTs:
unsichere Evidenz zu allen
Endpunkten

Table 3.2-7: Summary of findings table, on **tofacitinib vs standard care/placebo** (2 RCTs: STOP-COVID Guimaraes 2021; Murugesan 2021)

Tofacitinib compared to Standard Care/Placebo in hospitalised patients (last update 09/03/2022)

Patient or population: Hospitalised COVID-19 patients

Setting: Worldwide

Intervention: Tofacitinib

Comparison: Standard Care/Placebo

Outcome	Anticipated absolute effects (95% CI) ^a		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with Standard treatment/Placebo	Risk with Tofacitinib				
All-cause mortality D28	41 per 1000	21 per 1000	RR: 0.50 (0.16 - 1.64)	389 (2 RCTs) b	OO⊕⊕ LOW c	Absolute effect (95% CI) 21 fewer per 1000 (from 34 fewer to 26 more)
Clinical improvement D28	890 per 1000	934 per 1000	RR: 1.05 (0.97 - 1.12)	289 (1 RCT) d	OO⊕⊕ LOW e	Absolute effect (95% CI) 44 more per 1000 (from 27 fewer to 107 more)
WHO progression score (level 7 or above) D28	83 per 1000	35 per 1000	RR: 0.42 (0.15 - 1.16)	289 (1 RCT) f	OOO⊕ VERY LOW g	Absolute effect (95% CI) 48 fewer per 1000 (from 70 fewer to 13 more)
Number of patients with adverse events	221 per 1000	256 per 1000	RR: 1.16 (0.77 - 1.76)	289 (1 RCT) h	OO⊕⊕ LOW i	Absolute effect (95% CI) 35 more per 1000 (from 51 fewer to 168 more)
Number of patients with serious adverse events	117 per 1000	138 per 1000	RR: 1.18 (0.65 - 2.17)	289 (1 RCT) j	OO⊕⊕ LOW k	Absolute effect (95% CI) 21 more per 1000 (from 41 fewer to 137 more)

a The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI); b Guimaraes P, 2021; Murugesan H, 2021; c Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants; d Guimaraes P, 2021; e Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious due to low number of participants; f Guimaraes P, 2021; g Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect and low number of participants; h Guimaraes P, 2021; i Imprecision: Very serious due to wide confidence interval consistent with the possibility for no effect and the possibility for harm and low number of participants; j Guimaraes P, 2021; Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants

3.2.33 Fluvoxamine

The reader is referred to the earlier version (V17_August and September 2021) for more details on **fluvoxamine**.

Verweis auf v17

3.2.34 Nirmatrelvir and ritonavir (Paxlovid)

About the drug under consideration

PF-07321332 (now nirmatrelvir), an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity, and potent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency, in a phase 1 clinical trial in healthy human participants [110].

PF-07321332 with ritonavir (Paxlovid) is not authorised in Covid-19 patients (EMA, FDA).

On **December 16, 2021 EMA issued advice** on use of Paxlovid for the **treatment of COVID-19**. Paxlovid, which is **not yet authorised in the EU**, can be used to **treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease**. Paxlovid should be administered as soon as possible after diagnosis of COVID-19 and within 5 days of the start of symptoms. On **December 22, 2021 EMA published the conditions of use** for Paxlovid, following the CHMPs advice on its use to treat COVID-19. In parallel to the provision of this advice, a more comprehensive **rolling review started on 13 December 2021** ahead of application for a conditional marketing authorisation received on January 10, 2022 [111].

On **January 27, 2022 EMA's** human medicines committee (CHMP) has recommended granting a **conditional marketing authorisation** for the oral antiviral medicine Paxlovid (PF-07321332 / ritonavir) for the **treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe** [112]. The **European Commission authorised** the COVID-19 treatment Paxlovid, following evaluation by EMA on **January 28, 2022**.

On **December 22, 2021 FDA issued EUA** for Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the **treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients** (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with **positive results of direct SARS-CoV-2 testing**, and who are at **high risk for progression to severe COVID-19**, including hospitalization or death. It should be initiated as soon as possible after diagnosis of COVID-19 and **within five days of symptom onset**. The primary data supporting this EUA for Paxlovid are from EPIC-HR, a randomized, double-blind, placebo-controlled clinical trial studying Paxlovid for the treatment of non-hospitalised symptomatic adults with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Patients were adults 18 years of age and older with a prespecified risk factor for progression to severe disease or were 60 years and older regardless of prespecified chronic medical conditions. **All patients had**

Proteaseinhibitor

bislang nicht zugelassen

EMA: für mild bis moderat Erkrankte mit hohem Risiko auf Progression, innerhalb der ersten 5 Tage nach Krankheitsbeginn einzunehmen

Jän 2022: EMA vorläufige Zulassung für mild-moderat Hoch-Risiko Erkrankte

FDA: EUA (auch für Kinder)

EPIC-HR RCT an Ungeimpften mit (gewissen) Risikofaktoren

not received a COVID-19 vaccine and had not been previously infected with COVID-19. Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. It consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir's breakdown to help it remain in the body for a longer period at higher concentrations. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. It is not authorized for use for longer than five consecutive days [113].

In **June 2022 revision** of EUA [114], regarding **antiviral resistance**, the following Mpro amino acid substitutions were associated with reduced nirmatrelvir activity (≥ 3 -fold higher K_i values): G15S (4.4-fold), T135I (3.5-fold), S144A (91.9-fold), H164N (6.4-fold), H172Y (233-fold), Q189K (65.4-fold), and D248E (3.7-fold). G15S is present in the Lambda variant, which did not have reduced susceptibility to nirmatrelvir (relative to USA-WA1/2020) in cell culture. In addition, three SARS-CoV-2 Mpro amino acid positions where polymorphisms have not been naturally observed were evaluated by substituting alanine at these positions and assessing their impact on activity in biochemical assays. These Mpro amino acid substitutions were associated with reduced nirmatrelvir activity (i.e., higher K_i values): Y54A (23.6-fold), F140A (39.0-fold), and E166A (33.4-fold). The clinical significance of substitutions at these Mpro positions is unknown.

On **June 30, 2022** Pfizer **announced submission of New Drug Application to the FDA: approval** for the treatment of COVID-19 in **both vaccinated and unvaccinated individuals at high risk for progression to severe illness** from COVID-19; consistent with current emergency use authorization, <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda>

The US COVID-19 Treatment Guidelines Panel (last update **May 13, 2022**)

This statement contains the Panel's recommendations for treating **nonhospitalised patients** using the currently available therapies. The Panel recommends one of the following [12]:

Preferred therapies (listed in order of preference):

- **Ritonavir-boosted nirmatrelvir (Paxlovid) (AIIa)**
- **Remdesivir (BIIa)**

Alternative therapies (for use **ONLY** if none of the preferred therapies are available, feasible to use, or clinically appropriate, listed in alphabetical order):

- **Bebtelovimab 175 mg (CIII); or**
- **Molnupiravir 800 mg (CIIa)**

There are reports of SARS-CoV-2 viral rebound and the recurrence of COVID-19 symptoms in patients who completed a 5-day course of ritonavir-boosted nirmatrelvir. The frequency and clinical implications of these events are not yet known.

Many commonly used medications can be safely coadministered with ritonavir-boosted nirmatrelvir despite its drug-drug interaction potential. In

antivirale Resistenzen von Nirmatrelvir in Zellkulturen

Juni 2022: Pfizer beantragt FDA Zulassung auch für Geimpfte

US COVID-19 Treatment Guidelines Panel:

Empfehlung Therapie 1. Wahl

vermehrte Berichte zu Wiederauftreten von COVID-19-Symptomen nach Paxlovid Therapie

some cases, drug-drug interactions with ritonavir-boosted nirmatrelvir may lead to serious or life-threatening drug toxicities.

The WHO living guideline (22 April 2022) provided **strong recommendation** for the **use of nirmatrelvir-ritonavir** in patients with **non-severe COVID-19** at the **highest risk of hospitalisation** and **conditional recommendation against the use of nirmatrelvir-ritonavir** in patients with **non-severe COVID-19** at a **low risk of hospitalisation** [13].

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies were found for PF-07321332 in COVID-19 patients in ClinicalTrials.gov register.

Global development program on PF-07321332 includes a **phase 1**, double blind, sponsor open, single and multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of PF-07321332 in healthy participants (NCT04756531); a **phase 2/3** study of **PF-07321332/ritonavir** in **nonhospitalised high risk unvaccinated** adults with COVID-19 (**EPIC-HR**, NCT04960202) to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. On September 01, 2021 Pfizer announced that the first participant has been dosed in a pivotal **phase 2/3** clinical trial (**EPIC-SR**, NCT05011513) to evaluate the safety and efficacy of PF-07321332 in **non-hospitalised**, symptomatic adult participants who have a confirmed diagnosis of SARS-CoV-2 infection and are **not at increased risk** of progressing to severe illness, which may lead to hospitalisation or death. The randomized, double-blind trial will enroll approximately 1,140 participants (**unvaccinated** adults who were **at standard risk**, i.e., low risk of hospitalisation or death, as well as **vaccinated adults who have an acute breakthrough symptomatic COVID-19 infection and one or more risk factors for progressing to severe illness**), who will receive PF-07321332/ritonavir or placebo orally every 12 hours for five days. On **June 14, 2022** Pfizer **announced** that **enrolment into EPIC-SR trial is ceased** due to low rate of hospitalisation or death in the standard-risk population. One **phase 3 RCT (EPIC-PEP, NCT05047601)** evaluates effectiveness and safety of PF-07321332/ritonavir in **post-exposure prophylaxis**.

Results of publications

Currently, published results were found from one RCT related to PF-07321332/ritonavir in COVID-19 patients.

WHO Guideline: starke Empfehlung für Paxlovid für Pts. mit milder Erkrankung aber Risiko auf Progression

**Phase 1:
Studie zur Sicherheit**

**Phase 2/3 (EPIC-SR):
an nicht-hospitalisierten
ungeimpften Pts.**

PF-07321332/ritonavir

**auch Post-Exposure
Prophylaxe**

**Juni 2022: EPIC-SR
aufgrund geringer
Hospitalisierungs- oder
Sterberate eingestellt**

On **December 14, 2021** Pfizer **announced final results** from an analysis of all **2,246 adults** enrolled in its **phase 2/3 EPIC-HR** (Evaluation of Protease Inhibition for CCOVID-19 in High-Risk Patients, NCT04960202) trial of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), randomized, double-blind study of **non-hospitalised unvaccinated adult patients** with COVID-19, who are **at high risk of progressing to severe illness**. Most patients (2106, 93.8%) had not received or were not expected to receive monoclonal antibodies for Covid-19 treatment at randomization, and 1489 (66.3%) received the first dose of the trial drug or placebo within 3 days after the onset of symptoms. Before receiving the trial drug or placebo, 4 patients had received monoclonal antibodies for Covid-19 treatment (3 in the nirmatrelvir group and 1 in the placebo group). In **February 2022**, **Hammond et al.** published these results in the scientific journal [115]. Results were consistent with the interim analysis announced in November 2021 [116], showing Paxlovid significantly reduced the risk of hospitalisation or death for any cause by 89% (95% confidence interval CI, -9.04 to -3.59; $p < 0.001$; final analysis 95% CI, -7.78 to -3.84; $p < 0.001$) compared to placebo in non-hospitalised, high-risk adult patients with COVID-19 treated within three days of symptom onset. In a secondary endpoint, Paxlovid reduced the risk of hospitalisation or death for any cause by 88% (8 of 1039 patients (0.77%) in the nirmatrelvir group and 66 of 1046 (6.31%) in the placebo group were hospitalised for Covid-19 or died from any cause through day 28, $p < 0.001$) compared to placebo in patients treated within five days of symptom onset, an increase from the 85% observed in the interim analysis. A secondary endpoint, SARS-CoV-2 viral load at baseline and Day 5 have been evaluated for 499 patients. After accounting for baseline viral load, geographic region, and serology status, Paxlovid reduced viral load by approximately 10-fold, or 0.93 \log_{10} copies/mL, relative to placebo, indicating robust activity against SARS-CoV-2. Treatment-emergent adverse events were comparable between Paxlovid (23%) and placebo (24%), most of which were mild in intensity. Fewer serious adverse events (1.6% vs. 6.6%) and discontinuation of study drug due to adverse events (2.1% vs. 4.2%) were observed in patients dosed with Paxlovid, compared to placebo, respectively [117]. Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo.

Summary of Findings Table 3.2-8 related to this RCT mentioned above in outpatients (Hammond, 2022) can be found below. In Summary, Paxlovid probably reduces All-cause mortality at Day28 (RR 0.04, 95% CI 0.00 to 0.63, moderate certainty of evidence) compared to placebo. The same is true for the outcomes hospitalisation or death (RR 0.13, 95% CI 0.07 to 0.27, moderate certainty of evidence). Paxlovid probably does not increase AEs (RR 0.95, 95% CI 0.82 to 1.10, moderate certainty of evidence) and SAEs (RR 0.24, 95% CI 0.15 to 0.41, moderate certainty of evidence) compared to placebo.

On **June 14, 2022** Pfizer **announced** results from **EPIC-SR** trial: the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met. Pre-specified secondary endpoint resulted in a nominally significant 62% decrease in COVID-19-related medical visits per day across all patients, relative to placebo. In a sub-group analysis, non-significant 57% reduction in hospitalisations and death observed in PAXLOVID-treated vaccinated patients with at least one risk factor for severe COVID-19, <https://www.pfizer.com/news/press->

Phase 2/3 EPIC-HR
2.246 ambulante Pts,
ungeimpft

Informationen aus
Presseaussendung
89% Reduktion von
Hospitalisierung/ Tod

Publikation dazu im
Feb 2022:

signifikante Reduktion
von Hospitalisierungen
Behandlungsbeginn
innerhalb von 3 Tagen
nach Symptomen

vergleichbare
Nebenwirkungen

SoF (1 RCT)
87% RRR für
Hospitalisierung

EPIC-SR:
62% Reduktion von
Ambulanzbesuchen und
57% Reduktion von
Hospitalisierung

[release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting#:~:text=Additional%20analyses%20of%20secondary%20endpoints,placebo%20\(p%3D0.0228\)](#)

Recent **in vitro data** confirm that **nirmatrelvir** is a **potent inhibitor of the Omicron 3CL protease**, which, combined with existing in vitro antiviral and protease inhibition data from other Variants of Concern (VoC) including Delta, indicates that Paxlovid will retain robust antiviral activity against current VoCs as well as other coronaviruses [117].

**auch gegen Omicron
wirksam**

Currently, nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1 and BA.2. Several recently published laboratories studies, as preprint found potential resistance-conferring mutations. After 12 rounds of nirmatrelvir treatment, SARS-CoV-2 accumulated three mutations, at positions 50, 166 and 167 in MPRO, reducing susceptibility to nirmatrelvir 20-fold [118]. Zhou et al. 2022 [119] found potential resistance-conferring mutations at positions 50 and 166 in MPRO; with the combination of these mutations, the virus was 80 times less susceptible to nirmatrelvir. Hu et al. 2022 [120] reported 66 common mutations to MPRO near the nirmatrelvir binding site; five were resistance to nirmatrelvir, already known position 166, but also new ones, 144, 165, 172 and 192.

**..nur in Laborstudien
bislang potentielle
Resistenzen**

Recently published **preclinical study by Jeong et al. 2022** [121] shows that combination of nirmatrelvir and molnupiravir is more effective in transgenic mice than each treatment alone. This combination therapy effectively reduced clinical severity score, virus-induced tissue damage, and viral distribution compared to those in animals treated with these monotherapies. The nirmatrelvir and remdesivir combination showed less antiviral efficacy, with lower survival compared to nirmatrelvir monotherapy, demonstrating the inefficient therapeutic effect of this combination. Zhou et al. 2022 [119] found that remdesivir retained activity against nirmatrelvir resistant variants and combination of remdesivir and nirmatrelvir enhanced treatment efficacy compared to individual compounds.

Table 3.2-8: Summary of findings table, on nirmatrelvir/ritonavir vs placebo (1 RCT: Hammond, 2022)

Nirmatrelvir/ritonavir compared to Placebo for Mild COVID-19 – Outpatients (last update 30/03/2022)

Patient or population: Mild COVID-19 - Outpatients

Setting: Worldwide

Intervention: Nirmatrelvir/ritonavir

Comparison: Placebo

Outcome	Anticipated absolute effects (95% CI) ^a		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with Placebo	Risk with Nirmatrelvir/ritonavir				
All-cause mortality D28	0 per 1000	0 per 1000	RR: 0.04 (0.00 - 0.63)	2246 (1 RCT) ^b	⊕⊕⊕O MODERATE ^c	Absolute effect (95% CI) 11 fewer per 1000 (from 13 fewer to 6 fewer)
Clinical improvement D28	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported
WHO progression score (level 7 or above) D28	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported
Hospitalisation or death	60 per 1000	8 per 1000	RR: 0.13 (0.07 - 0.27)	2246 (1 RCT) ^d	⊕⊕⊕O MODERATE ^e	Absolute effect (95% CI) 53 fewer per 1000 (from 56 fewer to 44 fewer)
Viral negative conversion D7	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported
Number of patients with adverse events	236 per 1000	224 per 1000	RR: 0.95 (0.82 - 1.10)	2246 (1 RCT) ^h	⊕⊕⊕O MODERATE ⁱ	Absolute effect (95% CI) 12 fewer per 1000 (from 43 fewer to 24 more)
Number of patients with serious adverse events	66 per 1000	16 per 1000	RR: 0.24 (0.53 – 1.03)	2246 (1 RCT) ^j	⊕⊕⊕O MODERATE ^k	Absolute effect (95% CI) 50 fewer per 1000 (from 56 fewer to 39 fewer)

a The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI); b, d, h, j: Hammond, 2022; c, e, i, k: Imprecision: Serious due to low number of participants

3.2.35 AT-527

About the drug under consideration

AT-527 is a guanosine nucleotide analogue, a small molecule broad-spectrum antiviral against RNA viruses, which was initially developed to treat hepatitis C infection (flavivirus). It is administered orally as a pro-drug, which inside the cell is converted by phosphorylation into its active form (AT-9010). The compound interferes with the activity of the viral enzyme, which is carrying out the replication of the viral genome, by unique dual mechanisms targeting both RNA dependent RNA polymerase (RdRP) and the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) of viral non-structural protein (nsp12) polymerase [122, 123].

AT-527 is being developed for patients with mild to moderate COVID-19. The medicine is administered orally at 550 mg (two tablets) twice daily for five days.

AT-527 is not authorised in Covid-19 patients (EMA, FDA).

**antivirales Medikament
für HepC entwickelt**

**für milde und moderate
Covid-19 Erkrankung
orale Verabreichung**

Withdrawn, suspended or terminated studies

No withdrawn, or terminated studies were found for AT-527 in COVID-19 patients. One suspended trial was found (NCT05126576, MORNINGSKY) in ClinicalTrials.gov register (posted November 19, 2021: the phase 3 MORNINGSKY study (CV43043) has been temporarily paused due to the recent readout of preliminary results from the phase 2 MOONSONG dose-ranging study. A protocol amendment is under development by the Sponsor and co-development partner.).

**1 Studie angehalten
wegen Protokoll-
Veränderungen
(Ungeimpfte)**

It is now tested in **two phase 2** clinical trials (NCT04396106 and NCT04709835 – MOONSONG trial) for its safety and efficacy [124, 125]. The phase 2 trial enrolling hospitalised Covid-19 patients will be amended for unvaccinated, high-risk individuals' recruitment in the outpatient setting to assess the safety, virological activity and tolerability of the oral antiviral in unvaccinated individuals with moderate disease. The amended phase 2 trial is expected to enroll up to 200 patients. Atea anticipates reporting data from this trial during 2022 [126].

**2 laufende Studien:
Phase 2 MOONSONG**

AT-527 is being tested in one phase 3 global multicenter trial (NCT04889040, MORNINGSKY trial) evaluating efficacy and safety in patients with mild to moderate COVID-19 in **outpatient** setting; the results are expected in second half of 2022 [127]. As recently announced, the company will close this international phase 3 MORNINGSKY trial of its oral antiviral AT-527 due to changing COVID-19 landscape with the anticipated availability of new antiviral treatment regimens.

Phase 3 MORNINGSKY

AT-527 is being analysed for its potential to offer protection against Covid-19 disease progression and long-Covid complications development. Preclinical in vitro studies of AT-527 in combination with other compounds possessing different mechanisms of action to analyse additive and synergistic effects will be conducted also [126, 128].

präklinische Studien

Results of publications

Currently, no published results were found from phase 3 RCTs related to AT-527.

kein veröffentlichter RCT

Announced by Manufacturer, the **interim analysis** in **phase 2 RCT** (NCT04396106) showed a rapid decrease in the virus load (starting on day 2) and faster virus clearance [129].

On **October 19, 2021** Manufacturer announced results from **phase 2 MOONSONG trial** [130]: study did **not meet the primary endpoint** of reduction from baseline in the amount of SARS-CoV-2 virus in patients with **mild or moderate COVID-19** compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms. In high-risk patients with underlying health conditions, a reduction of viral load of approximately 0.5 log₁₀ at Day 7 was observed at 550 mg (prespecified subgroup analysis) and 1,100 mg BID (exploratory subgroup analysis) compared with placebo. AT-527 was generally safe and well tolerated. The proportion of patients experiencing any adverse event (AE) was 20% in the placebo group, 20% in the AT-527 550 mg BID group (Cohort A) and 27% in the AT-527 1100 mg BID group (Cohort B). There were 3 non-drug related serious adverse events (SAEs) in each of the treatment groups and all other AEs were grade 1 or 2. Gastrointestinal (GI)-related AEs were the most commonly reported AEs: 8% in the placebo group; 7% in the AT-527 550 mg BID group (Cohort A); 17% in the AT-527 1100 mg BID group (Cohort B), with mild to moderate nausea/vomiting resulting in premature study drug discontinuation of 3% in the placebo group, 0% in the AT-527 550 mg BID group (Cohort A) and 17% in the AT-527 1100 mg BID group (Cohort B). No clinically significant differences in laboratory abnormalities were observed in the treatment arms as compared to placebo.

**Firmenkommunikation zu
Zwischenauswertung
(MOONSONG)**

**in Hochrisiko Pts:
rasche Reduktion der
Viruslast**

3.2.36 Plonmarlimab (TJM2)

About the drug under consideration

Plonmarlimab (or TJM2) was discovered and developed by I-Mab to target human granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that plays a critical role in acute and chronic inflammation. Plonmarlimab specifically binds to human GM-CSF with high affinity and can block GM-CSF from binding to its receptor, thereby preventing downstream signalling and target cell activation. As a result, it can effectively inhibit inflammatory responses mediated by macrophages, neutrophils, and dendritic cells, leading to reduced tissue inflammation and damage.

Plonmarlimab is not authorised in Covid-19 patients (EMA, FDA).

**Inhibitor von
Entzündungs-reaktionen**

**nicht zugelassen für Covid-
19**

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies were found for plonmarlimab in COVID-19 patients.

Results of publications

On August 11 2021, Manufacturer I-Mab **announced positive interim data** from its U.S. phase 2/3 double-blind, placebo-controlled, randomized trial (NCT04341116) of plonmarlimab for the treatment of cytokine release syndrome (CRS) in 91 patients with **severe COVID-19**. The study aimed to determine the safety, efficacy and effects on cytokine levels following a single dose of 6 mg/kg of plonmarlimab or placebo in patients with severe COVID-19. Plonmarlimab treatment resulted in a higher mechanical ventilation free (MVf) rate (83.6% vs 76.7%) by day 30, lower mortality rate (4.9% vs 13.3%) by day 30, higher recovery rates (68.9% vs 56.7% at day 14 and 80.3% vs 70.0% at day 30), as well as reduced time to recovery and hospitalisation duration, as compared to placebo. A transient increase in Neutrophil to Lymphocyte Ratio (NLR) that is commonly associated with disease exacerbation was only observed in placebo. Plonmarlimab was well tolerated in all patients with no significant safety concerns [131].

Aug 2021:
Firmenkommunikation zu
Zwischenauswertung von
Phase 2/3, Pts mit
schwerer Erkrankung

Höhere Rat von
beatmungsfreien Tagen,
raschere Erholung

3.2.37 Mavrilimumab

About the drug under consideration

Mavrilimumab is a monoclonal antibody (human isoform IgG4) that binds to GM-CSF receptor alpha and disrupts downstream signalling. Before COVID-19, mavrilimumab was already in study as a potential treatment for giant cell arteritis, a chronic inflammatory disease of medium-large arteries [71, 132, 133].

monoklonaler Antikörper

On September 9, 2020, the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for mavrilimumab for giant cell arteritis [134]. Kiniksa Pharmaceuticals has received advice from the European Medicines Agency (EMA) during the clinical phase development of mavrilimumab as a potential immunomodulator for COVID-19 [135].

FDA: Orphan Drug
Designation

Mavrilimumab has not received approval by the EMA or the FDA for Covid-19 indication.

The **US COVID-19 Treatment Guidelines Panel** (update March 24, 2022):

- There is **insufficient evidence** for the COVID-19 Treatment Guidelines Panel to **recommend either for or against the use** of GM-CSF inhibitors for the treatment of hospitalised patients with COVID-19.

US COVID-19 Treatment
Guidelines Panel:
insuffiziente Evidenz

Withdrawn, suspended or terminated studies

There are two ongoing RCTs evaluating the efficacy of mavrilimumab against placebo in COVID-19 patients according to clinicaltrials.gov: a phase 2 trial (NCT04397497 EudraCT Number: 2020-001795-15) and a large phase 2/3 trial NCT04447469 to be completed in February 2022.

2 laufende RCTs:
Phase2 und Phase 2/3

Results of publications

There is one RCT with published results by **Cremer et al. 2021** that compared mavrilimumab against placebo, the **MASH-COVID** study (NCT04399980, NCT04463004, NCT04492514) [136]. The trial was terminated earlier than planned with 40 patients enrolled [137]. Regarding the effectiveness of mavrilimumab, the trial did not find differences between arms for any outcome. Regarding the safety, all patients completed the infusion without reaction, there were not any cases of neutropenia nor bacteraemia, and there were no treatment related deaths. Bacterial pneumonia was diagnosed in one patient who received placebo (5%) and two patients who received mavrilimumab (10%) [136, 138].

Results from the **phase 2 portion** of the on-going, global, randomized, double-blind, placebo-controlled seamless transition **phase 2/3 trial** designed to evaluate the efficacy and safety of mavrilimumab in adults hospitalised with severe COVID-19 pneumonia and hyperinflammation, showed that a single infusion of mavrilimumab **reduced progression to mechanical ventilation and improved survival**. Mavrilimumab recipients had a reduced requirement for mechanical ventilation and improved survival: at day 29, the proportion of patients alive and free of mechanical ventilation was 12.3 percentage points higher with mavrilimumab (86.7% of patients) than placebo (74.4% of patients) (Primary endpoint; $p=0.1224$). Mavrilimumab recipients experienced a **65% reduction in the risk of mechanical ventilation or death through Day 29 (Hazard Ratio (HR) = 0.35; $p=0.0175$)**. Day 29 mortality was 12.5 percentage points lower in mavrilimumab recipients (8%) compared to placebo (20.5%) ($p=0.0718$). Mavrilimumab recipients had a 61% reduction in the risk of death through Day 29 ($HR=0.39$; $p=0.0726$). Adverse events occurred less frequently in mavrilimumab recipients compared to placebo, including secondary infections and thrombotic events (known complications of COVID-19). Thrombotic events occurred only in the placebo arm (5/40 [12.5%]) [139] [140].

Follow-up overall survival data from the cohort of non-mechanically ventilated patients through **Day 90** demonstrated persistent clinical effect, confirming and extending the previously-reported Day 29 data. Kiniksa continues to enroll non-mechanically ventilated patients in the **phase 3** clinical trial of mavrilimumab in COVID-19 related ARDS, and expects data in the 1st quarter of 2022 [141].

On December 28, 2021 Kiniksa Pharmaceuticals, Ltd. **announced** that this **phase 3** portion of the trial in COVID-19 related ARDS (a total of 582 patients were randomized in a 1:1:1 ratio to receive a single intravenous dose of mavrilimumab 10 mg/kg, 6 mg/kg, or placebo) **did not meet its primary efficacy endpoint** of proportion of patients alive and free of mechanical ventilation at Day 29 [142].

Summary of Findings Table 3.2-9 related to 2 RCTs mentioned above can be found below. In Summary, evidence is very uncertain on outcome All-cause mortality at Day28 (RR 0.3, 95% CI 0.03 to 2.66, very low certainty of evidence) and on WHO progression score (level 7 or above) D28 (RR 0.23, 95% CI 0.03 to 1.85, very low certainty of evidence). Evidence is uncertain on Clinical improvement D28 (RR 1.51, 95% CI 1.06 to 2.15, low certainty of evidence), and on Serious adverse events (RR 1.13, 95% CI 0.35 to 3.6, low certainty of evidence).

**RCT MASH-COVID
40 Pts.
frühzeitiger Abbruch**

**kein Unterschied
zwischen den
Studienarmen**

**Phase 2/3 RCT
hospitalisierte Pts.**

**65% Reduktion der
künstlichen Beatmung
86,7% vs. 74,4% ohne
Beatmung nach 1 Monat**

geringere Mortalität

**Phase 3 Ergebnisse in
Q1/2022 erwartet**

**Presseaussendung zu
Phase 3 RCT: Pts
erreichten primären
Endpunkt nicht**

**SoF von 2 RCT:
sehr unsichere Evidenz**

Table 3.2-9: Summary of findings table, on **mavrilimumab vs placebo** (2 RCTs: Cremer, 2021; Pupim, 2021)

Mavrilimumab compared to Placebo for hospitalised patients (last update 09/02/2022)

Patient or population: Hospitalised patients

Setting: Worldwide

Intervention: Mavrilimumab

Comparison: Placebo

Outcome	Anticipated absolute effects (95% CI) ^a		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with Standard treatment/Placebo	Risk with Mavrilimumab				
All-cause mortality D28	158 per 1000	47 per 1000	RR: 0.3 (0.03 – 2.66)	40 (1 RCT) ^b	000⊕ VERY LOW ^c	Absolute effect (95% CI) 111 fewer per 1000 (from 153 fewer to 262 more)
Clinical improvement D28	632 per 1000	954 per 1000	RR: 1.51 (1.06 – 2.15)	40 (1 RCT) ^b	00⊕⊕ LOW ^d	Absolute effect (95% CI) 322 more per 1000 (from 38 more to 726 more)
WHO progression score (level 7 or above) D28	211 per 1000	48 per 1000	RR: 0.23 (0.03 – 1.85)	40 (1 RCT) ^b	000⊕ VERY LOW ^e	Absolute effect (95% CI) 111 fewer per 1000 (from 153 fewer to 262 more)
Number of patients with adverse events	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported	Outcome not yet measured or reported
Number of patients with serious adverse events	211 per 1000	238 per 1000	RR: 1.13 (0.35 – 3.6)	40 (1 RCT) ^b	00⊕⊕ LOW ^f	Absolute effect (95% CI) 27 more per 1000 (from 137 fewer to 547 more)

a The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI); b Cremer P, 2021; c Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants; d Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious due to low number of participants; e Indirectness: Serious, Multicentre study conducted across several countries, therefore not downgraded for indirectness Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants; f Indirectness: Serious Multicentre study conducted across several countries, therefore not downgraded for indirectness Imprecision: Serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants

3.2.38 SAB-185

About the drug under consideration

SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalised patients with mild to moderate COVID-19. It was developed in collaboration with the US government using SAB's novel proprietary DiversitAb™ Rapid Response Antibody Program, as part of the Countermeasures Acceleration Group, formerly Operation Warp Speed. The recent publication of nonclinical data demonstrating SAB-185's potent neutralization of multiple emerging SARS-CoV-2 variants including Delta and Lambda [143]. On December 16, 2021 SAB Biotherapeutics announced data demonstrating that SAB-185 retains neutralization activity against the Omicron SARS-CoV-2 variant in an *in vitro* pseudovirus model. The data were generated by scientists at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) [144]. Preclinical data has also indicated that SAB-185 is significantly more potent than human-derived convalescent immunoglobulin G (IgG).

SAB-185 is not authorised in Covid-19 patients (EMA, FDA).

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies were found for SAB-185 in COVID-19 patients.

It is being assessed in the **ACTIV-2 trial** funded and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) in collaboration with the AIDS Clinical Trials Group. SAB-185 advanced to the phase 3 trial based on meeting pre-defined graduation criteria. The **phase 3 portion** of the ACTIV-2 trial (**NCT04518410**) is a randomized, unblinded, active comparator-controlled adaptive platform study that assessing the clinical safety and efficacy of SAB-185 compared to active control monoclonal antibody treatment in people with mild to moderate COVID-19 who are at higher risk for progression to hospitalisation, enrolling approximately 600 participants to receive the investigational agent SAB-185 and 600 to receive an active comparator. The primary outcome measures of the phase 3 trial include safety and non-inferiority for the prevention of a composite endpoint of either hospitalisation or death from any cause through study day 28. On February 25, 2022 SAB Biotherapeutics announced an update to the design of this ongoing phase 3 ACTIV-2 trial (the phase 3 trial had been designed as an open-label, randomized non-inferiority study comparing SAB-185 to an active comparator—a monoclonal antibody cocktail casirivimab and imdevimab authorized for treatment of COVID-19). Going forward, the active comparator will be replaced with a placebo because the active comparator is not effective against the Omicron variant, which at the moment represents about 95% of new COVID-19 cases in the US [145].

Results of publications

Currently, no published results were found from phase 3 RCTs related to SAB-185 in COVID-19 patients.

**polyklonaler Antikörper
entwickelt in
Operation Warp Speed**

**Laborstudie zu Omicron:
wirksam**

**SAB-185 ist nicht
zugelassen für
Covid-19**

**ACTIV-2 , Phase 3
Pts mit milder oder
moderater Erkrankung**

**Feb 2022
Veränderung des
Studiendesigns:
aktiver Komparator wird
durch Placebo ersetzt**

kein veröffentlichter RCT

Announced by Manufacturer on September 24, 2021, both the low and high doses of SAB-185 tested in **phase 2** met the pre-defined efficacy goal for advancement to **phase 3** and appeared safe at the interim analysis [146]. On October 4, 2021 it was announced that the 1st patient has been dosed in the in phase 3 ACTIV-2 trial. The preferred dose to assess is the lower dose of SAB-185 (3,840 Units/kg) [147].

Sept/Okt 2021:
Firmenkommunikation
Beginn von ACTIV-2

3.2.39 Ensivibep (MP0420)

About the drug under consideration

Ensivibep is a small-molecule therapeutic designed by Molecular Partners in partnership with Novartis. It consists of a single kind of small molecule, from a novel class of antimicrobials known as DARPins (designed ankyrin repeat proteins). DARPins offer a differentiated approach to treating COVID-19 through a single molecule that can engage up to three parts of the SARS-CoV-2 virus simultaneously to neutralize the virus through multiple mechanisms. It is now being evaluated in clinical studies. Initial findings from the phase 1 trial of ensivibep showed it to be safe and well tolerated, with no significant adverse events and with the expected half-life of two to three weeks [148-150]. Ensivibep should be administered intravenously, as infusion.

Designed Ankyrin Repeat Protein (DARPin)

Antimikrobiotikum

IV Verabreichung

According to results of in vitro studies using pseudovirion models of SARS-CoV-2 to analyse for infectivity in the presence of ensivibep, the drug continues to retain full potency against the new viral variants of SARS-CoV-2 (i.e., UK (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.429), New York (B.1.526), emerging variants R.1 and A.23.1, the individual key mutations of the variants identified in India, B.1.617 and B.1.618, and other key spike mutations identified to date), and could have the potential for sustained binding to additional COVID-19 variants, as they may appear in the future [151]. In vitro testing has shown high neutralisation activity of ensivibep against SARS-CoV-2 variants, including Omicron.

auch bei unterschiedlichen Virus-Varianten (Omicron) wirksam

Ensivibep ist nicht zugelassen für Covid-19

Ensivibep is not authorised in Covid-19 patients (EMA, FDA).

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies in trial registers were found for ensivibep in COVID-19 patients.

On **November 17 2021**, Molecular Partners has announced to **stop** the **recruitment of hospitalised adult Covid-19 patients** in the **phase 3, ACTIV-3 clinical trial** of ensivibep (NCT04501978); after a futility analysis, it was found that ensivibep did not meet the thresholds needed to progress subject enrolment [152].

Phase 3, ACTIV-3 hospitalisierte Pts. angehalten (Unwirksamkeit)

Ensivibep is currently assessing in **phase 2/3 EMPHATY trial** (NCT04828161), in outpatients with early stages of infection, to prevent worsening symptoms and hospitalisation (adults, with a positive SARS-CoV-2 antigen test and who are experiencing at least two pre-determined mild/moderate symptoms of COVID-19 within 7 days of their diagnosis) [152]. EMPHATY Part A enrolled 407 patients to identify a dose of ensivibep with optimal safety and efficacy and recruited patients in the

Phase 2/3 EMPHATY 407 ambulante Pts.

USA, South Africa, India, the Netherlands and Hungary to explore three doses: 75mg, 225mg and 600mg.

Results of publications

Currently, no published results were found from phase 3 RCTs related to ensovibep in COVID-19 patients. **On January 10, 2022** Novartis and Molecular Partners **announced** that Part A of the EMPATHY clinical trial that compared single intravenous doses of ensovibep, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefit over placebo – composite endpoint of hospitalisation and/or Emergency Room (ER) visits or death, and time to sustained clinical recovery. No deaths occurred in any of the patients treated with ensovibep. All doses were well-tolerated and no unexpected safety issues were identified for any of the doses. The lowest dose of 75mg is the planned dose for further development [153].

keine veröffentlichten Studien

Presseaussendung

3.2.40 Bemcentinib

About the drug under consideration

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent and highly selective AXL inhibitor. It exhibits potent anti-viral activity in preclinical models against several enveloped viruses, including Ebola and Zika virus. Preclinical data suggest that bemcentinib is potentially useful for the treatment of early SARS-CoV-2 infection [154]. It targets a cell-surface protein called AXL, which is one of several cell surface receptors used by enveloped viruses to enter cells; it prevents inhibition of type I interferon, which is the cell's anti-viral defence mechanism, suggesting valuable utility in treatment of SARS-CoV-2 infection. New data investigating bemcentinib against SARS-CoV-2 mutations showed that bemcentinib is also efficacious in preventing SARS-CoV-2 infection by carrying circulating mutations [155]. It is administered as an oral capsule and taken once per day.

selektiver AXL Inhibitor

orale Verabreichung

Bemcentinib ist nicht zugelassen für Covid-19

Bemcentinib is not authorised in Covid-19 patients (EMA, FDA).

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies in trial registers were found for bemcentinib in COVID-19 patients.

Bemcentinib is investigated in **two phase 2 RCTs**, in **hospitalised COVID-19 patients**: one **BerGenBio's trial** conducted in South Africa and India (NCT04890509) is completed, but the results are not yet published.

2 laufende Studien Phase 2 RCTs hospitalisierte Pts.

The other is **ACCORD2 study**, sponsored by University Hospital Southampton, UK: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients (EudraCT 2020-001736-95).

ACCORD2 Plattform Studie

On **January 27, 2022** BerGenBio ASA and Oslo University Hospital **announced** to study bemcentinib in hospitalised COVID-19 patients in the EU funded **EU-SolidAct trial – European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial** as a part of EU-RESPONSE, a pan-European research project involved with the rapid and coordinated investigation of medications to treat COVID-19 during the ongoing pandemic. The EU-SolidAct (**EudraCT 2021-000541-41; NCT04891133**) is a multi-center, randomized, adaptive phase 2 and 3 platform trial, the master protocol of which has been developed to evaluate potential treatments in hospitalised patients with COVID-19, the disease caused by the SARS-CoV2 virus (coronavirus). Under the trial, bemcentinib will be studied in up to 500 hospitalised COVID-19 patients [156].

EU-SolidAct trial , Teil von EU-RESPONSE Adaptive Platform Trial:

500 hospitalisierte Pts.

Results of publications

Currently, no published results were found from phase 3 RCTs related to bemcentinib in COVID-19 patients.

keine veröffentlichten Studien

Firmenankündigungen:

bessere Wirksamkeit mit Bemcentinib bei Reduktion der Progression

In July 2021, **manufacturer** BerGenBio has **presented** a combined analysis of data from these two phase 2 studies mentioned above, at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Results favoured bemcentinib and showed survival 96.6% vs 91.2%; significantly reduced likelihood (69%) of progression to ventilation in higher severity cohort; and significantly increased likelihood (88%) of shorter time to recovery or discharge in higher severity cohort. Patients in the subgroup (higher severity cohort) were receiving oxygen (Grade 4) or non-invasive ventilation (Grade 5) and recorded serum levels of the inflammatory marker C-Reactive Protein (CRP) greater than 30mg/L. This subgroup represents more than 60% of the patients in the combined study population, and the previously reported treatment benefit in this group of patients in India and South Africa is reproduced in analysis of the patients studied in the UK. Bemcentinib was well tolerated throughout both studies [157].

3.2.41 Y180 - M^{pro} inhibitor

About the drug under consideration

The main protease (Mpro) of SARS-CoV-2 has central role in viral replication and its conservation among variants, and presents an attractive drug target. Quan et al. 2022 [158] published a **preclinical report** of a series of potent α -ketoamide-containing Mpro inhibitors obtained using the Ugi four-component reaction. The prioritized compound, oral **Y180**, showed an IC₅₀ of 8.1 nM against SARS-CoV-2 Mpro and had oral bioavailability of 92.9%, 31.9% and 85.7% in mice, rats and dogs, respectively.

Mpro inhibitor

Y180 protected against wild-type SARS-CoV-2, B.1.1.7 (Alpha), B.1.617.1 (Kappa) and P.3 (Theta), with EC₅₀ of 11.4, 20.3, 34.4 and 23.7 nM, respectively. Oral treatment with Y180 displayed a antiviral potency and substantially ameliorated the virus-induced tissue damage in both nasal turbinate and lung of B.1.1.7-infected K18-human ACE2 (K18-hACE2) transgenic mice. Therapeutic treatment with Y180 improved the survival of mice from 0 to 44.4% (p=0.0086) upon B.1.617.1 infection in the lethal infection model. Importantly, Y180 was also highly effective against the

vielversprechende präklinische Daten

B.1.1.529 (Omicron) variant both in vitro and in vivo. Preliminary preclinical safety evaluation did not show obvious toxicity both in vitro and in vivo. The safety of Y180 in humans remains to be determined in clinical trials.

In a head-to-head in vivo antiviral assay, therapeutic treatment with Y180/ritonavir was more potent than PF-07321332/ ritonavir against SARS-CoV-2 Omicron in K18-hACE2 transgenic mice [158].

Y180 is not authorised in Covid-19 patients (EMA, FDA).

Withdrawn, suspended or terminated studies

As of July 2022, there are no clinical trials registered in ClinicalTrials.gov register or EU Clinical Trials Register.

**keine klinischen Studien
laufend**

Results of publications

Currently, no published results were found from clinical trials related to Y180 in COVID-19 patients.

3.2.42 Ensitrelvir

About the drug under consideration

Ensitrelvir fumaric acid (S-217622; hereafter, ensitrelvir) is a novel oral SARS-CoV-2 3CL protease inhibitor discovered through joint research by Hokkaido University and Shionogi & Co., Ltd. [159] and is currently developed by Shionogi & Co., Ltd. for the treatment of COVID-19. As the SARS-CoV-2 3CL protease is essential for processing viral complex proteins needed for viral replication [160], its inhibition by ensitrelvir is expected to prevent viral replication. Ensitrelvir has shown antiviral efficacy in both in vitro and in vivo animal studies. Its safety, tolerability, and pharmacokinetic profile as single and multiple oral doses have been assessed in a phase 1 study (R. Shimizu, et al., unpublished data) [161].

oral Proteaseinhibitor

**erprobt in vitro + in vivo
(Tierstudien)**

Ensitrelvir is not authorised in Covid-19 patients (EMA, FDA).

Withdrawn, suspended or terminated studies

As of July 2022, there are no clinical trials on ensitrelvir registered in ClinicalTrials.gov register or EU Clinical Trials Register. No withdrawn, suspended or terminated studies in trial registers were found for ensitrelvir in COVID-19 patients.

One study registered in Japan Registry of Clinical Trials (jRCT2031210350) is currently ongoing (a multicenter, randomized, double-blind, placebo-controlled, phase 2/3 study to assess the efficacy, safety, and pharmacokinetics of 5-day oral administration of ensitrelvir) and the first results are published as preprint, see below.

1 Phase 2/3 Studie (Japan)

Results of publications

Currently, published results were found from one clinical trial related to ensitrelvir in COVID-19 patients.

Mukae et al. 2022 [161] published results as preprint from double-blind, **phase 2a part** of a phase 2/3 study (Japan Registry of Clinical Trials identifier: jRCT2031210350) assessed the efficacy and safety of ensitrelvir in Japanese patients with mild to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection. Sixty-nine patients enrolled from 56 sites were randomized (1:1:1) to orally receive 5-day ensitrelvir fumaric acid (375 mg on day 1 followed by 125 mg daily or 750 mg on day 1 followed by 250 mg daily) or placebo and followed up until day 28. The primary outcome was change from baseline in SARS-CoV-2 viral titer. A total of 16, 14, and 17 patients in the ensitrelvir 125 mg, ensitrelvir 250 mg, and placebo groups, respectively, were included in the intention-to-treat population (mean age: 38.8, 40.4, and 38.0 years, respectively). On day 4, the change from baseline in SARS-CoV-2 viral titer (log₁₀ 50% tissue culture infectious dose/mL) in patients with positive viral titer and viral RNA at baseline was greater with ensitrelvir 125 mg (mean [standard deviation], -2.42 [1.42]; $p = 0.0712$) and 250 mg (-2.81 [1.21]; $p = 0.0083$) versus placebo (-1.54 [0.74]), and ensitrelvir treatment reduced SARS-CoV-2 RNA by -1.4 to -1.5 log₁₀ copies/mL versus placebo. All adverse events were mild to moderate. Authors concluded that ensitrelvir treatment demonstrated rapid SARS-CoV-2 clearance and was well tolerated in patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection.

Mukae 2022
Phase 2a
(Dosisfindungsstudie) an
mild-moderat Erkrankten

3.2.43 Poly-ICLC (Hiltonol)

About the drug under consideration

Double-stranded RNA (dsRNA) and its mimic, polyinosinic acid: polycytidylic acid [Poly (I:C)], are recognized by toll-like receptor 3 (TLR3) and induce interferon (IFN)- β in many cell types. Poly (I:C) is the most potent IFN inducer. In vivo mouse studies, intraperitoneal injection of Poly (I:C) elicited IFN- α/β production and natural killer (NK) cells activation. The TLR3 pathway is suggested to contribute to innate immune responses against many viruses, including influenza virus, respiratory syncytial virus, herpes simplex virus 2, and murine cytomegalovirus [162-165].

Polyinosin-
Polycytidylsäure

Poly-ICLC (Hiltonol®) is an investigational drug and it is not authorised in Covid-19 patients (EMA, FDA).

Withdrawn, suspended or terminated studies

No withdrawn, suspended or terminated studies in trial registers were found for Poly-ICLC (Hiltonol®) in COVID-19 patients.

Currently, in ClinicalTrials.gov register one phase 1-1b study (NCT04672291) in Canada is registered to evaluate the safety and tolerability of nasally administered Poly-ICLC (Hiltonol®) treatment in study participants who are at high-risk for COVID-19.

1 Phase 1 Studie
registriert

Results of publications

Currently, no published results were found from clinical trials related to Poly-ICLC in COVID-19 patients.

3.2.44 Nitric Oxide Nasal Spray

About the drug under consideration

Nitric Oxide Nasal Spray (NONS) manufactured by SaNOTize is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. The NO molecule released from NONS is identical to the one delivered in its gaseous form to treat persistent pulmonary hypertension, or Blue Baby Syndrome, in newborn babies, <https://sanotize.com/>.

Nitric oxide is not authorised in Covid-19 patients (EMA, FDA). NONS has a marketing authorization as a Class I Medical Device in the EU.

Withdrawn, suspended or terminated studies

One withdrawn **phase 2** study was found (NCT04443868) in mild COVID-19 patients (no subjects enrolled).

As of July 2022, there are 2 clinical trials registered in ClinicalTrials.gov register. One is **phase 3** RCT (NCT05012319) in Bahrain to evaluate the efficacy of NONS compared to placebo in 500 asymptomatic or mild covid-19 patients to reduce the need for urgent medical care in term of the need of visiting the emergency room in participants with COVID-19 infection and reduce of symptoms. The other is a **phase 3** (NCT05109611) multicenter, randomized, double-blinded, placebo-controlled, clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of 13000 individuals at risk of exposure to COVID-19 infection in Canada and Sri Lanka. One is found in EU Clinical Trials Register (EudraCT 2020-004994-27).

Results of publications

Currently, two published results were found from clinical trials related to nitric oxide in COVID-19 patients.

Winchester et al. 2021 [166] showed the reduction of viral load in the UK **phase 2** RCT (EudraCT 2020-004994-27) trials aimed to measure whether nitric oxide nasal spray (NONS) could accelerate the reduction in SARS-CoV-2 RNA load versus control with a saline spray. Study recruited 80 mild, symptomatic COVID-19 infection participants who were divided into a NONS treatment or a placebo arm to test the efficacy of NONS as a treatment for mild COVID-19 infection. The nasal sprays were self-administered 5–6 times daily (two sprays per nostril/dose, 120–140 µL of solution/spray) for 9 days. Patients in the NONS treatment arm demonstrated viral loads, as determined from PCR testing of nose and throat swab sampling, that were lower at days 2 and 4 by a factor of 16.2 than those on placebo, and symptom resolution was also found to be faster on NONS treatment than on placebo in this study.

**Stickstoffmonoxid
Nasenspray**

**2 Phase 3 Studien
registriert
an asymptomatisch oder
mild Erkrankten**

**Winchester 2021
Phase 2 RCT
80 Pts**

**Administration des Sprays
5-6 x täglich**

**deutlich geringere
Viruslast und raschere
Symtombekämpfung**

Moni et al. 2021 [167] published as preprint results from the **phase 2** open label, randomised controlled feasibility trial (ISRCTN 16806663) conducted at a South Indian tertiary care referral centre, recruited COVID-19 pneumonia patients with hypoxic respiratory failure and allocated them into iNO cases and control groups(1:1). iNO was administered as pulses for 30 minutes for three consecutive days at 12-hour intervals in cases, in addition to standard of care received by the control group. The primary outcome was decline in viral load, as defined by a surrogate change in the RT-PCR cycle threshold. The co-primary clinical outcome was time to improvement of >2 points on the WHO Ordinal Scale(WOS). Among the 29 patients enrolled, 14 iNO cases and 11 controls completed the study protocol. Longitudinal analysis revealed a significant difference in the decline ($p<0.002$, $n=23$) in viral load among the iNO cases compared to controls. The proportion of patients achieving 2-point improvement in the WOS within 14 days of randomisation was significantly higher in the iNO cases ($n=11$, 79%), as compared to the controls ($n=4$, 36%) ($p=0.05$).

One RCT in **Canada** is completed: a multi-center, randomized, controlled, **phase 2** clinical efficacy study evaluating a novel nitric oxide releasing solution (NORS) treatment for the **prevention and treatment of COVID-19 in healthcare workers at risk of infection** (NCT04337918) but results are not posted in the clinicaltrial.gov register.

In **February 2022**, SaNOTize Research & Development Corp., (SaNOTize), and Glenmark Pharmaceuticals Limited (Glenmark), **announced** positive results of **phase 3** clinical trial and approval from India's drug regulator for the treatment of adult patients with COVID-19 who have a risk of progression of the disease, <https://www.businesswire.com/news/home/20220209005422/en/Phase-3-Clinical-Trial-Confirms-SaNOTize%E2%80%99s-Breakthrough-Treatment-is-99-Effective-Against-COVID-19-Receives-Regulatory-Approval-in-India>.

In this randomized, double-blind, placebo-controlled, parallel-arm study at 20 clinical sites across India that evaluated 306 patients, NONS reduced the SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours as compared to saline control. Treatment also demonstrated, in the high-risk group ($n=218$), a statistically significant greater proportion of patients who achieved a combination of clinical and virological cure, based on the World Health Organization (WHO) Progression Scale. The median time to negative PCR, in this group, was 4 days in the treatment group compared with 8 days in the control. Test subjects included patients infected with different variants, likely including Delta and Omicron. There were no significant adverse health events recorded in the phase 3 trial, or in over 500 subjects treated so far with NONS in clinical trials.

In **May 2022**, manufacturer **announced** results from the **real-word study**, conducted at Srinakharinwirot University in Bangkok, Thailand, with an Omicron outbreak in February, 2022. Authors found that participants who took NONS after COVID-19 after high-risk exposure were 75% less likely to become infected when compared to the control group, with a statistically significant reduction in infection rate. After exclusion for being low-risk or testing positive via antigen test kit (ATK) within 24 hours, 625 student participants were included in the analysis. Of these, 203 participants used NONS at least four times per day and 422 volunteers did not use NONS. All volunteers were tested via ATK on the fifth, seventh, and tenth day of quarantine, and positive tests were confirmed by PCR. Among the 203

Moni 2021
Phase 2 RCT
29 Pts.

deutlich raschere
Verringerung der
Viruslast

1 Phase 2 RCT aus Kanada
(ohne publizierten
Ergebnisse)

Pressemitteilung
Feb 2022 zu RCT (Indien)
306 Pts

raschere
Viruslastreduktion

Pressemitteilung
Mai 2022

RWE (Thailand)
625 Teilnehmer*innen
Post-Expositions-
prophylaxe

deutlich geringere
Infektionsrate

participants who used NONS, 13 tested positive (6.4% infection rate). Of the 422 in the control group, 108 participants tested positive (25.6% infection rate), a statistically significant difference from the treatment group ($p < 0.0001$). Participants in the NONS group reported only a mild side effect of nasal irritation (8 of the 203, or 3.9%), <https://www.businesswire.com/news/home/20220511005194/en/Clinical-Study-Suggests-SaNOtize-Nitric-Oxide-Nasal-Spray-Is-Effective-at-Preventing-COVID-19-after-High-Risk-Exposure>.

References

- [1] Pang J., Wang M., Ang I., Tan S., Lewis R., Chen J., et al. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. *J Clin Med.* 2020;9(3). Epub 2020/03/01. DOI: 10.3390/jcm9030623
- [2] Hodgson J. The pandemic pipeline. 2020 [cited 03.04.]. Available from: <https://www.nature.com/articles/d41587-020-00005-z>.
- [3] CureVac AG. COVID-19: Conference Call on Current Developments. Tübingen, Germany: 2020 [cited 03.04.]. Available from: <https://www.curevac.com/news/conference-call-on-current-developments>.
- [4] European Commission. Coronavirus: Commission offers financing to innovative vaccines company CureVac. 2020 [cited 03.04.]. Available from: https://ec.europa.eu/commission/presscorner/detail/en/IP_20_474
- [5] Boutron I. and et al. Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review Zenodo. 2020;April 8(<http://doi.org/10.5281/zenodo.3744600>).
- [6] Thorlund K., Dron L., Park J., Hsu G., Forrest J. and Mills E. A real-time dashboard of clinical trials for COVID-19. *Lancet.* 2020;April 24 (DOI:[https://doi.org/10.1016/S2589-7500\(20\)30086-8](https://doi.org/10.1016/S2589-7500(20)30086-8)).
- [7] Chen Q., Allot A. and Lu Z. Keep up with the latest coronavirus research. *Nature Communications.* 2020;579(7798):193.
- [8] European Medicines Agency (EMA). EMA adopts first list of critical medicines for COVID-19. 2022 [cited 08/06/2022]. Available from: <https://www.ema.europa.eu/en/news/ema-adopts-first-list-critical-medicines-covid-19>; https://www.ema.europa.eu/en/documents/other/list-critical-medicines-covid-19-public-health-emergency-phe-under-regulation-eu-2022/123_en.pdf.
- [9] European Medicines Agency (EMA). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December. 2021 [cited 17/12/2021]. Available from: <https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021>.
- [10] Federal Drug Administration (FDA). FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19. [cited 21/01/2022]. Available from: <https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19>.
- [11] Federal Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children. 2022 [cited 25/04/2022]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children?utm_campaign=&utm_content=1650912442&utm_medium=FDA&utm_source=linkedin
- [12] National Institute of Health (NIH). COVID-19 Treatment Guidelines. 2020. Available from: <https://covid19treatmentguidelines.nih.gov/introduction/>.
- [13] Agarwal A., Rochwerf B., Lamontagne F., Siemieniuk R., Agoritsas T., Askie L., et al. A living WHO guideline on drugs for covid-19. *BMJ.* 2020;370:m3379. Epub 2020/09/06. DOI: 10.1136/bmj.m3379.
- [14] Gottlieb R., Vaca C., Paredes R., Mera J., Webb B., Perez G., et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *New England Journal of Medicine.* 2021. DOI: 10.1056/NEJMoa2116846.
- [15] WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. *The Lancet.* 2022. DOI: 10.1016/S0140-6736(22)00519-0.

- [16] Fujii S. and Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. *Biochim Biophys Acta*. 1981;661(2):342-345. Epub 1981/10/13. DOI: 10.1016/0005-2744(81)90023-1.
- [17] Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181. Epub 2020/03/07. DOI: 10.1016/j.cell.2020.02.052.
- [18] Kawase M., Shirato K., van der Hoek L., Taguchi F. and Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. *J Virol*. 2012;86(12):6537-6545. Epub 2012/04/13. DOI: 10.1128/JVI.00094-12.
- [19] Zhou Y., Vedantham P., Lu K., Agudelo J., Carrion R., Jr., Nunneley J. W., et al. Protease inhibitors targeting coronavirus and filovirus entry. *Antiviral Res*. 2015;116:76-84. Epub 2015/02/11. DOI: 10.1016/j.antiviral.2015.01.011.
- [20] European network for health technology assessment (EUnetHTA). EUnetHTA Rolling Collaborative Review (RCR04). Authoring Team. Camostat for the treatment of Covid-19. Diemen (The Netherlands). 2020 [cited 15/08/2020]. Available from: https://eunetha.eu/wp-content/uploads/2020/08/EUnetHTA-Covid-19_RCR04_Camostat-v1.0.pdf.
- [21] Gunst J. and et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial *EclinicalMedicine*. 2021;<https://doi.org/10.1016/j.eclinm.2021.100849>.
- [22] Chupp G., Spichler-Moffarah A., Sogaard O., Esserman D., Dziura J., Danzig L., et al. A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste. *medRxiv : the preprint server for health sciences*. 2022:2022.2001.2028.22270035. DOI: 10.1101/2022.01.28.22270035.
- [23] Kinoshita T., Shinoda M., Nishizaki Y., Shiraki K., Hirai Y., Kichikawa Y., et al. Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study). *medRxiv*. 2022:2022.2003.2027.22271988. DOI: 10.1101/2022.03.27.22271988.
- [24] Apeiron Biologics. APN01. 2020 [cited 07.04.2020]. Available from: <https://www.apeiron-biologics.com/project-overview/#APN01>.
- [25] Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B., et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nature Medicine*. 2005;11(8):875-879. Epub 2005/07/10. DOI: 10.1038/nm1267.
- [26] Monteil V., Hyesoo K., Prado P., Hagelkrüys A., Wimmer R., Stahl M., et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. 2020 [cited 07.04.2020]. Available from: https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00739.pdf.
- [27] Federal Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19. 2021 [cited 24/06/2021]. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19>.
- [28] European Medicines Agency (EMA). EMA recommends approval for use of RoActemra in adults with severe COVID-19. 2021 [cited 06/12/2021]. Available from: <https://www.ema.europa.eu/en/news/ema-recommends-approval-use-roactemra-adults-severe-covid-19>.
- [29] World Health Organisation. Therapeutics and COVID-19. Living Guideline. 2021 [cited 06/07/2021]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2>.
- [30] European Medicines Agency (EMA). EPAR summary for the public: Kevzara (sarilumab). 2017. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara>.

- [31] Shankar-Hari M., Vale C., Godolphin P., Fisher D., Higgins J., Spiga F., et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. *JAMA*. 2021. Epub 2021/07/07. DOI: 10.1001/jama.2021.11330.
- [32] Lescure F., Honda H., Fowler R., Lazar J., Shi H., Wung P., et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Respiratory Medicine*. 2021. DOI: [https://doi.org/10.1016/S2213-2600\(21\)00099-0](https://doi.org/10.1016/S2213-2600(21)00099-0).
- [33] Gordon A., Mouncey P., Al-Beidh F., Rowan K., Nichol A., Arabi Y., et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report. *medRxiv*. 2021:2021.2001.2007.21249390. DOI: 10.1101/2021.01.07.21249390.
- [34] Gordon A., Mouncey P., Al-Beidh F., Rowan K., Nichol A., Arabi Y., et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med*. 2021;384(16):1491-1502. Epub 2021/02/26. DOI: 10.1056/NEJMoa2100433.
- [35] The REMAP-CAP Investigators and Derde L. Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. *medRxiv*. 2021:2021.2006.2018.21259133. DOI: 10.1101/2021.06.18.21259133.
- [36] Sivapalasingam S., Lederer D., Bhore R., Hajizadeh N., Criner G., Hosain R., et al. A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19. *medRxiv*. 2021:2021.2005.2013.21256973. DOI: 10.1101/2021.05.13.21256973.
- [37] Mariette X., Hermine O., Tharaux P., Resche-Rigon M., Porcher R., Ravaud P., et al. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. *The Lancet Rheumatology*. 2022;4(1):e24-e32. DOI: 10.1016/S2665-9913(21)00315-5.
- [38] Merchante N., Cárcel S., Garrido-Gracia J., Trigo-Rodríguez M., Esteban Moreno M., León-López R., et al. Early Use of Sarilumab in Patients Hospitalised with COVID-19 Pneumonia and Features of Systemic Inflammation. *Antimicrob Agents Chemother*. 2021:Aac0210721. Epub 2021/12/14. DOI: 10.1128/aac.02107-21.
- [39] Sancho-López A., Caballero-Bermejo A., Ruiz-Antorán B., Múñez Rubio E., García Gasalla M., Buades J., et al. Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study). *Infect Dis Ther*. 2021. DOI: 10.1007/s40121-021-00543-2.
- [40] Branch-Elliman W., Ferguson R., Doros G., Woods P., Leatherman S., Strymish J., et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. *PLoS One*. 2022;17(2):e0263591. Epub 2022/02/26. DOI: 10.1371/journal.pone.0263591.
- [41] García-Vicuña R., Rodríguez-García S., Abad-Santos F., Bautista Hernández A., García-Fraile L., Barrios Blandino A., et al. Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial. *Front Med (Lausanne)*. 2022;9:819621. Epub 2022/03/15. DOI: 10.3389/fmed.2022.819621.
- [42] National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2020 [cited 13/07/2020]. Available from: <https://www.covid19treatmentguidelines.nih.gov/>.
- [43] Food and Drug Administration (FDA). FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID-19 Treatment, Another Achievement in Administration's Fight Against Pandemic. 2020 [cited 23/08/2020]. Available from: <https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment>.
- [44] Federal Drug Administration (FDA). EUA Fact Sheet for Health Care Providers COVID-19 Convalescent Plasma 2021. Available from: <https://www.fda.gov/media/141478/download>.

- [45] Agarwal A., Rochwerf B., Siemieniuk R., Agoritsas T., Lamontagne F., Askie L., et al. A living WHO guideline on drugs for covid-19. (Update 7). Last update 6 Dec 2021. *BMJ*. 2020;370:m3379. Epub 2020/09/06. DOI: 10.1136/bmj.m3379.
- [46] Marovich M., Mascola J. and Cohen M. Monoclonal Antibodies for Prevention and Treatment of COVID-19. *JAMA*. 2020. DOI: 10.1001/jama.2020.10245.
- [47] World Health Organisation (WHO). Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). [cited 08/03/2022]. Available from: [https://www.who.int/news/item/08-03-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition-\(tag-co-vac\)-08-march-2022](https://www.who.int/news/item/08-03-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)-08-march-2022).
- [48] World Health Organisation (WHO). Statement on Omicron sublineage BA.2. [cited 22/02/2022]. Available from: <https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-ba.2>.
- [49] World Health Organisation (WHO). COVID-19 Weekly Epidemiological Update. Edition 90. 2022 [cited 04/05/2022]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>.
- [50] World Health Organisation (WHO). COVID-19 Weekly Epidemiological Update. Edition 97. 2022. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2022>.
- [51] World Health Organisation (WHO). COVID-19 Weekly Epidemiological Update. Edition 98. 2022 [cited 29/06/2022]. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---29-june-2022>.
- [52] National Institutes of Health (NIH). COVID-19 Treatment Guidelines. Last updated December 16, 2021. Available from: <https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/>; <https://www.covid19treatmentguidelines.nih.gov/tables/table-a/>.
- [53] RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2022;399(10325):665-676. Epub 2022/02/14. DOI: 10.1016/s0140-6736(22)00163-5.
- [54] European Medicines Agency (EMA). EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly. 2021 [cited 02/11/2021]. Available from: <https://www.ema.europa.eu/en/news/ema-ends-rolling-review-antibodies-bamlanivimab-etesevimab-covid-19-following-withdrawal-lilly>.
- [55] Federal Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals [cited 08/12/2021]. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure>.
- [56] Federal Drug Administration (FDA). Fact sheet for healthcare providers: Emergency use authorization for evusheld™ (tixagevimab co-packaged with cilgavimab). 2022 [cited 29/06/2022]. Available from: <https://www.fda.gov/media/154701/download>.
- [57] Montgomery H., Hobbs F., Padilla F., Arbetter D., Templeton A., Seegobin S., et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2022. Epub 2022/06/11. DOI: 10.1016/s2213-2600(22)00180-1.
- [58] Federal Drug Administration (FDA). FDA updates Sotrovimab emergency use authorization. 2022 [cited 04/05/2022]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization>.
- [59] Federal Drug Administration (FDA). Fact sheet for healthcare providers: Emergency use authorization for bebtelovimab. [cited 22/02/2022]. Available from: <https://www.fda.gov/media/156152/download>.

- [60] Federal Drug Administration (FDA). Bebtelovimab. Emergency use authorization revised fact sheets. 2022 [cited 16/06/2022]. Available from: <https://www.fda.gov/media/156152/download>.
- [61] Dougan M., Azizad M., Chen P., Feldman B., Frieman M., Igbinalolor A., et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. 2022:2022.2003.2010.22272100. DOI: 10.1101/2022.03.10.22272100.
- [62] Federal Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant. [cited 11/02/2022]. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains>.
- [63] European network for health technology assessment (EUnetHTA). Rolling Collaborative Review (RCR06) Authoring Team. Solnatide for the treatment of COVID-19. Diemen (The Netherlands). 2020 [cited 15/08/2020]. Available from: https://eunetha.eu/wp-content/uploads/2020/08/EUnetHTA-Covid-19_RCR06_SOLNATIDE_August2020_FINAL.pdf.
- [64] European Medicines Agency (EMA). Insufficient data on use of inhaled corticosteroids to treat COVID-19. 2021 [cited 27/05/2021]. Available from: <https://www.ema.europa.eu/en/news/insufficient-data-use-inhaled-corticosteroids-treat-covid-19>.
- [65] Ramakrishnan S., Nicolau D., Langford B., Mahdi M., Jeffers H., Mwasuku C., et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine. 2021. DOI: 10.1016/S2213-2600(21)00160-0.
- [66] Yu L., Bafadhel M., Dorward J., Hayward G., Saville B., Gbinigie O., et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv. 2021:2021.2004.2010.21254672. DOI: 10.1101/2021.04.10.21254672.
- [67] Yu L., Bafadhel M., Dorward J., Hayward G., Saville B., Gbinigie O., et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843-855. Epub 2021/08/14. DOI: 10.1016/s0140-6736(21)01744-x.
- [68] Zhuravel S., Khmelnskiy O., Burlaka O., Gritsan A., Goloshchekin B., Kim S., et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine. 2021;41:101169. Epub 2021/11/02. DOI: 10.1016/j.eclinm.2021.101169.
- [69] Criner G. J., Lang F. M., Gottlieb R. L., Mathews K. S., Wang T. S., Rice T. W., et al. Anti-GM-CSF Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Respir Crit Care Med. 2022. Epub 2022/03/16. DOI: 10.1164/rccm.202108-1859OC.
- [70] Rizk J., Kalantar-Zadeh K., Mehra M., Lavie C., Rizk Y. and Forthal D. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80(13):1267-1292. Epub 2020/07/23. DOI: 10.1007/s40265-020-01367-z.
- [71] Bonaventura A., Vecchié A., Wang T., Lee E., Cremer P., Carey B., et al. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front Immunol. 2020;11:1625. Epub 2020/07/29. DOI: 10.3389/fimmu.2020.01625.
- [72] Temesgen Z. and al. e. Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: Results from the live-air phase 3 randomized double-blind placebocontrolled trial. medRxiv preprint. 2021;May 5. DOI: <https://doi.org/10.1101/2021.05.01.21256470>.
- [73] Temesgen Z., Burger C., Baker J., Polk C., Libertin C., Kelley C., et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. The Lancet Respiratory Medicine. 2021. DOI: 10.1016/S2213-2600(21)00494-X.
- [74] European Medicines Agency (EMA). Olimiant (baricitinib): EPAR – Medicine overview. 2020. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant>.
- [75] European network for health technology assessment (EUnetHTA). Rolling Collaborative Review (RCR18) Authoring Team. Baricitinib for the treatment of COVID-19. Diemen (The Netherlands):

2020. Available from: https://eunethta.eu/wp-content/uploads/2020/12/EUnetHTA-Covid-19_RCR18_Baricitinib_v1.0_FINAL.pdf.
- [76] Federal Drug Administration (FDA). Fact sheet for healthcare providers emergency use authorization (EUA) of Baricitinib. 2020. Available from: <https://www.fda.gov/media/143823/download>.
- [77] Federal Drug Administration (FDA). Fact sheet for healthcare providers Emergency Use Authorization (EUA) of baricitinib. 2021 [cited 28/07/2021]. Available from: <https://www.fda.gov/media/143825/download>.
- [78] Federal Drug Administration (FDA). FDA Roundup: May 10 2022. 2022. Available from: <https://www.fda.gov/news-events/press-announcements/fda-roundup-may-10-2022>.
- [79] European Medicines Agency (EMA). EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen. EMA- News 29/04/2021: <https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-olumiant-hospitalised-covid-19-patients-requiring-supplemental-oxygen>. 2021.
- [80] RECOVERY Study protocol. Randomised evaluation of Covid-19 therapy (RECOVERY). 2021 [cited 10/03/2021]. Available from: <https://www.recoverytrial.net/files/recovery-protocol-v14-0-2021-02-15.pdf>.
- [81] Kalil A., Patterson T., Mehta A., Tomashek K., Wolfe C., Ghazaryan V., et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *New England Journal of Medicine*. 2020. DOI: 10.1056/NEJMoa2031994.
- [82] European network for Health Technology Assessment (EUnetHTA). Rolling Collaborative Review (RCR18) Authoring Team. Baricitinib for the treatment of COVID-19. Diemen (The Netherlands). February 2021. 3.0. Available from: <https://www.eunethta.eu>.
- [83] Marconi V. and et al. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19. medRxiv preprint. 2021;May 3, doi: <https://doi.org/10.1101/2021.04.30.21255934>.
- [84] Marconi V., Ramanan A., de Bono S., Kartman C., Krishnan V., Liao R., et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med*. 2021. Epub 2021/09/05. DOI: 10.1016/s2213-2600(21)00331-3.
- [85] Ely E., Ramanan A., Kartman C., de Bono S., Liao R., Piruzeli M., et al. Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial. medRxiv. 2021:2021.2010.2011.21263897. DOI: 10.1101/2021.10.11.21263897.
- [86] Ely E., Ramanan A., Kartman C., de Bono S., Liao R., Piruzeli M., et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. *Lancet Respir Med*. 2022. Epub 2022/02/07. DOI: 10.1016/s2213-2600(22)00006-6.
- [87] Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation. [cited 03/08/2021]. Available from: <https://investor.lilly.com/news-releases/news-release-details/lilly-and-incytes-baricitinib-reduced-deaths-among-patients>.
- [88] Recovery Collaborative Group, Horby P., Emberson J., Mafham M., Campbell M., Peto L., et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medRxiv. 2022:2022.2003.2002.22271623. DOI: 10.1101/2022.03.02.22271623.
- [89] Wolfe C., Tomashek K., Patterson T., Gomez C., Marconi V., Jain M., et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. *Lancet Respir Med*. 2022. Epub 2022/05/27. DOI: 10.1016/s2213-2600(22)00088-1.
- [90] Karampitsakos T., Papaioannou O., Tsiri P., Katsaras M., Katsimpris A., Kalogeropoulos A., et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label,

- randomized controlled trial. medRxiv. 2022:2022.2006.2013.22276211. DOI: 10.1101/2022.06.13.22276211.
- [91] Cox R., Wolf J. and Plemper R. Therapeutic MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets. Research Square. 2020:rs.3.rs-89433. DOI: 10.21203/rs.3.rs-89433/v1.
- [92] European network for health technology assessment (EUnetHTA). Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): 2020. Available from: https://eunetha.eu/wp-content/uploads/2020/12/EUnetHTA-Covid-19_RCR19_Molnupiravir_v1.0_FINAL.pdf.
- [93] European Medicines Agency (EMA). COVID-19: EMA starts rolling review of molnupiravir. [cited 25/10/2021]. Available from: <https://www.ema.europa.eu/en/news/covid-19-ema-starts-rolling-review-molnupiravir>.
- [94] European Medicines Agency (EMA). EMA reviewing new data on effectiveness of Lagevrio (molnupiravir) for the treatment of COVID-19. 2021 [cited 14/12/2021]. Available from: <https://www.ema.europa.eu/en/news/ema-reviewing-new-data-effectiveness-lagevrio-molnupiravir-treatment-covid-19>.
- [95] Federal Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. 2021 [cited 23/12/2021]. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain>.
- [96] Hill A. Molnupiravir's authorisation should be re-evaluated after the Panoramic trial is reported. BMJ. 2022;377:o973. Epub 2022/04/28. DOI: 10.1136/bmj.o973.
- [97] Fischer W., Eron J., Holman W., Cohen M., Fang L., Szewczyk L., et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv. 2021. Epub 2021/06/24. DOI: 10.1101/2021.06.17.21258639.
- [98] Caraco Y., Crofoot G., Moncad P., Galustyan A., Musungaie D., Payne B., et al. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. NEJM Evidence. 2021. DOI: 10.1056/EVIDoa2100043.
- [99] Arribas J., Bhagani S. and Lobo S. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. NEJM Evidence. 2021. DOI: 10.1056/EVIDoa2100044. .
- [100] Jayk Bernal A., Gomes da Silva M., Musungaie D., Kovalchuk E., Gonzalez A., Delos Reyes V., et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2116044.
- [101] Fischer W., Eron J., Holman W., Cohen M., Fang L., Szewczyk L., et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eab17430. Epub 2021/12/24. DOI: 10.1126/scitranslmed.abl7430.
- [102] Johnson M., Puenpatom A., Moncada P., Burgess L., Duke E., Ohmagari N., et al. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. Ann Intern Med. 2022. Epub 2022/06/07. DOI: 10.7326/m22-0729.
- [103] Tippabhotla S., Lahiri S., Rama R., Kandi C. and PV. N. Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial. Preprints with The Lancet. 2022. DOI: Available at SSRN: <https://ssrn.com/abstract=4042673> or <http://dx.doi.org/10.2139/ssrn.4042673>.
- [104] World Health Organisation (WHO). Therapeutics and COVID-19 living guideline. 2021;31 March
- [105] Rochwerg B. and et al. A living WHO guideline on drugs for COVID-19, Visual summary of recommendation, fourth version (update 3) of the living guideline. BMJ. 2020;BMJ 2020;370:m3379(<https://www.bmj.com/content/370/bmj.m3379>).

- [106] Abani O., Abbas A., Abbas F., Abbas M., Abbasi S., Abbass H., et al. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet*. 2022;399(10320):143-151. DOI: 10.1016/S0140-6736(21)01825-0.
- [107] European Medicines Agency (EMA). Xeljanz: EPAR – Product Information. Last update 06/05/2021. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz#product-information-section>.
- [108] Guimarães P., Quirk D., Furtado R., Maia L., Saraiva J., Antunes M., et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med*. 2021. Epub 2021/06/17. DOI: 10.1056/NEJMoa2101643.
- [109] Murugesan H., Gauthaman C., Nasreen H., Santhanam S., Govrishanker M., Ravi S., et al. An Evaluation of Efficacy and Safety of Tofacitinib, A JAK Inhibitor in the Management of Hospitalized Patients with Mild to Moderate COVID-19 - An Open-Label Randomized Controlled Study. *J Assoc Physicians India*. 2022;69(12):11-12. Epub 2022/01/22.
- [110] Owen D., Allerton C., Anderson A., Aschenbrenner L., Avery M., Berritt S., et al. An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19. *medRxiv*. 2021:2021.2007.2028.21261232. DOI: 10.1101/2021.07.28.21261232.
- [111] European Medicines Agency (EMA). EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel. 2021 [cited 16/12/2021]. Available from: <https://www.ema.europa.eu/en/news/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19-rolling-review-starts>.
- [112] European Medicines Agency (EMA). COVID-19: EMA recommends conditional marketing authorisation for Paxlovid. [cited 27/01/2022]. Available from: <https://www.ema.europa.eu/en/news/covid-19-ema-recommends-conditional-marketing-authorisation-paxlovid>.
- [113] Federal Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. 2021 [cited 22/12/2021]. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19>.
- [114] Federal Drug Administration (FDA). Fact sheet for healthcare providers: Emergency use authorization for paxlovid™. Revised 06/2022. 2022. Available from: <https://www.fda.gov/media/155050/download>.
- [115] Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med*. 2022. Epub 2022/02/17. DOI: 10.1056/NEJMoa2118542.
- [116] Pfizer. Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study. [cited 05/11/2021]. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate>.
- [117] Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results>.
- [118] Jochmans D., Liu C., Donckers K., Stoycheva A., Boland S., Stevens S., et al. The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor &in vitro& and confer resistance to nirmatrelvir. *bioRxiv*. 2022:2022.2006.2007.495116. DOI: 10.1101/2022.06.07.495116.
- [119] Zhou Y., Gammeltoft K., Ryberg L., Pham L., Fahnøe U., Binderup A., et al. Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro. *bioRxiv*. 2022:2022.2006.2006.494921. DOI: 10.1101/2022.06.06.494921.

- [120] Hu Y., Lewandowski E., Tan H., Morgan R., Zhang X., Jacobs L., et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. *bioRxiv*. 2022:2022.2006.2028.497978. DOI: 10.1101/2022.06.28.497978.
- [121] Jeong J., Chokkakula S., Min S., Kim B., Choi W., Oh S., et al. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. *bioRxiv*. 2022:2022.2006.2027.497875. DOI: 10.1101/2022.06.27.497875.
- [122] Good S., Westover J., Jung K., Zhou X., Moussa A., La Colla P., et al. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. *Antimicrob Agents Chemother*. 2021;65(4). Epub 2021/02/10. DOI: 10.1128/aac.02479-20.
- [123] Do T., Donckers K., Vangeel L., Chatterjee A., Gallay P., Bobardt M., et al. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. *Antiviral Res*. 2021;192:105122. Epub 2021/06/30. DOI: 10.1016/j.antiviral.2021.105122.
- [124] NCT04396106. Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting. 2020. Available from: <https://clinicaltrials.gov/ct2/show/NCT04396106>.
- [125] NCT04709835. Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19. 2021. Available from: <https://clinicaltrials.gov/ct2/show/NCT04709835>.
- [126] Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19. [cited 14/12/2021]. Available from: <https://ir.ateapharma.com/node/7646/pdf>.
- [127] NCT04889040. Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 (MORNINGSKY). 2021. Available from: <https://clinicaltrials.gov/ct2/show/NCT04889040>.
- [128] Atea to study AT-527 as monotherapy and in combination for Covid-19. [cited 15/12/2021]. Available from: <https://www.pharmaceutical-technology.com/news/atea-at-527-monotherapy-covid-19/>.
- [129] Atea Pharmaceuticals. Atea's AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis. 2021. Available from: <https://ir.ateapharma.com/news-releases/news-release-details/ateas-527-oral-antiviral-drug-candidate-reduces-viral/>.
- [130] Atea Pharmaceuticals. Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting. 2021. Available from: <https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-and-topline-results-phase-2>.
- [131] I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19. 2021. Available from: <https://www.prnewswire.com/news-releases/i-mab-reports-positive-interim-analysis-from-phase-23-study-of-its-gm-csf-antibody-plonmarlimab-tjm2-to-treat-patients-with-severe-covid-19-301353101.html>.
- [132] De Luca G., Cavalli G., Campochiaro C., Della-Torre E., Angelillo P., Tomelleri A., et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. *Lancet Rheumatol*. 2020;2(8):e465-e473. Epub 2020/08/25. DOI: 10.1016/s2665-9913(20)30170-3.
- [133] Cantini F., Goletti D., Petrone L., Najafi Fard S., Niccoli L. and Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. *Drugs*. 2020;80(18):1929-1946. Epub 2020/10/18. DOI: 10.1007/s40265-020-01421-w.
- [134] Food and Drug Administration (FDA). Search Orphan Drug Designations and Approvals. Available from: <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm>.
- [135] European Medicines Agency (EMA). Treatments and vaccines for COVID-19. Available from: <https://www.ema.europa.eu/en/human-regulatory/overview/public-healththreats/coronavirus-disease-covid-19/treatments-vaccines-covid-19>.

- [136] Cremer P., Abbate A., Hudock K., McWilliams C., Mehta J., Chang S., et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. *Lancet Rheumatol.* 2021;3(6):e410-e418. Epub 2021/03/24. DOI: 10.1016/s2665-9913(21)00070-9.
- [137] Kiniksa Pharmaceuticals Ltd. Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation. 2021. Available from: <https://investors.kiniksa.com/node/8456/pdf>.
- [138] European Network for health technology assessment (EUnetHTA). Rolling Collaborative Review (RCR21). Mavrilimumab for the treatment of COVID-19. Diemen (The Netherlands): 2021 RCR21, v4.0. Available from: https://www.eunetha.eu/wp-content/uploads/2021/05/EUnetHTA-Covid-19_RCR21_Mavrilimumab_v4.0.pdf?x50316.
- [139] Kiniksa Pharmaceuticals Ltd. Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients. 2021. Available from: <https://investors.kiniksa.com/node/8701/pdf>.
- [140] Pupim L., Wang T., Hudock K., Denson J., Fourie N., Hercilla Vasquez L., et al. LB0001 mavrilimumab improves outcomes in phase 2 trial in non-mechanically-ventilated patients with severe covid-19 pneumonia and systemic hyperinflammation. *Annals of the Rheumatic Diseases.* 2021;80(Suppl 1):198. DOI: 10.1136/annrheumdis-2021-eular.5012.
- [141] Kiniksa Pharmaceuticals Ltd. Mavrilimumab. COVID-19 related ARDS. Available from: <https://www.kiniksa.com/pipeline>.
- [142] Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS. [cited 28/12/2021]. Available from: <https://www.biospace.com/article/releases/kiniksa-announces-results-from-phase-3-trial-of-mavrilimumab-in-covid-19-related-ards/>.
- [143] Luke T., Wu H., Egland K., Sullivan E. and Bausch C. Fully Human Antibody Immunoglobulin from Transchromosomal Bovines is Potent Against SARS-CoV-2 Variant Pseudoviruses. *bioRxiv.* 2021:2021.2008.2009.454215. DOI: 10.1101/2021.08.09.454215.
- [144] SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro. [cited 16/12/2021]. Available from: <https://www.biospace.com/article/releases/sab-biotherapeutics-announces-sab-185-retains-neutralization-against-omicron-sars-cov-2-variant-in-vitro/>.
- [145] SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19. [cited 25/02/2022]. Available from: <https://www.globenewswire.com/news-release/2022/02/25/2392191/0/en/SAB-Biotherapeutics-Announces-Update-to-the-Phase-3-NIH-ACTIV-2-Trial-Design-Evaluating-SAB-185-for-Treatment-of-COVID-19.html>.
- [146] SAB Biotherapeutics. SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19. 2021. Available from: <https://www.sabbiotherapeutics.com/2021/09/24/sab-biotherapeutics-announces-sab-185-receives-positive-dsmb-review-and-advances-to-phase-3-in-nih-sponsored-activ-2-trial-for-treatment-of-covid-19/>.
- [147] SAB Biotherapeutics. SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19. 2021. Available from: <https://www.sabbiotherapeutics.com/2021/10/04/sab-biotherapeutics-announces-first-patient-dosed-in-phase-3-nih-activ-2-trial-evaluating-sab-185-for-treatment-of-covid-19/>.
- [148] Ensovibep: COVID-19. Available from: <https://www.molecularpartners.com/product/ensovibep-mp0420-covid-19/>.
- [149] National Institutes of Health (NIH). Ensovibep. 2021. Available from: <https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials>.
- [150] Ensovibep initial results from phase 1 study. 2021. Available from: <https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-and-novartis-report-positive-initial-results/>.

- [151] Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19. 2021. Available from: <https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-announce-start-empathy-clinical-trial-ensovibep-treatment-covid-19>
- [152] Molecular Partners to suspend subject enrolment in Phase III Covid-19 trial. [cited 17/11/2021]. Available from: <https://www.clinicaltrialsarena.com/news/molecular-partners-enrolment-covid-trial/>.
- [153] Novartis. Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPIn antiviral therapeutic for COVID-19. [cited 10/01/2022]. Available from: <https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-report-positive-topline-data-from-phase-2-study-ensovibep-mp0420-darpin-antiviral-therapeutic-covid-19>.
- [154] Bohan D., Van Ert H., Dhakal S., Ruggio N., Rogers K., Stokowy T., et al. Targeting the receptor axl by bemcentinib prevents SARS-CoV-2 infection. *Topics in Antiviral Medicine*. 2021;29(1):137-138.
- [155] Bemcentinib. Available from: <https://www.bergenbio.com/pipeline/bemcentinib-covid-19/>.
- [156] Bergenbio and Oslo University Hospital announce the axl inhibitor bemcentinib will be studied in the EU funded EU-SOLIDACT trial in hospitalised covid-19 patients. [cited 27/01/2022]. Available from: <https://www.bergenbio.com/bergenbio-and-oslo-university-hospital-announce-the-axl-inhibitor-bemcentinib-will-be-studied-in-the-eu-funded-eu-solidact-trial-in-hospitalised-covid-19-patients/>.
- [157] BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID. 2021. Available from: <https://www.biospace.com/article/releases/bergenbio-presents-encouraging-combined-data-for-bemcentinib-from-two-phase-ii-covid-19-studies-at-eccmid/>.
- [158] Quan B., Shuai H., Xia A., Hou Y., Zeng R., Liu X., et al. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. *Nature Microbiology*. 2022;7(5):716-725. DOI: 10.1038/s41564-022-01119-7.
- [159] Unoh Y., Uehara S., Nakahara K., Nobori H., Yamatsu Y., Yamamoto S., et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. *J Med Chem*. 2022;65(9):6499-6512. Epub 2022/03/31. DOI: 10.1021/acs.jmedchem.2c00117.
- [160] He J., Hu L., Huang X., Wang C., Zhang Z., Wang Y., et al. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. *Int J Antimicrob Agents*. 2020;56(2):106055. Epub 2020/06/14. DOI: 10.1016/j.ijantimicag.2020.106055.
- [161] Mukae H., Yotsuyanagi H., Ohmagari N., Doi Y., Imamura T., Sonoyama T., et al. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. *medRxiv*. 2022:2022.2005.2017.22275027. DOI: 10.1101/2022.05.17.22275027.
- [162] Li Y., Siripanyaphinyo U., Tumkosit U., Noranate N., A A. N., Pan Y., et al. Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells. *Virol J*. 2012;9:114. Epub 2012/06/16. DOI: 10.1186/1743-422x-9-114.
- [163] Salem M., Kadima A., Cole D. and Gillanders W. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. *J Immunother*. 2005;28(3):220-228. Epub 2005/04/20. DOI: 10.1097/01.cji.0000156828.75196.0d.
- [164] Ngoi S., Tovey M. and Vella A. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. *J Immunol*. 2008;181(11):7670-7680. Epub 2008/11/20. DOI: 10.4049/jimmunol.181.11.7670.
- [165] Trumpfheller C., Caskey M., Nchinda G., Longhi M., Mizenina O., Huang Y., et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. *Proc Natl Acad Sci U S A*. 2008;105(7):2574-2579. Epub 2008/02/08. DOI: 10.1073/pnas.0711976105.

References

- [166] Winchester S., John S., Jabbar K. and John I. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. *J Infect.* 2021;83(2):237-279. Epub 2021/05/17. DOI: 10.1016/j.jinf.2021.05.009.
- [167] Moni M., Madathil T., Sathyapalan D., Menon V., Gutjahr G., Edathadathil F., et al. A Feasibility Trial to Evaluate the Composite Efficacy of Inhaled Nitric Oxide in the Treatment of Covid 19 Pneumonia : Impact on Viral Load and Clinical Outcomes. *medRxiv.* 2021:2021.2004.2015.21255300. DOI: 10.1101/2021.04.15.21255300.



HTA Austria

Austrian Institute for
Health Technology Assessment
GmbH